I. Introduction {#s1}
===============

Glucagon-like peptide (GLP)-1 is a gastrointestinal peptide hormone secreted from three major tissues in humans, enteroendocrine L cells in the distal intestine, *α* cells in the pancreas, and the central nervous system, which has multiple therapeutic effects useful in the management of type 2 diabetes mellitus (T2DM). These include most prominently a glucose-dependent insulinotropic function and other actions on glucose homeostasis, as well as benefits to gastric emptying and appetite regulation valuable in reducing food intake and body weight. This hormone exerts its effects by binding to and activating a class B G protein--coupled receptor (GPCR), namely, GLP-1 receptor (GLP-1R). We review the current understanding of the structures of GLP-1 and GLP-1R, the molecular basis of their interaction, and the signaling events associated with it. We also discuss the peptide analogs and nonpeptidic ligands that have been developed to target GLP-1R, the molecular basis of their action, and the implications for ligand-biased activity and allosteric regulation of this hormone-receptor system. Some of these GLP-1R agonists are already in clinical use, with many more currently being developed, and likely to provide enhancements in their ease of administration, tolerability, and effectiveness.

II. Glucagon-Like Peptide-1 {#s2}
===========================

A. Discovery {#s3}
------------

GLP-1 is a member of the incretin family of gastrointestinal hormones ([@B70]; [@B20]; [@B52]; [@B190]). In 1906, Moore and his colleagues tested the hypothesis that the pancreas might be stimulated by factors from the gut to help disposal of nutrients and started using porcine small intestine extract to treat diabetic patients ([@B318]). In 1928, Zunc and LaBarre were able to show a hypoglycemic effect following injection of secretin extracted from the small intestinal mucosa, and this effect was mediated through the pancreas ([@B546]). Subsequently, the term incrétine (incretin) was introduced by LaBarre for a substance extracted from the upper gut mucosa, which produces hypoglycemia, but does not stimulate pancreatic exocrine secretion ([@B255]). It was later observed that orally administered glucose evoked a much stronger insulin release than that induced by i.v. injected glucose, supporting the concept of an entero-insular axis, that is, gut factor--stimulated insulin secretion ([@B115]; [@B304]; [@B371]). The first discovered incretin hormone was gastric inhibitory polypeptide (GIP), which was isolated from crude extracts of the porcine small intestine for its activity to inhibit gastric acid secretion ([@B41]). This was followed by the observation that GIP could also stimulate insulin secretion in animals and humans, and thus, it was later renamed as glucose-dependent insulinotropic polypeptide, while retaining the same acronym ([@B102]; [@B112]; [@B413]; [@B72]). GIP is released from the K cells of the small intestine. However, antibodies raised against GIP did not abolish the incretin effect, implying the existence of other prominent gut insulinotropic factors ([@B107]).

In 1981, GLP-1, the second incretin hormone, was identified in the translational products of mRNAs isolated from the pancreatic islets of anglerfish ([@B277]; [@B432]). Subsequently, both GLP-1 and GLP-2 were confirmed from cloned hamster and human preproglucagon cDNAs, but only GLP-1 was able to stimulate insulin secretion ([@B30], [@B31]; [@B311]). The proglucagon gene is expressed in the *α* cells of the pancreas, the L cells of the intestine, and neurons in the caudal brainstem and hypothalamus ([@B310]; [@B96]) ([Fig. 1](#F1){ref-type="fig"}). Although its transcription produces the same single mRNA in these cell types, the 180-residue preproglucagon protein translated from it is cleaved differently in the pancreas than in the intestine (and brain) by differential posttranslational processing: the former releases glicentin-related pancreatic peptide, glucagon, intervening peptide 1 (IP1), and major proglucagon fragment (containing GLP-1, IP1, and GLP-2 as a single fusion peptide), whereas the latter releases glicentin, oxyntomodulin, GLP-1, IP1, and GLP-2 ([@B310]) ([Fig. 1](#F1){ref-type="fig"}). Endogenous GLP-1 exists in two forms: one corresponds to proglucagon 78--107 with its C-terminal Arg amidated, that is, GLP-1~7--36\ amide~, and the other is longer and not amidated, GLP-1~7--37~ ([@B203]; [@B352]). Both have similar biologic activities, although the amide form may have slightly improved stability in the circulation ([@B502]). GLP-1, but not GLP-2, was later demonstrated to enhance glucose-stimulated insulin secretion in response to nutrient ingestion ([@B420]; [@B251]; [@B311]; [@B354]).

![Gene structure, expression, processing, degradation, and elimination of proglucagon. The proglucagon gene is located in human chromosome 2 and transcribed as one single mRNA in three major tissues, namely, the pancreas, the intestine, and the CNS. The mRNA is first translated into one single protein and then processed by prohormone convertase (PC) in different tissues. In the pancreatic *α* cells, proglucagon protein is processed by PC2 into glicentin-related polypeptide (GRPP), glucagon (Gluc), intervening peptide-1 (IP-1), and major proglucagon fragment, whereas in L cells of the small intestine and the brain, proglucagon is processed by PC1/3 into oxyntomodulin, intervening peptide-2 (IP-2), GLP-1, and GLP-2. GLP-1 is degraded by DPP-4 via cleavage of two amino acids from the N terminus, or by NEP-24.11 through cleavage of the C terminus in vivo. The cleaved products are eventually eliminated in the kidney. UTR, untranslated region.](pr.115.011395f1){#F1}

The half-life of GLP-1 peptide in the circulation is very short (less than 2 minutes). Its rapid inactivation is mainly due to the cleavage of two amino acids from the N terminus by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-4) ([@B87]) ([Fig. 1](#F1){ref-type="fig"}). In addition, a membrane-bound zinc metallopeptidase, neutral endopeptidase 24.11 (NEP 24.11), has also been shown to cleave GLP-1 at its C terminus both in vitro and in vivo ([@B376]). The metabolites of GLP-1 are then subject to renal clearance by several mechanisms ([@B403]).

B. Physiology {#s4}
-------------

The main action of GLP-1 is to work as an incretin, that is, as a gut-derived hormone capable of potentiating insulin secretion in the presence of high plasma glucose levels. The incretin concept came from observations that insulin release was higher when the glucose was administered orally rather than i.v., even when the same plasma glucose concentration was achieved from both routes ([@B304]; [@B371]). Although many hormones were originally suspected to contribute to the incretin effect, the current view is that GLP-1 and GIP are responsible for most incretin activity normally observed ([@B202]; [@B488]; [@B71]; [@B52]). Oral administration of glucose results in a two- to threefold greater insulin secretion than i.v. glucose. Both GLP-1 and GIP can enhance insulin secretion after a mixed meal, but GLP-1 is more potent than GIP ([@B334]; [@B113]). In the human circulation, GIP concentration is eightfold higher than GLP-1; in type 2 diabetic patients, GLP-1 has more activity than GIP, but their effects on insulin secretion seem to be additive ([@B332], [@B331]; [@B113]).

### 1. Effect on Glucose Homeostasis. {#s5}

The insulinotropic activity of GLP-1 is strictly glucose-dependent mediated through its receptor at the membrane of pancreatic *β* cells ([@B251]; [@B311]; [@B200]). GLP-1 could not stimulate insulin secretion at low levels of glucose in humans ([@B251]). GLP-1R belongs to the class B GPCR subfamily whose members include receptors for peptidic hormones such as glucagon, secretin, GIP, etc. The binding of GLP-1 to its receptor activates heterotrimeric Gs protein, which subsequently elicits adenylate cyclase activity, resulting in cAMP formation ([@B161], [@B159]). The increased level of cAMP in turn leads to activation of protein kinase A (PKA) and the cAMP-regulated guanine nucleotide exchange factor II ([@B356]). In the presence of high levels of glucose, GLP-1 has an effect on ATP-sensitive (K~ATP~) or voltage-gated potassium and calcium channels, resulting in membrane depolarization and Ca^2+^ release from both internal and extracellular stores. Increased Ca^2+^ together with cAMP will then promote exocytosis of vesicles containing insulin ([@B379]; [@B394]). This glucose-dependent insulinotropic action of GLP-1 involves the glucose transporter, metabolic ADP/ATP ratio, K~ATP~ inhibition, Ca^2+^ channel opening, and, ultimately, insulin secretion ([@B159]; [@B105]).

Another major activity of GLP-1 to reduce blood glucose relates to the suppression of glucagon secretion from *α* cells of the endocrine pancreas ([@B162]). Glucagon is a major hyperglycemic hormone, in addition to epinephrine, and its release is reciprocally correlated with insulin secretion in glucose oscillation to mobilize hepatic glucose in the fasting state, thereby helping to ensure the maintenance of normoglycemia. In T2DM, both fasting hyperglucagonemia and exaggerated glucagon responses, which most likely contribute to the hyperglycemia of patients, were observed ([@B429]; [@B463]). Interestingly, only GLP-1, but not GIP, inhibits glucagon secretion ([@B334]). However, the detailed mechanism(s) by which GLP-1 suppresses glucagon secretion remains unclear. Because the levels of GLP-1 mRNA detected in *α* cells varied between none and 20% of a cell population, it is generally thought that local elevated insulin and somatostatin in response to GLP-1 stimulation are capable of suppressing glucagon secretion in *α* cells ([@B353]; [@B188]; [@B81]; [@B143]). Nonetheless, in type 1 diabetic patients with absent *β* cell activity who lack insulin and somatostatin, GLP-1 could still reduce glucose concentrations, suggesting a direct suppression of glucagon secretion ([@B73]; [@B162]).

### 2. Effect on Gastric Emptying. {#s6}

GLP-1 also has an important inhibitory activity on gut motility and gastrointestinal secretion ([@B503]; [@B337]). It not only inhibits meal-induced pancreatic secretion, but also the gastric emptying process in humans ([@B503]). Its suppression of gastrin-induced acid secretion was demonstrated by injection of GLP-1 and/or peptide YY. Both peptides are released from L cells in the ileal mucosa of healthy people ([@B500]) and can exhibit additive effects on gastrin-stimulated acid secretion, a function of unabsorbed nutrients in the ileum ([@B199]). It was subsequently shown that this inhibitory action of GLP-1 is mediated via a vagal pathway ([@B501]). This ileal-brake activity of GLP-1 was further demonstrated using the GLP-1R antagonist exendin~9--39~, and therefore, is believed to have physiologic relevance ([@B418]; [@B287]).

### 3. Effect on Food Intake. {#s7}

Another physiologic function of GLP-1 concerns inhibition of food intake that may have therapeutic value for body weight reduction. Whether this is related to its ileal brake effect is still debated. At least two neural mechanisms, central and peripheral, are involved in GLP-1 suppression of appetite and food intake. GLP-1 is expressed in the neurons of the brain stem, and GLP-1R is present in the hypothalamic areas that control energy homeostasis and food intake, including the arcuate nucleus, paraventricular nucleus, and dorsomedial nucleus ([@B219]; [@B225]; [@B542]). Intracerebroventricular injection of GLP-1 inhibits food intake in rats, and this activity is blocked by exendin~9--39~ ([@B453]; [@B472]), or by the arcuate nucleus-damaging reagent, monosodium glutamate ([@B454]). In contrast, GLP-1 released by L cells of the intestine after a meal inhibits gut mobility and gastric emptying, allowing nutrients in the ileum to reduce food intake ([@B391]). Indeed, infusion of GLP-1 into normal human subjects significantly enhances satiety and decreases food intake ([@B124]). Consistent findings have shown that GLP-1R agonism promotes weight loss and improves glucose homeostasis in rodents, monkeys, and humans ([@B484]; [@B25]), and such weight-reducing properties have also been well-documented for two marketed GLP-1 mimetics, exenatide (exendin-4) and liraglutide ([@B319]; [@B15]; [@B348]; [@B260]). Although the exact mechanism mediating reduced food intake by peripherally administered GLP-1 has yet to be elucidated, it may involve signals generated by GLP-1 binding to its receptors on neurons in the gastrointestinal tract or hepatoportal bed ([@B44]; [@B200]).

### 4. Effect on Cardiovascular Activity. {#s8}

Recently, there is increasing evidence suggesting that GLP-1 may play a crucial role in the cardiovascular system ([@B158]; [@B479]). GLP-1R is widely expressed in the heart and blood vessels, such as vascular smooth muscle, cardiomyocytes, endocardium, and coronary endothelium/smooth muscle, in both rodents and humans ([@B53]; [@B496]; [@B43]). In an early study, treatment of adult rat cardiac myocytes with GLP-1 increased cAMP levels, but did not lead to increased cardiomyocyte contractility, as would be anticipated in the heart ([@B486]). Interestingly, treatment of mouse cardiomyocytes with GLP-1~9--36\ amide~ (a GLP-1 degradation product in vivo) resulted in Akt activation, extracellular regulated kinase (ERK) phosphorylation, and reduced apoptosis induced by hypoxia or hydrogen peroxide stress, implying an unconventional action of GLP-1 ([@B23]). In a rat ischemia-reperfusion model using isolated perfused heart and whole animal, GLP-1 significantly decreased infarction size, and this protection was abolished by exendin~9--39~, as well as inhibitors of adenylyl cyclase, phosphatidylinositol 3-kinase (PI3K), and p42/44 mitogen-activated protein kinase (MAPK), suggesting that these pathways were involved in GLP-1--mediated cardio-protection ([@B36]). A direct action of GLP-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts was also observed ([@B543]). GLP-1 treatment significantly increased glucose uptake and decreased left ventricular end-diastolic and developed pressures. Infusion of GLP-1 into live dogs increased myocardial glucose uptake, which could be blocked by p38 MAPK kinase or endothelial nitric oxide synthase inhibitors, pointing to a direct effect of GLP-1 in myocardium ([@B345]; [@B34]). Meanwhile, GLP-1R was detected in human coronary artery endothelial cells and umbilical vein endothelial cells, and GLP-1 or exendin-4 treatment led to nitric oxide production in both cell types, indicative of GLP-1 involvement in the vasculature ([@B350]; [@B118]; [@B549]). GLP-1 infusion into rats also increased heart rate and blood pressure, thereby reflecting its direct role in the heart ([@B24]). In recent clinical trials with either GLP-1R agonists or DPP-4 inhibitors, general beneficial effects of GLP-1 on the cardiovascular system in both normal and diabetic subjects have been revealed, an interesting finding that may lead to potential new treatment of cardiovascular diseases, although these effects require a long-term validation ([@B480]; [@B19]; [@B479]; see *V.* *Pharmaceutical Development and Therapeutics*).

### 5. Effect on Immune Response. {#s9}

GLP-1 can also regulate immune responses. Its receptor mRNA was discovered in multiple immune cell types from mice, including thymoyctes, splenocytes, bone marrow--derived cells, regulatory T cells, macrophages, and invariant natural killer T cells ([@B169]; [@B196]; [@B359]). Liraglutide treatment of patients with psoriasis, an inflammatory condition associated with metabolic diseases such as obesity, diabetes, and dyslipidemia, led to improvement of psoriasis area and severity index as well as decreased cytokine secretion from invariant natural killer T cells in a glycemic control-independent manner ([@B196]). High-fat diet--fed mice treated with exendin-4 displayed decreased mRNA levels of the proinflammatory cytokines monocyte chemoattractant protein 1, tumor necrosis factor-*α*, and signal transducer and activator of transcription 3 ([@B240]), and, in a type 1 diabetes animal model in which islets were transplanted into nonobese diabetic mice, GLP-1/gastrin treatment increased the number of transforming growth factor-*β*1--secreting lymphocytes and decreased IFN-*γ*--secreting lymphocytes with delayed onset of diabetes ([@B446]).

### 6. Effect on Kidney Function. {#s10}

Some experimental data point to the participation of GLP-1 in kidney function. Infusion of GLP-1 into healthy and obese human subjects enhanced sodium excretion, urinary secretion, and glomerular filtration rate, suggesting a renal protective effect of this peptide ([@B168]). In rats, GLP-1 was able to downregulate Na^+^/H^+^ exchanger isoform 3 (NHE3) in the renal proximal tubule, implying a potential therapeutic value for hypertension and disorders of sodium retention ([@B69]). Rats administered with exendin-4 significantly improved renal function and reduced inflammation, proteinuria, and fibrosis in the kidney via a mechanism that was independent of glucose lowering ([@B239]).

### 7. Effect on Nervous System. {#s11}

In addition to the metabolic function in the brain, GLP-1 may also exert neuroprotective and neurotropic effects ([@B190]). The aggregation of amyloid *β* protein (A*β*) and the microtubule-associated protein Tau cause senile plaques and neurofibrillary tangles, resulting in loss of long-term potentiation, one of the major characteristics of Alzheimer's disease (AD). Infusion of GLP-1 or exendin-4 into the lateral ventricles of mice decreased endogenous level of A*β*, and treatment of rat hippocampus neurons with GLP-1 and exendin-4 prevented A*β*-induced cell death ([@B374]). Intracerebroventricular dosing of GLP-1 enhanced synaptic plasticity in the hippocampus and completely reversed impairment in long-term potentiation caused by subsequent injection of A*β* ([@B136]). GLP-1R was found in nigrostriatal neurons, and loss of these neurons is a feature of Parkinson's disease (PD). GLP-1 or exendin-4 supported cell viability during hypoxic injury in primary neurons from rat cerebral cortical tissues; this activity was blocked by GLP-1~9--36~ (a GLP-1R antagonist) and not observed in neurons from *GLP-1^−/−^* mice ([@B264]). Exendin-4 also maintained cell viability and reduced apoptosis caused by H~2~O~2~-induced oxidative stress in NSC19 neuronal cells, a spinal cord cell line with similarities to cells in the central nervous system (CNS) ([@B263]).

Obviously, GLP-1 and GLP-1R are widely expressed in many tissues, and their physiologic actions have been incrementally elucidated, especially after the extensive clinical application of GLP-1 mimetics, including GLP-1R agonists and DPP-4 inhibitors, in the last decade. Although its roles in some tissues, such as adipocytes or skeletal muscles, are still illusive, GLP-1--related therapies have clearly provided multiple benefits to millions of patients suffering from metabolic disorders, and such effects are predominantly, but perhaps not always, based on signaling pathways mediated by its receptor.

C. Structure {#s12}
------------

Structurally, class B GPCRs consist of a large N-terminal extracellular domain (ECD) and a seven-transmembrane (7TM) helix domain, comprising the GPCR signature of seven membrane spanning *α*-helices \[transmembrane (TM)1--7\], connected by three extracellular (ECL) and intracellular (ICL) loops, and a C-terminal helix 8 ([@B147]; [@B197]). Pharmacological studies with truncated, chimeric, and mutated ligand and receptor variants, together with peptide ligand-bound ECD crystal structures and the first 7TM crystal structures of class B GPCRs, have provided the basis for a two-domain--binding mechanism of peptide hormone ligands to secretin-like class B GPCRs ([@B363]; [@B95]; [@B197]). According to this peptide ligand-binding mechanism: 1) the C terminus of the peptide ligand forms an initial complex with the ECD, and this allows 2) the N terminus of the peptide ligand to interact with the 7TM domain (7TMD) and activate the class B GPCR to couple to G proteins and other effectors to mediate intracellular signaling processes (see *III. Glucagon-Like Peptide-1 Receptor*). This section gives an overview of the structure--activity relationship (SAR) of GLP-1 peptides, thereby providing important information regarding the molecular determinants of ligand binding and functional activities at the GLP-1R. The development of GLP-1 analogs is described in detail in *V.* *Pharmaceutical Development and Therapeutics*, whereas SAR of GLP-1R will be discussed explicitly in *III*. *Glucagon-Like Peptide-1 Receptor*. Alignments of the sequences and structures of GLP-1 with GLP-2, glucagon, GIP, and exendin-4 are presented in [Fig. 2](#F2){ref-type="fig"}. This also annotates the structural properties of GLP-1, effects of GLP-1 mutation studies, and GLP-1R and exendin-4 interaction sites in the corresponding GLP-1R ECD crystal structures ([@B406]; [@B475]). Peptide ligand residues shown are annotated as three-letter amino acid codes with residue number as superscripts (e.g., His^7^, histidine at position 7), whereas receptor residue numbers are annotated as single-letter codes, Uniprot numbers, and Ballesteros-Weinstein/Wootten numbers/secondary structure motif as superscripts, according to IUPHAR guidelines ([@B369]) and class B GPCR residue-numbering guidelines ([@B525]; [@B214]), respectively. According to the Ballesteros--Weinstein class A GPCR ([@B22]) and Wootten class B GPCR ([@B525]) residue-numbering schemes, the single most conserved residue in each TM helix is designated X.50 (Ballesteros-Weinstein number used for comparison within class A GPCRs as well as to compare across GPCR classes) or X.50b (Wootten number for comparison with class B GPCRs). X is the TM helix number, and all other residues in that helix are numbered relative to this conserved position ([@B197]). GLP-1R residues that are most conserved in secretin-like class B GPCRs are S155^1.50b^, H180^2.50b^, E247^3.50b^, W274^4.50b^, N320^5.50b^, G361^6.50b^, and G395^7.50b^. GLP-1 and glucagon peptide ligands start with amino acid residue 7 (His^7^) due to post-translational processing ([Fig. 2](#F2){ref-type="fig"}), whereas the homologous GLP-2, GIP, and exendin-4 start with His^1^ and Tyr^1^, respectively.

![Structural characteristics of GLP-1 and its cognate receptor. (A) GLP-1--bound full-length GLP-1R homology model based on a previously published full-length glucagon-bound GCGR model combining structural and experimental information from the GCGR 7TMD crystal structure (PDB: 4L6R), the GCGR ECD structure (PDB: 4ERS), and the ECD structure of GLP-1--bound GLP-1R (PDB: 3IOL), complemented by site-directed mutagenesis, electron microscopy, hydrogen-deuterium exchange, and cross-linking studies ([@B435]; [@B535], [@B534]). The C-terminal helix of GLP-1 bound to the ECD region of GLP-1R is depicted as cartoon, whereas the atoms of the flexible N-terminal region of GLP-1 predicted to be bound to the 7TMD of GLP-1R are depicted as spheres. GLP-1 is color coded according to mutation effects (blue: \<fourfold effect, orange: 4- to 10-fold effect, red: \>10-fold effect IC~50~; see II. Glucagon-Like Peptide-1); mutation effects of GLP-1R are reported in [Fig. 3](#F3){ref-type="fig"} and [Table 1](#T1){ref-type="table"}. The C*α*/C*β* atoms of GLP-1/GLP-1R residue pairs identified in photo cross-linking studies ([@B58], [@B59]; [@B306]) are depicted as green-colored spheres. (B) Structural alignment of the ECD structures of GLP-1 and exendin~9--39~--bound GLP-1R (PDB: 3IOL, 3C59), GIP-bound GIPR (PDB: 2QKH), and the mAb23-bound GCGR ECD structure (PDB: 4ERS). Comparison of the crystal structure binding modes of (C) GLP-1 and (D) exendin~9--39~. The surfaces of GLP-1R residues involved in important apolar interactions with GLP-1/apolar are colored pink, whereas residues involved in polar interactions described in *II. Glucagon-Like Peptide-1* are also depicted as sticks (and their H-bond interaction networks are depicted as dashed lines). (E) Structure-based sequence alignment of GLP-1, exendin~9--39~, glucagon, GIP, and GLP-2. The regions of the peptide ligands solved in ECD--ligand complex crystal structures are marked above the amino acid sequences using the same color coding as in (B). Amino acids of GLP-1 are marked according to mutation study effects, as indicated in (A). The residues that are boxed are found in an *α*-helical conformation in the crystal structure complex (solid lines: GLP-1, exendin~9--39~, GIP) or in NMR studies in micelle DPC (dashed lines: glucagon, GLP-2), as described in *II. Glucagon-Like Peptide-1*.](pr.115.011395f2){#F2}

### 1. *α*-Helical C-Terminal Region. {#s13}

NMR, circular dichroism (CD) spectroscopy, and X-ray crystallography studies show that GLP-1 is unstructured in aqueous solution, but adopts a helical structure in a membrane-like environment and by binding to its receptor ([@B461]; [@B340]; [@B405]; [@B475]). This conformational change upon receptor binding is also proposed for other class B GPCR peptide ligands, including glucagon ([@B39]; [@B435]), GIP ([@B6]; [@B362]), and exendin-4 ([@B405], [@B406]) ([Fig. 2](#F2){ref-type="fig"}), implying a conserved receptor-ligand--binding mechanism ([@B363]). Two-dimensional NMR experiments indicate that the C-terminal region of GLP-1 (Thr^13^-Lys^34^) is in an *α*-helical conformation in trifluorethanol and dodecylphosphocholine (DPC) micelles, with a less well-defined *α*-helical region around Gly^22^ ([@B461]; [@B340]; [@B475]). NMR studies suggest that exendin-4 adopts a more well-defined single helix (Ser^11^-Lys^27^) than GLP-1 in DPC micelles ([@B340]). These NMR data are in line with ligand-bound GLP-1R ECD crystal structures showing that the GLP-1 is a kinked but continuous *α*-helix (Thr^13^--Val^33^), whereas the truncated exendin~9--39~ is a straighter helix (Leu^10^-Lys^27^) than GLP-1 when bound to GLP-1R ([@B406]; [@B475]). In the ECD-bound crystal structure, the C-terminal *α*-helix of GLP-1 (Ala^24^-Val^33^) is stabilized by interaction with the ECD of GLP-1R, whereas the N-terminal helix (Thr^13^-Glu^21^) does not interact with the ECD. Although it cannot be excluded that the kink in GLP-1 observed in the crystal structure is a result of crystal packing between the N-terminal part of GLP-1 (Gly^10^-Glu^21^) and symmetry-related ECDs, the presence of two helical segments is consistent with the SAR studies with conformationally constrained GLP-1 analogs ([@B308]; [@B328]). Cyclization of (mutated) residues Lys^16^-Glu^20^ and Met^18^-Ala^22^ by a lactam bridge (constraining these regions in an *α*-helical conformation) does not affect binding affinity and activity, whereas cyclization of residues Thr^11^-Asp^15^ even improved potency for GLP-1R compared with the corresponding linear analogs ([@B308]; [@B328]).

Characterization of the stability and conformational changes of full-length, truncated, and GLP-1/exendin-4 chimeric peptides upon binding to the isolated ECD of GLP-1R by far-UV CD, differential scanning calorimetry, and fluorescence spectroscopy measurements demonstrated that exendin-4 has a higher *α*-helical propensity than GLP-1 in solution ([@B405]). Combination of these biophysical data with pharmacological studies showed that there is a positive correlation between the stability and *α*-helical propensity of the ligand in solution and its affinity for the ECD of GLP-1R ([@B405]). Comparison of the crystal structures of GLP-1--bound and exendin~9--39~-bound ECD provides possible explanations for the higher stability of the *α*-helix of exendin-4 as opposed to GLP-1 ([@B406]; [@B475]). Although the *α*-helix of exendin-4 is stabilized by strong intramolecular ionic interactions between Glu^16^/Glu^17^ and Arg^20^ and between Glu^24^ and Lys^27^, corresponding (Gln^23^, Lys^26^) or differentially positioned (Glu^27^, Lys^34^) polar residues in GLP-1 do not form such intramolecular interactions when bound to the isolated ECD of GLP1-R \[Protein Data Bank (PDB): 3IOL\]. The GIP-bound GIP receptor (GIPR) ECD crystal structure indicates that the *α*-helix of GIP is stabilized by similar (Asp^15^-Gln^19^) and alternative (Gln^20^-Asn^24^) intramolecular H-bond interactions ([@B362]), whereas glucagon may also be able to form helix-stabilizing intramolecular H-bond networks (e.g., Asp^21^-Arg^24^, Arg^23^-Asp^27^) ([@B435]). In addition to the higher *α*-helix propensity, the more pronounced amphiphilic nature of exendin-4 enables stronger polar and hydrophobic interactions with the ECD of GLP-1R via opposite sides of the *α*-helix than GLP-1 (vide infra). Moreover, exendin-4 is eight residues longer than GLP-1, and NMR studies have shown that this extended C-terminal region, comprising Ser^32^-Ser^39^, forms a stable tertiary structure that folds around Trp^25^ in trifluorethanol and glycol ([@B340]). This Trp-cage conformation is, however, not observed in NMR studies in DPC micelles ([@B340]) and has weak electron density in the exendin~9--39~-bound ECD GLP-1R crystal structure ([@B406]), suggesting that a stable Trp-cage conformation (which is absent in GLP-1) is only partially populated in the receptor-bound state of exendin-4.

### 2. Flexible N-Terminal Region. {#s14}

NMR and X-ray crystallography studies indicate that the N-terminal regions preceding the conserved *α*-helix of GLP-1 (His^7^-Thr^13^), exendin-4 (His^1^-Thr^7^), GIP (Tyr^1^-Ile^7^), glucagon (His^7^-Thr^13^), and other class B GPCR peptide ligands are flexible in solution as well as in membrane-bound and ligand-bound states ([@B39]; [@B340]; [@B362]; [@B406]; [@B475]). The structure of the N-terminal region of GLP-1 (His^7^-Thr^13^) was not clearly elucidated in NMR studies in DPC micelles due to high conformational flexibility ([@B340]). In the ECD-bound GLP-1 crystal structure, this N-terminal region is unstructured, and no electron density was observed for His^7^-Glu^9^ ([@B475]). Whereas the GLP-1R ECD crystal structures provide atomic details of the molecular interactions of the C-terminal regions of GLP-1 and exendin~9--39~ with the ECD of GLP-1R ([@B406]; [@B475]), these structures do not give information on the receptor-bound conformation of the flexible ligand N terminus, nor on its interactions with GLP-1R. Ligand and receptor mutation studies suggest that an extended flexible conformation of these first residues allows the peptide ligands of class B GPCRs to reach deep into the pocket ([@B197]). This receptor-bound peptide conformation is proposed to be stabilized by an amino acid motif (Thr^11^-Phe^12^-Thr^13^ in GLP) that is conserved in class B GPCR ligands ([@B341]), which can induce an N-capping conformation similar to the one observed in the receptor-bound NMR structure of pituitary adenylate cyclase--activating polypeptide (PACAP) ([@B212]). Substituting three residues in the flexible N terminus of GLP-1 by corresponding PACAP residues (Ala^8^Ser/Glu^9^Asp/Thr^11^Ile) does not affect affinity and potency for GLP-1R ([@B528]), implying that GLP-1 adopts a similar conformation to PACAP upon binding to its receptor. Recently, NMR structures of an 11-mer GLP-1 analog were solved in alterative conformations containing a C-terminal *α*-helix (PDB: 2N08) and an N-terminal *β*-turn (PDB: 2N09), and stabilization of these conformations by cyclization cross-links (PDB: 2N0N and 2N0I) differentially influenced GLP-1R--binding affinity and agonist potency ([@B194]). The accumulated ligand and receptor SAR (see *II*. *Glucagon-Like Peptide-1* and *III*. *Glucagon-Like Peptide-1 Receptor*) suggests that a flexible conformation of the first seven residues allows GLP-1 to interact with residues in the 7TM-binding pocket of GLP-1R, and that the ligand N terminus may adopt a more constrained conformation to activate the receptor.

### 3. Interaction between the C-Terminal Helix and ECD. {#s15}

Comparison of the crystal structures of GLP-1 and exendin~9--39~-bound GLP-1R ECD ([@B406]; [@B475]), GIP-bound GIPR ECD ([@B362]), and the antibody bound glucagon receptor (GCGR) ECD ([@B250]) provides information about similarities and differences in class B GPCR-bound peptide ligand conformations, and gives insights into the structural determinants of class B GPCR ligand recognition and selectivity ([Fig. 2](#F2){ref-type="fig"}). The crystal structures of the ECDs of different class B GPCRs show that this domain has a conserved fold, including two central antiparallel *β*-sheets (*β*~1~-*β*~4~) and an N-terminal *α*-helix (*α*~1~) interconnected by several loops and stabilized by three conserved disulfide bonds ([@B95]; [@B357]; [@B197]) (for more detailed description of the ECD of GLP-1R, see *III.* *Glucagon-Like Peptide-1 Receptor*). Class B GPCR ECD peptide ligand complexes exhibit overall a similar binding mode in which the C terminus of the peptide ligand adopts an *α*-helical conformation that binds between *α*~1~ and *β*~1~--*β*~4~ of the ECD ([@B363]; [@B95]; [@B197]). The conserved structural fold and binding orientation suggest that common mechanisms underlie ligand recognition of class B GPCRs and indicate that peptide ligand selectivity is in part determined by specific interactions of the C-terminal *α*-helix of the ligand with the ECD. The ligand-binding mode observed in the GLP-1R crystal structure is consistent with GLP-1 (vide infra) and GLP-1R (see *III.* *Glucagon-Like Peptide-1 Receptor*) mutation studies, as well as photo cross-linking experiments placing Gly^35^ located in the *α*-helix of GLP-1 in close proximity to E125^ECD^ located in the linker region between the ECD and 7TMD of GLP-1R ([@B58]). The structural details of the ECD and 7TMD of GLP-1R are discussed in detail in *III.* *Glucagon-Like Peptide-1 Receptor*.

The *α*-helices of GLP-1, exendin-4, glucagon, and GIP are amphiphilic, containing a hydrophilic and hydrophobic region at opposite sides of the helix. Conserved apolar residues in the C-terminal part of GLP-1 (Phe^28^, Ile^29^, Leu^32^), exendin-4 (Phe^22^, Ile^23^, Leu^26^), GIP (Phe^22^, Val^23^, Leu^26^), and glucagon (Phe^28^, Val^29^, Leu^32^) share a similar hydrophobic interaction site with the ECD of the corresponding receptor (GLP-1R/GIPR/GCGR: L32^ECD^/A32/M29, T35^ECD^/L35/L32, V36^ECD^/Y36/F33, and W39^ECD^/39/36 in *α*~1~, Y69^ECD^/68/65 in *β*-turn 1 connecting *β*~1~-*β*~2~, Y88^ECD^/87/84, L89^ECD^/88/85, and P90^ECD^/89/86 in *β*-turn 2 connecting *β*~3~-*β*~4~) ([@B362]; [@B406]; [@B475]; [@B250]). Differences in hydrophobic/polar interactions with the N-terminal part of the ligand *α*-helix as well as ligand-specific ionic interactions with the ECD can partially explain the different relative affinities of GLP-1, exendin-4, GIP, and glucagon for the ECD of the corresponding receptor. The positively ionizable Lys^26^ of GLP-1 and homologous Arg^20^ of exendin~9--39~ both form ionic interactions with E128^ECD^ in the C-terminal region of the ECD of GLP-1R. The Lys^27^ residue of exendin~9--39~ forms an additional ionic interaction with E128^ECD^ in GLP-1R ([@B406]; [@B475]), which in combination with the higher *α*-helical propensity of exendin-4 compared with GLP-1 ([@B405]) might explain the increased affinity of exendin-4/exendin~9--39~ for the isolated ECD of GLP-1R compared with GLP-1. There is no ionic interaction between peptide ligand and ECD side chains observed in the GIP-bound GIPR ECD crystal structure and the ECD GCGR-glucagon docking model based on the antibody-bound GCGR and GLP-1--bound GLP-1R crystal structures. It should be noted, however, that the apolar residues of GLP-1 (Val^33^), GIP (Leu^27^), and glucagon (Met^33^) that are aligned with Lys^27^ of exendin~9--39~ form an additional hydrophobic interaction site with the ECD of GLP-1 (Y69^ECD^/L123^ECD^), GIPR (Y68^ECD^ /H115^ECD^), and GCGR (Y65^ECD^/A118^ECD^), respectively. Ala^24^ and Ala^25^ of GLP-1 and Val^19^ in exendin-4 form another hydrophobic interaction surface with *α*~1~ of the ECD of GLP-1R. The structurally aligned Gln^19^ of GIP forms an H-bond network with Asp^15^ and the N-terminal backbone of *α*~1~ of the GIPR ECD (Q30^ECD^ and A32^ECD^), whereas corresponding residues in glucagon (Arg^24^, Ala^25^) may form a polar/apolar interaction site with the N-terminal region of the *α*~1~ helix of GCGR ([Fig. 2](#F2){ref-type="fig"}).

### 4. Interaction between Flexible N terminus and 7TMD. {#s16}

The peptide ligand-bound crystal structures of the ECDs of class B GPCRs (including GLP-1-- and exendin-4--bound GLP-1R, GIP-bound GIPR, and antibody-bound GCGR) do not provide information about the molecular interactions between the receptor and the flexible N-terminal region of peptide ligands. Receptor/ligand mutagenesis and photo cross-linking studies nevertheless indicate that the 7TMD of class B GPCRs determines binding (selectivity) of the flexible N-terminal region of peptide ligands ([@B95]; [@B357]; [@B197]). A recently reported full-length GCGR--glucagon model based on the crystal structures of the GCGR 7TMD ([@B435]), the antibody-bound GCGR ECD ([@B250]), the GLP-1--bound GLP-1R ECD ([@B475]), and the N-capped conformation of PACAP ([@B212]) offers a template for full-length GLP-1--bound GLP-1R models ([Fig. 2A](#F2){ref-type="fig"}) that is consistent with the results of mutation studies of GLP-1 (vide infra), GLP-1R (see *III.* *Glucagon-Like Peptide-1 Receptor*), and other class B GPCRs ([@B197]). This full-length GLP-1R model furthermore satisfies spatial constraints defined by GLP-1R cross-linking studies connecting the following: 1) Ala^24^ in the C-terminal part of the *α***-**helix of GLP-1 to E133^ECD^ in the region linking the ECD and 7TMD of GLP-1R (not solved in the GLP-1R crystal structure); 2) Leu^20^ in the N-terminal part of the *α*-helix of GLP-1 to W297^ECL2^ in ECL2 between TM4 and TM5 in GLP-1R; 3) Phe^12^ and Val^16^ in the flexible N-terminal region of GLP-1 that are positioned near Y145^1.40b^ and L141^1.36b^ in the TM1 of GLP-1R, respectively; and 4) a photolabile probe at position 6 (one position before His^7^) in GLP-1 to Y205^ECL1^ in ECL1 between TM2 and TM3 in GLP-1R ([@B58], [@B59]; [@B306]) ([Fig. 2A](#F2){ref-type="fig"}).

D. Mutagenesis {#s17}
--------------

The molecular determinants of GLP-1R ligand binding and functionality have been investigated extensively using truncated, chimeric, and site-specifically substituted GLP-1, exendin-4, and peptide ligands of closely related class B GPCRs (including glucagon and GIP). This section gives an overview as to how these data complement the structural information on GLP-1 (and the ECD--GLP-1 complex) described above. It should be noted that the current overview only focuses on changes to natural amino acids, as the incorporation of photoactive labels in GLP-1 for GLP-1/GLP-1R cross-linking studies ([@B58], [@B59]; [@B306]) is covered in this section, whereas the development of GLP-1 analogs by other modifications, for example, unnatural amino acid substitution and conjugation ([@B289]), is discussed in *V.* *Pharmaceutical Development and Therapeutics*.

### 1. Truncated GLP-1 Analogs. {#s18}

N-terminally truncated forms of GLP-1 (including des-\[His^7^\]-GLP-1~8--36~ and des-\[His^7^,Ala^8^\]-GLP-1~9--36~) are competitive antagonists of GLP-1R, whereas C-terminally truncated GLP-1 constructs (including des-\[Gly^37^,Arg^36^\]-GLP-1~7--37~) remain agonists ([@B309]; [@B314]). The binding affinities of N-terminally truncated GLP-1 constructs are not affected by mutations in the 7TMD of GLP-1R ([@B4],[@B5]; [@B270]), indicating that interactions between the N-terminal region of GLP-1 and the 7TMD of GLP-1R are required for receptor activation. Most truncated GLP-1 constructs have a decreased affinity for GLP-1R ([@B309]; [@B314]; [@B95]), suggesting that interactions with both the ECD and the 7TMD are important determinants of GLP-1 binding. Similar SARs have been observed for the endogenous ligands of related class B GPCRs, including glucagon/GCGR ([@B478]) and GIP/GIPR ([@B192]), demonstrating that interactions of peptide ligands in the 7TMD of class B GPCRs are required for receptor activation. The N-terminally truncated des-\[His^7^\]-GLP-1~8--36~ and des-\[His^7^,Ala^8^\]-GLP-1~9--36~ variants of GLP-1 have a 100- and 1000-fold lower affinity than that of wild-type, whereas truncation of more than two N-terminal residues further diminishes GLP-1R binding ([@B309]; [@B314]). Truncation of up to three C-terminal residues (Gly^35^, Arg^36^, and Gly^37^) only has a moderate effect on GLP-1R--binding affinity (up to fivefold decrease), but further deletion of C-terminal residues decreases binding affinity significantly. Nevertheless, several undecapeptide GLP-1~7--15~ analogs in which the C-terminal 21 residues are replaced with a biphenylalanine dipeptide have been reported to possess almost the same potency as wild-type GLP-1 ([@B295]).

In contrast to GLP-1, which requires its N-terminal region for high-affinity binding to GLP-1R, the homologous agonist exendin-4 and the N-terminally truncated antagonist exendin~9--39~ have similar affinities for GLP-1R ([@B314]). Although full-length GLP-1R binds exendin-4 and GLP-1 with similar high affinity, the isolated ECD maintains high affinity for exendin-4 and exendin~9--39~, but has decreased affinity for GLP-1 ([@B4]; [@B271]). In addition, GLP-1 binding is more sensitive to site-directed mutagenesis of the 7TMD of GLP-1R than exendin-4 ([@B4],[@B5]; [@B271]; see *III.* *Glucagon-Like Peptide-1 Receptor*). Consistently, radioligand competition studies combining isolated C-terminal (ECD) and N-terminal (7TMD) GLP-1R constructs with native and N-terminally or C-terminally truncated GLP-1 and exendin-4 showed that: 1) GLP-1 binding is primarily determined by interactions with the ECD, but also requires interactions with the 7TMD of GLP-1R; and 2) exendin-4--binding affinity is mainly determined by interactions with the ECD of GLP-1R and does not heavily depend on interactions with the 7TMD ([@B271]). Based on pharmacological studies with truncated GLP-1 and exendin-4, it was further postulated that the eight-residue C-terminal extension of exendin-4 (Trp-cage, see above) may play a role in its superior affinity for the ECD of GLP-1R ([@B4]).

### 2. Chimeric GLP-1 Analogs. {#s19}

Chimeric constructs of GLP-1 in combination with other class B GPCR peptide ligands (including exendin-4, glucagon, GIP, and PACAP) have been used to identify structural determinants of ligand selectivity for GLP-1R (and other class B GPCRs). Radioligand competition studies with truncated and chimeric GLP-1 and exendin-4 peptides suggested that divergent residues in the central part of GLP-1 (Val^16^-Arg^36^) and exendin-4 (Leu^10^-Gly^30^) determine GLP-1/exendin-4 selectivity for the ECD of GLP-1R, and indicated that the Trp-cage only plays a minor role in the increased affinity of exendin-4 for the ECD of GLP-1R compared with GLP-1 ([@B407]). These pharmacological data are consistent with comparative CD and fluorescence spectroscopy, NMR, and X-ray crystallography analyses of (truncated and chimeric forms of) GLP-1 and exendin-4 ([@B405]), implying that the differential affinity for the ECD can be explained by the higher *α*-helical propensity of exendin-4 in solution and by stronger (ionic) interactions between GLP-1R and exendin-4, compared with GLP-1 (see above). GLP-1/glucagon chimera experiments showed that a peptide ligand consisting of the N-terminal part of glucagon combined with the C-terminal part of GLP-1 has high affinity for both GCGR and GLP-1R ([@B193]). Substitution of N-terminal GLP-1 residues with corresponding glucagon residues \[e.g., (Ala^8^Ser/Glu^9^Gln)-GLP-1 and (Val^16^Tyr/Ser^12^Lys)-GLP-1\] maintains high GLP-1R--binding and low GCGR-binding affinities, whereas substitution of N-terminal glucagon residues with corresponding GLP-1 residues decreases GCGR binding and maintains low GLP-1R--binding affinities. In contrast, substitution of C-terminal GLP-1 residues with corresponding glucagon residues decreases GLP-1R binding and maintains low GCGR-binding affinities, whereas replacement of, for example, the last three C-terminal residues of glucagon (Met^33^, Asn^34^, and Thr^35^) with the corresponding GLP-1 residues (Val^33^, Lys^34^, and Gly^35^) and an additional C-terminal GLP-1 residue (Arg^36^) increases GLP-1R binding with affinity for GCGR remaining moderate. Glucagon/GLP-1 chimeras were combined with GCGR/GLP-1R chimeras to identify the receptor domains that interact with N-terminal and C-terminal parts of glucagon and GLP-1 ([@B407]). The chimeric GLP-1-(His^7^-Leu^20^)/glucagon-(Asp^21^-Thr^35^) is unable to bind and activate GCGR, but its binding affinity and potency are rescued by substituting the 7TMD of GCGR with the 7TMD of GLP-1R, suggesting that the N-terminal region of GLP-1 (His^7^-Leu^20^) interacts with the 7TMD of GLP-1R ([@B407]). The GCGR(ECD)/GLP-1R(7TM) chimera has equal binding affinity and potency for GLP-1 and the chimeric glucagon-(His^7^-Leu^20^)/GLP-1-(Asp^21^-Gly^37^), although these are decreased compared with wild-type GLP-1R, indicating that the ECD of GLP-1R is the major determinant of GLP-1/glucagon selectivity by interacting with the C-terminal region of GLP-1. Chimeras combining different N-terminal and C-terminal regions of GLP-1 (His^7^-Leu^20^, Asp^21^-Arg^36^) and GIP (His^1^-Leu^14^, Asp^14^-Lys^30^), or substituting the middle parts of GIP with corresponding residues of GLP-1 (Ser^18^-Ala^24^, Glu^21^-Ala^24^), all had more than 100-fold lower binding affinity for GLP1-R compared with GLP-1-(His^7^-Arg^36^) ([@B175]). Substituting three to five residues in the N-terminal part of GLP-1 by corresponding residues from GIP (His^7^Tyr/Thr^13^Ile/Val^16^Tyr), secretin (Ala^8^Ser/Glu^9^Asp/Asp^15^Glu/Val^16^Leu), vasoactive intestinal peptide (Ala^8^Ser/Glu^9^Asp/Gly^10^Ala/Thr^11^Val), or PACAP (Ala^8^Ser/Glu^9^Asp/Thr^11^Ile/Ser^14^Asp/Asp^15^Ser) diminished ligand potency and decreased binding affinity by more than 10-fold ([@B175]). Substituting two to three residues in the N-terminal part of GLP-1 by corresponding residues from glucagon (Ala^8^Ser/Glu^9^Gln), peptide histidine isoleucine (Glu^9^Asp/Thr^11^Ile), or PACAP (Ala^8^Ser/Glu^9^Asp/Thr^11^Ile), in contrast, had only small effects on affinity for GLP-1R.

### 3. Substituted GLP-1 Analogs. {#s20}

In addition to ligand (and receptor) truncation and chimera studies, several site-directed substitution experiments were performed to provide more detailed information regarding the molecular determinants of GLP-1/GLP-1R binding and selectivity.

#### a. GLP-1 hydrophobic region I. {#s21}

Point substitution of Phe^28^, Ile^29^, and Leu^32^ residues into Ala all had a significant negative impact on GLP-1--binding affinity and potency, confirming the important role of this hydrophobic region I in the C terminus of GLP-1 in binding the ECD of GLP-1R ([@B2]; [@B132]). The effect of substitution on binding affinity (GLP-1 radioligand competition IC~50~) and potency (cAMP activity EC~50~) was, however, much larger for Phe^28^ (1300/1000-fold decrease in affinity/potency) and Ile^29^ (93/27-fold reduction) compared with Leu^32^ (17/twofold decrease), indicating that interactions of Phe^28^ and Ile^29^ with the conserved hydrophobic core of the ECD of GLP-1R are particularly important ([@B2]). Substitution of Ala^24^ by Arg (the corresponding residue in glucagon) did not affect GLP-1 affinity, whereas Val^33^Ala (glucagon mimicking) and Ala^30^Gln mutations only had a moderate 5- to 6-fold effect on GLP-1 affinity ([@B2]). These results imply that apolar interactions of Ala^24^ and Val^33^ with the ECD of GLP-1R \[observed in the GLP-1--bound GLP-1R ECD crystal structure ([@B475])\] are not essential for GLP-1R binding and suggest that GLP-1 residues at positions 24 (Ala/Arg) and 30 (Ala/Gln) are not key determinants of GLP-1R/GCGR selectivity.

#### b. GLP-1 hydrophobic region II. {#s22}

Substitution of Val^16^, Tyr^19^, and Leu^20^ into Ala decreased GLP-1 affinity by six-fold (Val^16^, Leu^20^) to 19-fold (Tyr^19^), and had similar negative effects on potency ([@B2]), showing that Tyr^19^ in particular is an important interaction site in hydrophobic region II located in the middle of the GLP-1 *α*-helix.

#### c. Polar residues in *α*-helix. {#s23}

Alanine substitution of most polar residues in the *α*-helix of GLP-1 had either no significant (Ser^14^, Ser^17^, Ser^18^, Gly^22^, Gln^23^, Trp^32^) or only a moderate 6-fold effect (Lys^26^, Lys^34^) on GLP-1R--binding affinity and potency, with the exception of the three negatively charged residues Asp^15^, Glu^21^, and Glu^27^ ([@B2]). Replacement of Asp^15^ by Ala resulted in a 41-fold decrease in affinity and loss of potency ([@B2]). A recent systematic mutation study combining GLP-1 (Asp^15^Glu, Asp^15^Lys, Asp^15^Arg) and GLP-1R (residues L379^ECL3^R/E, R380^ECL3^D/G, F381^ECL3^R/E) demonstrated that an ionic interaction between Asp^15^ and R380^ECL3^ in the third extracellular loop of GLP-1R is indeed required for ligand recognition and receptor activation ([@B316]). The diminished GLP-1 binding of the GLP-1R R380^ECL3^D mutant was partially restored by Asp^15^Glu substitution and almost fully restored by the Asp^15^Lys and inverted Asp^15^Arg substitutions of GLP-1. The abolished potency of GLP-1 for the GLP-1R R380^ECL3^D was partially restored by the Asp^15^Lys and inverted Asp^15^Arg substitutions. Replacement of Glu^21^ by Ala and Gly significantly decreased GLP-1 affinity by 15-fold and 60-fold, respectively ([@B2]; [@B495]), indicating that the side chain of Glu^21^ plays a key role in GLP-1 binding. Glu^27^Ala substitution had a moderate sixfold effect on binding affinity, but a greater, 240-fold, effect on potency, albeit with a large S.E.M. in the EC~50~ of the mutant ([@B2]). Replacement of Glu^27^ by Lys did not have a significant effect on binding affinity or potency ([@B495]), suggesting that a charged/polar residue at position 27 may facilitate GLP-1R activation, possibly by stabilizing the *α*-helix of GLP-1 and/or stabilizing the active conformation of GLP-1R.

#### d. N-capping motif in GLP-1. {#s24}

Alanine substitution of Thr^11^, Phe^12^, and Thr^13^, the three residues in GLP-1 that are proposed to stabilize the N-capped conformation ([@B212]; [@B341]) of the N terminus of GLP-1, had a significant impact on ligand affinity. The effect of the Thr^11^Ala substitution was, however, smaller (13-fold decrease) compared with Phe^12^Ala and Thr^13^Ala substitutions (133-fold decrease), whereas GLP-1 potency was only significantly affected by the latter two substitutions. These results suggest that Phe^12^ and Thr^13^ play a more important role in stabilizing the N-capped conformation via intramolecular interactions within GLP-1 and/or in stabilizing the activated conformation of GLP-1R via intermolecular interactions with the receptor.

#### e. N terminus of GLP-1. {#s25}

Substitution studies indicate that the electrostatic, steric, and conformational properties of the four residues following the N-capping motif of GLP-1 (His^7^, Ala^8^, Glu^9^, Gly^10^) are important determinants for GLP-1R binding and/or activation. Substitution of His^7^ by Phe did not affect binding affinity or ligand potency, whereas substitution with positively ionizable (Arg, Lys), smaller (Ala), or larger (Trp, GIP-mimicking Tyr) residues diminished binding affinity ([@B2]; [@B175]; [@B131]; [@B412]). Altogether, these amino acid replacement data suggest that a small aromatic residue is required at position 7 that is sterically compatible with the GLP1-R binding site. The Ala^8^-Val and the exendin-4--mimicking Ala^8^-Gly mutants only showed a small (two- to threefold) decrease in binding affinity and potency, the Ala^8^-Ser analog displayed moderate to large impact (4- to 10-fold) on binding affinity, whereas substitution of Ala^8^ with Leu or Thr reduced GLP-1R binding ([@B2]; [@B175]; [@B86]; [@B45]). These observations demonstrate that only small residues are tolerated at position 8, suggesting that steric constraints of the GLP-1R binding site and/or conformational flexibility of the N-terminal region around Ala^8^ play a crucial role in GLP-1 binding. Substitution of Glu^9^ with Asp, Met, or Leu did not significantly affect ligand affinity/potency; substitution with Ser, Tyr, Phe, or Pro moderately decreased affinity (5- to 10-fold); whereas replacement with Ala, Lys, and Val reduced ligand binding ([@B528]; [@B156], [@B157]; [@B412]). The substitution data of Glu^9^ indicate that residues with similar negative charge (Asp) or comparable size (Met, Leu) are preferred, and positively charged moieties (Lys) are not tolerated at position 9. Substitution of Gly^10^ by Ala, Asp, Glu, His, Lys, or Arg diminished both GLP-1 affinity and potency ([@B2]; [@B316]), demonstrating the essential function of this residue in GLP-1R binding. Combined GLP-1 and GLP-1R mutation studies showed that diminished binding affinity and potency of GLP-1 for the GLP-1R R380^ECL3^D mutant could, for a small part, be recovered by the GLP-1 Gly^10^-Arg mutant ([@B316]), indicating that the Gly/Arg^10^ is in the vicinity of R/D380^ECL3^.

In summary, combining GLP-1 truncation, chimera, and point substitution studies presented in this section with structural information on GLP-1 conformation and interactions with GLP-1R and GLP-1R mutation data, a binding model for the full-length GLP-1--GLP-1R complex can be proposed ([Fig. 2](#F2){ref-type="fig"}), in which: 1) hydrophobic region I in the C-terminal *α*-helix of GLP-1 consisting of Phe^28^, Ile^29^, and Leu^32^ binds the ECD (as observed in the GLP-1--bound GLP-1R ECD crystal structure); 2) a second hydrophobic region II in the middle of GLP-1 (Val^16^, Tyr^19^, Leu^20^) interacts with the region connecting the ECD and 7TMD (the so-called stalk region in the GCGR crystal structure); 3) the N terminus (His^7^-Thr^13^) of glucagon interacts with the 7TMD in a so-called N-capped conformation (stabilized by Thr^11^, Phe^12^, Thr^13^). In addition to these main determinants of GLP-1/GLP-1R binding, other residues in the C-terminal/*α*-helical region can play an important role in stabilizing and maintaining the amphiphilic character of the *α*-helix of GLP-1 or by forming additional hydrophobic (Ala^24^/Ala^25^ with the ECD) or ionic/polar (Lys^26^ with the ECD, D^15^ with ECL3) interaction sites with GLP-1R.

III. Glucagon-Like Peptide 1 Receptor {#s26}
=====================================

A. Discovery {#s27}
------------

Between 1979 and early 1980, Habener and colleagues found that 29--amino-acid pancreatic glucagon was the major bioactive peptide released from the pancreatic islets ([@B151]; [@B275]). The anglerfish islet was thus regarded as a rich source containing coding sequences for glucagon-related peptides. Hybrid arrest and hybrid selection of mRNAs encoding two preproglucagons led to the first identification of a cDNA encoding a 29-residue peptide highly homologous to mammalian glucagon ([@B152]; [@B277]), which was then used as a hybridization probe to screen the anglerfish islet cDNA library for other cDNAs to derive the entire coding sequence of anglerfish preproglucagon ([@B276]).

In 1982, the first mammalian (hamster) pancreatic preproglucagon cDNA was reported ([@B30]), which resulted in the rapid isolation and sequencing of the human glucagon gene ([@B31]), followed by bovine and rat preproglucagon cDNAs ([@B186]). These landmark discoveries led to our current concepts of GLP-1 as an incretin and a satiety hormone ([@B108]; [@B251]; [@B101]; [@B298]). It was found that truncated forms of GLP-1 are also biologically active in stimulating both insulin gene transcription and insulin secretion ([@B310]; [@B98]; [@B122]; *II*. Glucagon-Like Peptide-1).

### 1. Receptor Cloning. {#s28}

To better understand the action of GLP-1, Thorens isolated and characterized the first cDNA of the rat pancreatic *β* cell GLP-1 receptor in 1992 ([@B459]), followed by cloning of the human receptor in 1993 ([@B91]; [@B155]; [@B460]), revealing a sequence of 463 residues. This deduced primary sequence resembled that of the receptors for secretin, parathyroid hormone, and calcitonin, and hence enabled it to be classified within what was then a new branch of the GPCR superfamily (family B, class B, or secretin receptor-like) that now includes 15 members ([@B426]; [@B195]).

### 2. Receptor Expression. {#s29}

Using RNA enzyme protection techniques, GLP-1R was found widely expressed in the human and mouse pancreas, lung, brain, stomach, heart, and kidney, but was not seen in tissues involved in glucose metabolism, such as the liver, skeletal muscle, and fat ([@B100]). DNA hybridization experiments showed that the human GLP-1R (*hGLP-1R*) gene is localized to chromosome 6p21, and the size is 40 kb, containing about 14 exons. Both human and rat receptors contain 463 amino acids, whereas that of the mouse has 489 amino acids, displaying a homology with hGLP-1R of 91% and 84%, respectively. Although the expression levels of GLP-1R vary among different tissues and cell types, Northern hybridization studies demonstrated that its expression in pancreatic islets, heart, and lungs is significantly higher ([@B100]). In addition, GLP-1R was also found in the lateral septum, thalamus, and hippocampus of the rat brain, and the cDNA fragment cloned from the brain, heart, and pancreas encodes the same amino acids of the receptor, suggesting its physiologic relevance in the cardiovascular and central nervous systems ([@B414]).

It is known that the expression of GLP-1R in the islets of Langerhans is regulated by glucose and dexamethasone, but not by the PKA-dependent signaling pathway ([@B1]). Starvation and refeeding could influence its expression in the rat hypothalamus and other sites of the CNS ([@B281]). Although our knowledge about the transcriptional regulation mechanisms of GLP-1R is still limited, promoter analysis indicate that 1) transcription factors Sp1 and Sp3 may play important regulatory roles and 2) homologous desensitization and internalization are closely related to the intracellular sites of 441/442, 444/445, and 451/452 ([@B514]).

### 3. Receptor Biosynthesis. {#s30}

About 5--10% of GPCRs contain an N-terminal cleavable signal peptide ([@B424]). Most GPCRs mediate the integration of receptor into cell membrane by a signal anchor sequence that is located at the first TMD ([@B16]; [@B491]). Both types of signal sequences regulate the endoplasmic reticulum (ER) signal process at the beginning of the secretory pathway ([@B29]; [@B238]).

The signal peptide is a sequence of approximately 20 amino acids in the N terminus of the receptor that includes a polar and charged N-terminal (n) region, a central hydrophobic (h) region, and a polar C-terminal (c) region ([@B421]; [@B65]). The C-terminal side regularly contains helix-breaking proline and glycine residues and small uncharged residues at positions 1 and 3 of the cleavage site. After synthesis of the receptor\'s N-tail in the cytoplasm, the translation ceases by its binding to the signal recognition particle (SRP) ([@B171]; [@B430]). A translocon complex is attached to the membranes of ER that includes a GTP-dependent interaction between SRP and SRP receptor, translocon gating, protein synthesis, and integration of nascent chains with the bilayer ([@B238]). The signal peptide is finally cleaved off by signal peptidases on the ER membrane. In contrast, signal anchor sequences are not cleaved and form a part of the mature protein ([@B16]; [@B491]; [@B191]; [@B424]). In addition to recognition and binding of SRP and translocation to ER, the N-terminal signal sequence may play key roles in protein folding and trafficking. This is highly dependent upon whether the signal sequence is a cleaved signal peptide or an uncleaved signal anchor.

For GLP-1R, studies on the signal peptides of corticotropin-releasing factor-1 receptor (CRF~1~R) and corticotropin-releasing factor-2 receptor give a good model to compare. Both CRF receptors exhibit a high probability of N-terminal cleavable signal peptide by computational prediction. In reality, however, only the signal peptide of CRF~1~R is cleaved, whereas that of corticotropin-releasing factor-2 receptor is translocated and embedded to the plasma membrane by taking TM1 as a signal anchor sequence. It is thus integrated to be a part of the N-terminal ECD: not mediating ER targeting, but contributing to receptor activation ([@B8]). Interestingly, a mutant of rat CRF~1~R without the signal peptide sequence was able to translocate to the cell surface and display similar biologic function to the wild-type. The rat CRF~2a~R contains an uncleaved N-terminal signal peptide, and deletion of this resulted in a significant reduction in its membrane expression, suggesting that receptor transportation was affected ([@B408]). The complexity of these signal sequences highlights the need for experimental verification of the role of the signal sequence in GLP-1R.

According to the signal peptide prediction program "SignalP 4.0" ([@B343]; [@B32]), the sequence of the first 23 amino acids in GLP-1R fits all the criteria of an N-terminal signal peptide. The existence of a functional signal peptide was demonstrated experimentally by [@B207], who showed that it was required for GLP-1R synthesis and was cleaved thereafter. Mutation of the signal peptide (A21-R) resulted in retention of the receptor within ER, whereas mutation of E34-R augmented its cell surface expression when the signal peptide was deleted. The amino acid sequence following the signal peptide in the GLP-1R, G27^ECD^-W39^ECD^, is relatively hydrophobic, and this region may be recognized by SRP ([@B207]). [@B137] went deep into the function of this signal peptide by use of constructs containing epitope tags at the N and/or C terminus. A mutant GLP-1R without the signal peptide sequence was expressed in human embryonic kidney (HEK) 293 cells and displayed normal functionality with respect to ligand binding and cAMP activation, suggesting that the putative signal peptide may not be required for receptor synthesis. Immunoblotting analysis showed that the amount of GLP-1R synthesized in HEK293 cells was low without the signal peptide, indicating its role in facilitating receptor expression ([@B137]). Epitope tags at the N terminus of GLP-1R were detectable by immunofluorescence and immunoblotting, an observation that is inconsistent with another report that studied both signal peptide and the hydrophobic region after the signal peptide. It was found that the signal peptide was cleaved in the mature hGLP-1R, and cell surface expression was almost abolished by the mutation A21-R that prevented the cleavage, demonstrating that hydrophobic region after the signal peptide is necessary for efficient hGLP-1R trafficking to the cell surface. Because glycosylation is vital to cell surface expression, cleavage of the signal peptide will affect this process. In addition, mutating W39^ECD^, Y69^ECD^, and Y88^ECD^ of hGLP-1R to alanine eliminated its cell surface expression without influencing N-linked glycosylation and cleavage of the signal peptide ([@B457]).

Clearly, such discrepancies may not only reflect differences in the methods employed among these three studies, but also the cellular background and the complexity of the underlying mechanism(s).

B. Structure {#s31}
------------

The human GLP-1R is a 463-residue glycoprotein containing an N-terminal signal peptide and various glycosylation sites that are essential for the correct trafficking and processing of the receptor ([@B459]; [@B91]; [@B155]; [@B460]; [@B145]; [@B57]; [@B207]). Like all class B GPCRs, GLP-1R possesses an N-terminal ECD of 100--150 residues connected to an integral TM domain (7TM) that is typical of all GPCRs, having seven *α*-helices (TM1--TM7) separated by ICL1--ICL3 and ECL1--ECL3 ([@B358]; [@B435]). However, despite this structural resemblance to other GPCRs, the sequence of the class B 7TMD is devoid of the consensus sequence motifs that typify the class A GPCRs (e.g., rhodopsin and adrenergic receptors). In contrast, the N-terminal ECD of class B GPCRs is a unique domain found only in this GPCR subfamily and is central to ligand recognition. Class B GPCRs are believed to all bind their peptide ligands via a common mechanism known as the two-domain model, in which the ECD first binds to the C-terminal region of the ligand, enabling a second interaction between the N-terminal region of the ligand and the 7TMD of the receptor ([@B33]; [@B195]).

### 1. N-Terminal Domain. {#s32}

#### a. Structure determination of the N-terminal ECD. {#s33}

The two-domain structure of GLP-1R enabled a strategy whereby the ECD could be expressed as an isolated domain suitable for structural and functional studies that were used to demonstrate its critical role in ligand binding ([@B517]; [@B529]; [@B27]; [@B4]; [@B271]; [@B292], [@B294]; [@B405], [@B406]; [@B475]). The definitive study came from X-ray crystallography whereby the isolated ECD of hGLP-1R from an *Escherichia coli* inclusion body preparation was incubated with the peptide antagonist exendin~9--39~, before being further purified, crystallized, and analyzed using X-ray diffraction to yield a 2.2Å crystal structure ([@B406]). The protein fold closely resembles that of other class B GPCR ECD structures ([@B363]) and contained two regions of antiparallel *β*-sheet, three disulfide bonds (46^ECD^--71^ECD^, 62^ECD^--104^ECD^, and 85^ECD^--126^ECD^), and an N-terminal *α*-helix. The core of the structure contains six conserved residues (D67^ECD^, W72^ECD^, P86^ECD^, R102^ECD^, G108^ECD^, and W110^ECD^), which are critical for the folding stability. Residues on the *α*-helix, turn 1, loop 2, and the C-terminal region form a ligand-binding groove for the antagonist's well-defined *α*-helix (Leu^10^-Asn^28^) that interacts with the ECD using residues within the Glu15^ECD^-Ser32^ECD^ region, the most critical residues being Val19^ECD^, Phe22^ECD^, Ile23^ECD^, and Leu26^ECD^, which are deeply buried in the ECD's groove. The residues on the N-terminal side of Glu^15^ of exendin~9--39~ do not interact with the ECD, although residues 10--14 are nevertheless critical for high-affinity binding ([@B405]), presumably because they are required to stabilize the helical structure of the ligand. The nine-residue C-terminal extension of exendin~9--39~, which has no equivalent in GLP-1, plays no significant role in the peptide's affinity at hGLP-1R ([@B405]; [@B294]). A later crystal structure showed that GLP-1 also forms an *α*-helix when bound to the ECD, with the principal contacts being the equivalent hydrophobic interface formed by residues Ala^24^, Ala^25^, Phe^28^, Ile^29^, Leu^32^, and Val^33^ ([@B475]). In contrast to that in exendin~9--39~, the ECD-bound *α*-helix of GLP-1 is kinked around Gly^22^, as observed in earlier NMR studies ([@B461]). The modest eightfold differential affinity between exendin-4 and GLP-1 at the isolated membrane-bound ECD of hGLP-1R ([@B294]) could largely be explained through E127^ECD^, which interacts with exendin~9--39~ but not GLP-1, where mutagenesis to Ala resulted in a sevenfold reduction in affinity for exendin~9--39~ ([@B475]; [@B364]). Leu32^ECD^ also appears to play a role in ligand selectivity, although it is less clear from the crystal structure how this occurs: substitution of Leu32^ECD^ by Ala had no effect upon GLP-1 affinity or potency but did reduce exendin~9--39~ affinity by sevenfold and Gly^2^--GLP-1 by 10-fold ([@B475]; [@B364]).

#### b. Site-directed mutagenesis of the ECD. {#s34}

The N-terminal domain has been the subject of a number of mutagenesis studies summarized in [Table 1](#T1){ref-type="table"} and [Fig. 3](#F3){ref-type="fig"} ([@B518]; [@B462]; [@B294]; [@B475]; [@B79]; [@B248]; [@B364]). Residues that have been mutated but do not greatly affect GLP-1 affinity/efficacy include P7^ECD^L, R20^ECD^K, L32^ECD^A, T35^ECD^A, V36^ECD^A, R44^ECD^H, E68^ECD^A, L123^ECD^A, E127^ECD^A, E127^ECD^Q, E128^ECD^A, E128^ECD^Q, and E128^ECD^M. To study a species-selective small-molecule antagonist, [@B462] mutated W33^ECD^ to Ser (the human to rat GLP-1R substitution), as well as to various other residue types, showing that there was no effect on GLP-1 albeit that the affinity and potency values were not given for the peptide ligands used. [@B518] substituted six Trp residues in the ECD with Ala and found that, whereas W87A behaved like wild-type GLP-1R in binding and cAMP assays, the remaining substitutions at 39, 72, 91, 110, and 120 resulted in the abolition of detectable radioligand binding. Modest five- to eightfold reductions in GLP-1 potency have been observed for E68^ECD^K, P90^ECD^A, and R121^ECD^A ([@B475]; [@B79]). The ECD structures suggest that E68^ECD^ is close to the C-terminal region of the peptide ligand, but, although it appears to have little significant interaction with exendin~9--39~ in the human receptor, the equivalent residue in rat GLP-1R, D68^ECD^, enhances exendin~9--39~ affinity by forming a hydrogen bond with Ser^32^ of the peptide ([@B294]). Other mutations, Y69^ECD^A, Y88^ECD^A, and L89^ECD^A, have caused catastrophic effects on the ability of the receptor to be detected in binding or signaling assays ([@B475]).

###### 

Summary of effects on GLP-1 pharmacology (affinity and ability to activate cAMP pathway) in published site-directed mutagenesis studies of GLP-1R

WT (wild-type) refers to mutations that resulted in either \<fivefold or no statistically significant change from wild-type GLP-1R. ND (not determinable) refers to a property that was measured, but for which a value was not determinable. Blank cells mean that the assays used to estimate that particular pharmacological property were not carried out in the cited work. Residues with symbol **[^†^](#t1n1){ref-type="table-fn"}** refer to data from rat GLP-1R (if different, the equivalent human residue number is displayed in the table to aid comparison). GLP-1 affinity or potency fold-change values with suffix **^M^** are from membrane preparations, whereas suffix **^C^** is from whole-cell assays. Cell surface expression values below 75% of WT are shown (\>75% are shown as WT): a suffix **^E^** represents estimation from ELISAs; suffix **^mic^** was evaluated from immunofluorescent microscopy; suffix **^cyt^** was evaluated by flow cytometry with an anti-Flag antibody; suffix **^Ag^** refers to affinity or cell surface expression levels determined from agonist radioligand-binding assays, whereas suffix **^Ant^** was from antagonist radioligand-binding assays. ΔLog *τ*~c~ values relative to WT are shown where \>0.5 and were calculated from data where the expression-corrected efficacy term *τ*~c~ had been calculated using the operational model of agonism, as defined in Wootten et al. (2013c). Residues with transmembrane helices are numbered according to Wootten et al. (2013c).

  Residue                                                                        Mutated to                          -Fold Reduction Affinity   -Fold Reduction Potency^‡^   Cell Surface Expression (% Wild-Type)   Comments and/or Other Observed Effects                                                                                          Reference
  ------------------------------------------------------------------------------ ----------------------------------- -------------------------- ---------------------------- --------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- ------------------
  P7^ECD^                                                                        L                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B248]
  R20^ECD^                                                                       K                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B248]
  L32^ECD^                                                                       A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  L32^ECD^                                                                       A                                                              WT                                                                                                                                                                                                   [@B364]
  W33^ECD^                                                                       S                                   WT^C,Ant^                                                                                       Species change (human to rat)--- the expected lack of effect on GLP-1 pharmacology was implied in text, but no data are shown   [@B462]
  T35^ECD^                                                                       A                                   WT                                                      7%^Ag^                                                                                                                                                                  [@B475]
  Val-36^ECD^                                                                    A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  W39^ECD^[^†^](#t1n1){ref-type="table-fn"}                                                                          ND^C,Ag^                                                                                        Membrane expression confirmed via WB                                                                                            [@B518]
  R44^ECD^                                                                       H                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B248]
  N63^ECD^                                                                       L                                   WT^C,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B57]
  E68^ECD^                                                                       A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  E68^ECD^                                                                       K                                                              8                                                                                                                                                                                                    [@B79]
  Y69^ECD^                                                                       A                                   ND^M,Ag^                   ND                                                                   ND^Ag^                                                                                                                          [@B475]
  W72^ECD^[^†^](#t1n1){ref-type="table-fn"}                                                                          ND^C,Ag^                                                                                        Membrane expression confirmed via WB                                                                                            [@B518]
  N82^ECD^                                                                       L                                   WT^C,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B57]
  W87^ECD^                                                                                                           WT^C,Ag^                   WT                           24--62%                                 Transient and stable cell lines analyzed                                                                                        [@B518]
  Y88^ECD^                                                                       A                                   ND^M,Ag^                   ND                                                                   ND^Ag^                                                                                                                          [@B475]
  L89^ECD^                                                                       A                                   ND^M,Ag^                   ND                                                                   ND^Ag^                                                                                                                          [@B475]
  Pro-90^ECD^                                                                    A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  W91^ECD^[^†^](#t1n1){ref-type="table-fn"}                                                                          ND^C,Ag^                                                                                        Membrane expression confirmed via WB                                                                                            [@B518]
  W110^ECD^[^†^](#t1n1){ref-type="table-fn"}                                                                         ND^C,Ag^                                                                                        Membrane expression confirmed via WB                                                                                            [@B518]
  N115^ECD^                                                                      L                                   WT^C,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B57]
  W120^ECD^[^†^](#t1n1){ref-type="table-fn"}                                                                         ND^C,Ag^                                                                                        Membrane expression confirmed via WB                                                                                            [@B518]
  R121^ECD^                                                                      A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  L123^ECD^                                                                      A                                   WT^M,Ag^                   WT                           47%^Ag^                                                                                                                                                                 [@B475]
  E127^ECD^                                                                      A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  E127^ECD^                                                                      A                                                              WT                                                                                                                                                                                                   [@B364]
  E127^ECD^                                                                      E                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  E128^ECD^                                                                      A                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  E128^ECD^                                                                      A                                                              WT                                                                                                                                                                                                   [@B364]
  E128^ECD^                                                                      Q                                   WT^M,Ag^                   WT                           WT^Ag^                                                                                                                                                                  [@B475]
  E128^ECD^                                                                      M                                                              WT                                                                                                                                                                                                   [@B79]
  R131^1.26b^                                                                    N                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B248]
  L141^1.36b^                                                                    A                                   WT^C,Ag^                   WT                           67%^cyt^                                                                                                                                                                [@B534]
  Y145^1.40b^                                                                    A                                   WT^C,Ag^                   WT                           47%^cyt^                                                                                                                                                                [@B534]
  Y148^1.43b^                                                                    A                                   ND^C,Ag^                   26                           WT^cyt^                                                                                                                                                                 [@B534]
  Y148^1.43b^                                                                    N                                   15^C,Ag^                   8                            WT^cyt^                                                                                                                                                                 [@B534]
  Y148^1.43b^                                                                    F                                   ND^C,Ag^                   14                           WT^cyt^                                                                                                                                                                 [@B534]
  Y148^1.43b^                                                                    F                                   10^C,Ant^                  14                           WT^cyt^                                                                                                                                                                 [@B534]
  T149^1.44b^                                                                    M                                   60^C,Ant^                  14--33                       WT^E^ ^&^ ^Ant^                                                                                                                                                         [@B28]
  T149^1.44b^                                                                    M[\*](#t1n2){ref-type="table-fn"}   250^C,Ant^                 160                          \<50%^E^                                E~max~ = ND                                                                                                                     [@B248]
  For additional residue substiutions, see [@B246]                                                                                                                                                                                                                                                                                                   
  T149^1.43b^                                                                    M                                   ND^C,Ag^                   59                           WT^cyt^                                                                                                                                                                 [@B534]
  T149^1.43b^                                                                    A                                   ND^C,Ag^                   82                           WT^cyt^                                                                                                                                                                 [@B534]
  T149^1.43b^                                                                    S                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  Y152^1.47b^                                                                    A                                   30^M,Ant^                  ND                           7%^Ant^                                                                                                                                                                 [@B68]
  Y152^1.47b^                                                                    H                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  S155^1.50b^                                                                    A                                   WT^C,Ant^                  10                           55%^E^, 48%^Ant^                        ΔLog *τ*~c~ = 0.75                                                                                                              [@B525]
  G168^ICL1^                                                                     S                                   WT^C,Ant^                  WT                           \<50%^E^                                                                                                                                                                [@B248]
  F169^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  R170^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  H171^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  L172^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                35%^Ag^                                 WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  H173^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                48%^Ag^                                 WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  C174^ICL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                45%^Ag^                                 37% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  C174^ICL1^                                                                     A                                                              6                                                                                                                                                                                                    [@B476]
  C174^ICL1^                                                                     S                                                              7                                                                                                                                                                                                    [@B476]
  T175^2.45b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                57%^Ag^                                 WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  R176^2.46b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                   13                           WT^Ag^                                  26% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  N177^2.47b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                22%^Ag^                                 43% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  H180^2.50b^[^†^](#t1n1){ref-type="table-fn"}                                   R                                   21^C,Ag^                                                WT^mic^                                                                                                                                                                 [@B187]
  H180^2.50b^                                                                    A                                   ND^C,Ant^                  12                           18%^E^, ND^Ant^                         ΔLog *τ*~c~ = 0.86                                                                                                              [@B525]
  N182^2.52b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                24%^Ag^                                 "36% of WT" cAMP                                                                                                                [@B529]
  S186^2.56b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E,Ant^                                                                                                                                                               [@B525]
  F187^2.57b^                                                                    A                                   ND^C,Ag^                   ND                           5%^cyt^                                                                                                                                                                 [@B534]
  R190^2.60b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   \>20^C,Ag^                                              21%^Ag^                                 "27% of WT" cAMP                                                                                                                [@B529]
  R190^2.60b^                                                                    A                                   32^M,Ant^                  270                          7%^Ant^                                                                                                                                                                 [@B68]
  R190^2.60b^                                                                    A                                   20^C,Ant^                  34                           53%^E^, 44^Ant^                         ΔLog *τ*~c~ = 0.53                                                                                                              [@B525]
  R190^2.60b^                                                                    A                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  R190^2.60b^                                                                    K                                   ND^C,Ag^                   17                           WT^cyt^                                                                                                                                                                 [@B534]
  R190^2.60b^                                                                    K                                   32^C,Ant^                  17                           WT^cyt^                                                                                                                                                                 [@B534]
  L192^2.62b^                                                                    S                                                              WT                                                                                                                                                                                                   [@B477]
  L192^2.62b^                                                                    S                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  V194^2.64b^                                                                    A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  F195^2.65b^                                                                    L                                                              WT                           59%^Ag^                                                                                                                                                                 [@B477]
  I196^2.66b^[^†^](#t1n1){ref-type="table-fn"}                                   S                                   WT^C,Ag^                   ND                                                                                                                                                                                                   [@B315]
  K197^2.67b^                                                                    A                                   28^M,Ant^                  630                          57%^Ant^                                                                                                                                                                [@B68]
  K197^2.67b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   5^C,Ag^                                                 30%^Ag^                                 "25% of WT" cAMP                                                                                                                [@B529]
  K197^2.67b^                                                                    A                                   ND^C,Ag^                   ND                           51%^cyt^                                                                                                                                                                [@B534]
  K197^2.67b^                                                                    I                                   ND^C,Ag^                   ND                           51%^cyt^                                                                                                                                                                [@B534]
  K197^2.67b^                                                                    I                                   28^C,Ant^                  ND                           51%^cyt^                                                                                                                                                                [@B534]
  K197^2.67b^                                                                    Q                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  K197^2.67b^                                                                    R                                   ND^C,Ag^                   23                           WT^cyt^                                                                                                                                                                 [@B534]
  D198^2.68b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   10^C,Ag^                                                16%^Ag^                                 "45% of WT" cAMP                                                                                                                [@B529]
  D198^2.68b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   63^M,Ant^                  44                           WT^Ant^                                                                                                                                                                 [@B269]
  D198^2.68b^                                                                    A                                   43^M,Ant^                  977                          66%^Ant^                                                                                                                                                                [@B68]
  D198^2.68b^                                                                    A                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  D198^2.68b^[^†^](#t1n1){ref-type="table-fn"}                                   N                                   WT^M,Ag^                                                                                                                                                                                                                        [@B269]
  D198^2.68b^                                                                    N                                   ND^C,Ag^                   89                           WT^cyt^                                                                                                                                                                 [@B534]
  D198^2.68b^                                                                    E                                   ND^C,Ag^                   434                          WT^cyt^                                                                                                                                                                 [@B534]
  D198^2.68b^                                                                    E                                   58^C,Ant^                  434                          WT^cyt^                                                                                                                                                                 [@B534]
  A200-L201[^†^](#t1n1){ref-type="table-fn"}                                     V/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  L201^2.68b^                                                                    A                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  K202^ECL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                45%^Ag^                                 "71% of WT" cAMP                                                                                                                [@B529]
  K202/W203[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  W203^ECL1^                                                                     T                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  M204/Y205[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 37^M,Ant^                  51                           28%^Ant^                                                                                                                                                                [@B270]
  M204/Y205[^†^](#t1n1){ref-type="table-fn"}                                     V/A                                 23^M,Ag^                   32                           WT^Ant^                                                                                                                                                                 [@B270]
  M204/Y205[^†^](#t1n1){ref-type="table-fn"}                                     A/V                                 29^M,Ag^                   87                           WT^Ant^                                                                                                                                                                 [@B270]
  M204^ECL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^M,Ag^                   WT                           44%^Ant^                                                                                                                                                                [@B270]
  M204^ECL1^                                                                     A                                   ND^C,Ag^                   334                          WT^cyt^                                                                                                                                                                 [@B534]
  M204^ECL1^                                                                     R                                   ND^C,Ag^                   93                           WT^cyt^                                                                                                                                                                 [@B534]
  Y205^ECL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^M,Ag^                   WT                           WT^Ant^                                                                                                                                                                 [@B270]
  Y205^ECL1^                                                                     A                                   ND^C,Ag^                   62                           WT^cyt^                                                                                                                                                                 [@B534]
  S206/T207[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  A208/A209[^†^](#t1n1){ref-type="table-fn"}                                     V/V                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  Q210Q211[^†^](#t1n1){ref-type="table-fn"}                                      A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  Q211^ECL1^                                                                     D                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  Q211^ECL1^                                                                     R                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  H212^ECL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  "WT cAMP"                                                                                                                       [@B529]
  H212^ECL1^                                                                     A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  H212/Q213[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  D215^ECL1^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                51%^Ag^                                 "57% of WT" cAMP                                                                                                                [@B529]
  W214^ECL1^                                                                     V                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  W214/D215[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  G216/L217[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  L217^ECL1^                                                                     A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  L218/S219[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  Y220/Q221[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  Y220^ECL1^                                                                     D                                   ND^C,Ag^                   105                          WT^cyt^                                                                                                                                                                 [@B534]
  D222^3.25b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  "82% of WT" cAMP                                                                                                                [@B529]
  D222/S223[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  L224/G225[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  C226^3.29b^[\*](#t1n2){ref-type="table-fn"}[^†^](#t1n1){ref-type="table-fn"}   A                                   25^M,Ant^                  38                           65%^Ant^                                                                                                                                                                [@B293]
  C226^3.29b^                                                                    A                                                              \>90                                                                                                                                                                                                 [@B476]
  R227^3.30b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   \>20^C,Ag^                                              31%^Ag^                                 "90% WT" cAMP                                                                                                                   [@B529]
  R227/L228[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  V229/F230[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B270]
  L232/M233[^†^](#t1n1){ref-type="table-fn"}                                     V/T                                 10^C,Ag^                   100                                                                                                                                                                                                  [@B315]
  M233^3.36b^                                                                    A                                   ND^C,Ag^                   70                           WT^cyt^                                                                                                                                                                 [@B534]
  M233^3.36b^                                                                    A                                   16^C,Ant^                  70                           WT^cyt^                                                                                                                                                                 [@B534]
  M233^3.36b^                                                                    T                                   ND^C,Ag^                   62                           WT^cyt^                                                                                                                                                                 [@B534]
  M233^3.36b^                                                                    F                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  Q234^3.37b^                                                                    A                                   13^M,Ant^                  45                           27%^Ant^                                                                                                                                                                [@B68]
  Q234^3.37b^                                                                    A                                   ND^C,Ag^                   151                          35%^cyt^                                                                                                                                                                [@B534]
  Q234^3.37b^                                                                    N                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  Q234^3.37b^                                                                    E                                   ND^C,Ag^                   29                           69%^cyt^                                                                                                                                                                [@B534]
  Q234^3.37b^                                                                    E                                   17^C,Ant^                  29                           69%^cyt^                                                                                                                                                                [@B534]
  Y235^3.38b^                                                                    A                                   24^M,Ant^                  23                           12%^Ant^                                                                                                                                                                [@B68]
  C236^3.39b^                                                                    A                                                              WT                                                                                                                                                                                                   [@B476]
  N240^3.43b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   \>20^C,Ag^                                              14%^Ag^                                 "8% WT" cAMP                                                                                                                    [@B529]
  N240^3.43b^                                                                    A                                   WT^C,Ant^                  7                            WT^E,Ant^                               ΔLog *τ*~c~ = 0.67                                                                                                              [@B525]
  N240^3.43b^                                                                    Q                                   WT^C,Ant^                  WT                           WT^E,Ant^                                                                                                                                                               [@B526]
  N240/Q394                                                                      A/A                                 WT^C,Ant^                  WT                           71%^E,Ant^                              ΔLog *τ*~c~ = 0.70                                                                                                              [@B526]
  N240/Q394                                                                      Q/N                                 5^C,Ant^                   WT                           71%^E,Ant^                                                                                                                                                              [@B526]
  Y241^3.44b^                                                                    A                                                              WT                           42%^Ag^                                                                                                                                                                 [@B477]
  Y241^3.44b^                                                                    A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  E247^3.50b^                                                                    A                                   WT^C,Ag^                                                64%^Ag^                                 "39% WT" cAMP                                                                                                                   [@B529]
  E247^3.50b^                                                                    A                                   ND^C,Ant^                  14                           18%^E^, ND^Ant^                         ΔLog *τ*~c~ = 0.99                                                                                                              [@B525]
  F260^ICL2^                                                                     L                                   WT^C,Ant^                  WT                           \<50%^E^                                                                                                                                                                [@B248]
  E262^ICL2^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  Q263^ICL2^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  R264^ICL2^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  I265^ICL2^[^†^](#t1n1){ref-type="table-fn"}                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  F266^4.42b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  K267^4.43b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  L268^4.44b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  L278^4.54b^                                                                    M                                                              WT                                                                                                                                                                                                   [@B477]
  W284^4.60b^                                                                    A                                   32^M,Ant^                  1349                         34%^Ant^                                                                                                                                                                [@B68]
  G285^4.61b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  I286^4.62b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  V287^4.63b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  I286/V287                                                                      A/A                                                            WT                                                                   85% SB^M,Ag^                                                                                                                    [@B92]
  K288^4.64b^                                                                    A                                   126^C,Ant^                 ND                           WT^E^                                                                                                                                                                   [@B245]
  K288^4.64b^                                                                    A                                   23^M,Ant^                  5732                         WT^Ant^                                 ΔLog *τ*~c~ = 1.39                                                                                                              [@B92]
  K288^4.64b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   79^M,Ant^                  251                                                                                                                                                                                                  [@B5]
  K288^4.64b^[^†^](#t1n1){ref-type="table-fn"}                                   L                                   63^M,Ant^                  79                                                                                                                                                                                                   [@B5]
  K288^4.64b^                                                                    L                                   ND^C,Ag^                   ND                           70%^cyt^                                                                                                                                                                [@B534]
  K288^4.64b^[^†^](#t1n1){ref-type="table-fn"}                                   R                                   WT^M,Ag^                   WT                                                                                                                                                                                                   [@B5]
  K288/Y289                                                                      A, A                                                           2188                                                                 28% SB^M,Ag^                                                                                                                    [@B92]
  Y289^4.65b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  Y289^4.65b^                                                                    A                                   WT^M,Ant^                  WT                           20%^Ant^                                                                                                                                                                [@B92]
  L290^4.66b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  Y291^4.67b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  L290/Y291[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B293]
  L290-Y291                                                                      A/A                                                            WT                                                                   99% SB^M,Ag^                                                                                                                    [@B92]
  E292^ECL2^                                                                     A                                   100^C,Ant^                 126                          WT^E^                                   ΔLog *τ*~c~ = 0.57                                                                                                              [@B245]
  E292^ECL2^                                                                     A                                   ND^C,Ag^                   33                           39%^cyt^                                                                                                                                                                [@B534]
  D293^ECL2^                                                                     A                                   25^C,Ant^                  16                           62%^E^                                                                                                                                                                  [@B245]
  E292/D293[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 8^M,Ag^                    79                                                                                                                                                                                                   [@B293]
  E292/D293                                                                      A/A                                                            25                                                                   75% SB^M,Ag^                                                                                                                    [@B92]
  E294^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           WT^E^                                   ΔLog *τ*~c~ = 0.65                                                                                                              [@B245]
  G295^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  E294-G295[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B293]
  E294-G295                                                                      A/A                                                            WT                                                                   97% SB ^M,Ag^                                                                                                                   [@B92]
  C296^ECL2^[\*](#t1n2){ref-type="table-fn"}[^†^](#t1n1){ref-type="table-fn"}    A                                   18^M,Ant^                  WT                           23%^Ant^                                                                                                                                                                [@B293]
  C296^ECL2^                                                                     A                                   13^C,Ant^                  126                          60^E^                                                                                                                                                                   [@B245]
  C296^ECL2^                                                                     S                                   ND^C,Ag^                   96                           WT^cyt^                                                                                                                                                                 [@B534]
  W297^ECL2^                                                                     A                                   63^C,Ant^                  316                          WT^E^                                   ΔLog *τ*~c~ = 1.00                                                                                                              [@B245]
  W297^ECL2^                                                                     A                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  W297^ECL2^                                                                     H                                   ND^C,Ag^                   50                           40%^cyt^                                                                                                                                                                [@B534]
  T298^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  W297/T298[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 100^M,Ant^                 50                                                                                                                                                                                                   [@B293];
  [@B95]                                                                                                                                                                                                                                                                                                                                             
  W297/T298                                                                      A/A                                                            22                                                                   57% SB^M,Ag^                                                                                                                    [@B92]
  R299^ECL2^                                                                     A                                   32^C,Ant^                  85                           WT^E^                                                                                                                                                                   [@B245]
  R299^ECL2^                                                                     A                                   WT^M,Ant^                  WT                           40%^Ant^                                ΔLog *τ*~c~ = 0.60                                                                                                              [@B92]
  R299^ECL2^                                                                     S                                   ND^C,Ag^                   43                           WT^cyt^                                                                                                                                                                 [@B534]
  N300^ECL2^                                                                     A                                   126^C,Ant^                 501                          WT^E^                                   ΔLog *τ*~c~ = 0.80                                                                                                              [@B245]
  N300^ECL2^                                                                     A                                   36^M,Ant^                  104                          18%^Ant^                                                                                                                                                                [@B92]
  N300^ECL2^                                                                     A                                   ND^C,Ag^                   ND                           16%^cyt^                                                                                                                                                                [@B534]
  R299/N300[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 25^M,Ant^                  \>3000                                                                                                                                                                                               [@B293];
  [@B95]                                                                                                                                                                                                                                                                                                                                             
  R299/N300                                                                      A/A                                                            331                                                                  41% SB^M,Ag^                                                                                                                    [@B92]
  S301^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           63%^E^                                                                                                                                                                  [@B245]
  N302^ECL2^                                                                     A                                   25^C,Ant^                  16                           WT^E^                                   ΔLog *τ*~c~ = 0.53                                                                                                              [@B245]
  S301/N302[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B293]
  S301/N302                                                                      A/A                                                            WT                                                                   86% SB^M,Ag^                                                                                                                    [@B92]
  N302/M303[^†^](#t1n1){ref-type="table-fn"}                                     V/K                                 WT^C,Ag^                   10                                                                                                                                                                                                   [@B315]
  M303^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           WT^E^                                                                                                                                                                   [@B245]
  N304^ECL2^                                                                     A                                   WT^C,Ant^                  WT                           70%^E^                                  ΔLog *τ*~c~ = 0.74                                                                                                              [@B245]
  N304^ECL2^                                                                     A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  M303/N304[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^M,Ag^                   WT                                                                                                                                                                                                   [@B293]
  M303/N304                                                                      A/A                                                            WT                                                                   91% SB^M,Ag^                                                                                                                    [@B92]
  Y305^5.35b^                                                                    A                                   79^C,Ant^                  40                           52%^E^                                                                                                                                                                  [@B245]
  Y305^5.35b^                                                                    A                                   WT^M,Ant^                  WT                           22%^Ant^                                                                                                                                                                [@B92]
  W306^5.36b^                                                                    A                                   ND^C,Ant^                  ND                           ND                                      No receptor expression                                                                                                          [@B245]
  W306^5.36^                                                                     A                                   109^M,Ant^                 206                          41%^Ant^                                                                                                                                                                [@B92]
  W306^5.36^                                                                     A                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  [^†^](#t1n1){ref-type="table-fn"}Y305/W306[^†^](#t1n1){ref-type="table-fn"}    A/A                                 316^M,Ant^                 50                                                                                                                                                                                                   [@B293];
  [@B95]                                                                                                                                                                                                                                                                                                                                             
  Y305/W306                                                                      A/A                                                            263                                                                  60% SB^M,Ag^                                                                                                                    [@B92]
  L307^5.37b^                                                                    A                                   13^C,Ant^                  25                           47%^E^                                                                                                                                                                  [@B245]
  L307^5.37b^                                                                    A                                                              WT                                                                   87% SB^M,Ag^                                                                                                                    [@B92]
  I308^5.38b^                                                                    A                                                              WT                                                                   78% SB^M,Ag^                                                                                                                    [@B92]
  L307/I308[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 251^M,Ant^                 6                                                                                                                                                                                                    [@B293];
  [@B95]                                                                                                                                                                                                                                                                                                                                             
  I309^5.39b^                                                                    A                                   WT^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B92]
  R310^5.40b^                                                                    A                                   10^M,Ant^                  1259                         17%^Ant^                                                                                                                                                                [@B68]
  R310^5.40b^                                                                    A                                   WT^M,Ant^                  1290                         19%^Ant^                                ΔLog *τ*~c~ = 0.75                                                                                                              [@B92]
  I309/R310[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 50^M,Ant^                  \>3000                                                                                                                                                                                               [@B293];
  [@B95]                                                                                                                                                                                                                                                                                                                                             
  I309/R310                                                                      A/A                                                            13,490                                                               13% SB^M,Ag^                                                                                                                    [@B92]
  L311/P312                                                                      A/A                                                            WT                                                                   91% SB^M,Ag^                                                                                                                    [@B92]
  A316^5.46b^                                                                    T                                   WT^C,Ant^                  WT                           \<25%^E^                                                                                                                                                                [@B248]
  N320^5.50b^                                                                    A                                   18^C,Ant^                  10                           WT^E,Ant^                               ΔLog *τ*~c~ = 0.50                                                                                                              [@B525]
  F321^5.51b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  L322^5.52b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  I323^5.53b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                35%^Ant^                                WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  F324^5.54b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  I325/F326[^†^](#t1n1){ref-type="table-fn"}                                     A/A                                 WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  V327^5.57b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                   15                           WT^Ag^                                  42% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  I328^5.58b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                   9                            WT^Ant^                                 39% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  C329^5.59b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ant^                                 WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  I330^5.60b^                                                                    A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  V331^5.61b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                   14                           WT^Ag^                                  45% cAMP 10^−7^ M GLP-1                                                                                                         [@B297]
  I332^5.62b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  A333^5.63b^[^†^](#t1n1){ref-type="table-fn"}                                   L                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B297]
  S333^5.63b^                                                                    C                                   WT^C,Ant^                  WT                           \<50%^E^                                For additional residue substiutions, see [@B246]                                                                                [@B248]
  K334^5.64b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  28% cAMP 10^−7^ M GLP-1                                                                                                         [@B452]; [@B297]
                                                                                                                                                                                                                                                                                                                                                     
  L335^5.65b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B452]; [@B297]
                                                                                                                                                                                                                                                                                                                                                     
  K336^5.66b^[^†^](#t1n1){ref-type="table-fn"}                                   L                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B452]; [@B297]
                                                                                                                                                                                                                                                                                                                                                     
  K334/K351                                                                      Deletions                           WT^C,Ag^                                                ^Ag^ See paper for details                                                                                                                                              [@B452]
  C347^6.36b^                                                                    A                                                              WT                                                                                                                                                                                                   [@B476]
  R348^6.37b^[^†^](#t1n1){ref-type="table-fn"}                                   G                                   12^C,Ag^                   ND                           WT^mic^                                                                                                                                                                 [@B187]
  R348^6.37b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B452]
  L349^6.38b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                76%^Ag^                                 WT cAMP 10^−7^ M GLP-1                                                                                                          [@B452]
  A-350^6.39b^[^†^](#t1n1){ref-type="table-fn"}                                  E                                   ND^C,Ag^                                                \<10%^Ag^                               5% cAMP 10^−7^ M GLP-1                                                                                                          [@B452]
  A-350^6.39b^[^†^](#t1n1){ref-type="table-fn"}                                  K                                   WT^C,Ag^                                                21%^Ag^                                 2% cAMP 10^−7^ M GLP-1                                                                                                          [@B452]
  K351^6.40b^[^†^](#t1n1){ref-type="table-fn"}                                   A                                   WT^C,Ag^                                                WT^Ag^                                  WT cAMP 10^−7^ M GLP-1                                                                                                          [@B452]
  T353^6.42b^                                                                    A                                   ND^C,Ant^                  22                           30%^E^, ND^Ant^                         ΔLog *τ*~c~ = 0.84                                                                                                              [@B525]
  H363^6.52b^                                                                    A                                   98^M,Ant^                  ND                           24%^Ant^                                                                                                                                                                [@B68]
  H363^6.52b^                                                                    A                                   23^C,Ant^                  4                            59%^E^, 53%^Ant^                        ΔLog *τ*~c~ = 1.71                                                                                                              [@B525]
  E364^6.53b^                                                                    A                                   58^M,Ant^                  15                           42%^Ant^                                                                                                                                                                [@B68]
  E364^6.53b^                                                                    A                                   25^C,Ant^                                               51%^E,Ant^                              ΔLog *τ*~c~ = 0.66                                                                                                              [@B526]
  E364^6.53b^                                                                    A                                   ND^C,Ag^                   ND                           6%^cyt^                                                                                                                                                                 [@B534]
  E364^6.53b^                                                                    Q                                   WT^C,Ag^                   WT                           42%^cyt^                                                                                                                                                                [@B534]
  E364^6.53b^                                                                    Q                                   0.2^C,Ant^                 WT                           42%^cyt^                                                                                                                                                                [@B534]
  E364/E387                                                                      N/Q                                 ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  E364^6.53b^                                                                    Y                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  E364^6.53b^                                                                    D                                   WT^C,Ag^                   WT                           53%^cyt^                                                                                                                                                                [@B534]
  F367^6.56b^                                                                    A                                   ND^C,Ag^                   72                           WT^cyt^                                                                                                                                                                 [@B534]
  F367^6.56b^                                                                    A                                   32^C,Ant^                  72                           WT^cyt^                                                                                                                                                                 [@B534]
  F367^6.56b^                                                                    I                                   ND^C,Ag^                   20                           WT^cyt^                                                                                                                                                                 [@B534]
  F367^6.56b^                                                                    H                                   7^C,Ag^                    131                          WT^cyt^                                                                                                                                                                 [@B534]
  M371^ECL3^                                                                     A                                   WT ^M,Ant^                 WT                           54%^Ant^                                                                                                                                                                [@B92]
  D372^ECL3^                                                                     A                                   WT ^M,Ant^                 59                           13%^Ant^                                                                                                                                                                [@B92]
  E373^ECL3^                                                                     A                                   WT^M,Ant^                  WT                           28%^Ant^                                                                                                                                                                [@B92]
  H374^ECL3^                                                                     A                                   WT^M,Ant^                  WT                           22%^Ant^                                                                                                                                                                [@B92]
  H374^ECL3^                                                                     A                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  A-375^ECL3^                                                                    A                                   10^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B92]
  R376^ECL3^                                                                     G                                   WT^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B92]
  R376^ECL3^                                                                     Q                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  G377^ECL3^                                                                     A                                   WT^M,Ant^                  WT                           19%^Ant^                                                                                                                                                                [@B92]
  T378^7.32b^                                                                    A                                   WT^M,Ant^                  WT                           12%^Ant^                                                                                                                                                                [@B92]
  L379^7.33b^                                                                    R                                   12^C,Ag^                   141                          WT^Ag^                                                                                                                                                                  [@B316]
  L379^7.33b^                                                                    E                                   11^C,Ag^                   165                          WT^Ag^                                                                                                                                                                  [@B316]
  L379^7.33b^                                                                    A                                   WT^M,Ant^                  WT                           31%^Ant^                                                                                                                                                                [@B92]
  R380^7.34b^                                                                    D                                   21^C,Ag^                   1853                         WT^Ag^                                                                                                                                                                  [@B316]
  R380^7.34b^                                                                    G                                   4^C,Ag^                    40                           WT^Ag^                                                                                                                                                                  [@B316]
  R380^7.34b^                                                                    A                                   128^M,Ant^                 263                          68%^Ant^                                                                                                                                                                [@B92]
  R380^7.34b^                                                                    Q                                   ND^C,Ag^                   ND                           WT^cyt^                                                                                                                                                                 [@B534]
  F381^7.35b^                                                                    R                                   WT ^C,Ag^                  WT                           WT^Ag^                                                                                                                                                                  [@B316]
  F381^7.35b^                                                                    E                                   \>200^C,Ag^                234                          WT^Ag^                                                                                                                                                                  [@B316]
  F381^7.35b^                                                                    A                                   WT^M,Ant^                  WT                           16%^Ant^                                                                                                                                                                [@B92]
  F381^7.35b^                                                                    S                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  I382^7.36b^                                                                    A                                   WT^M,Ant^                  WT                           23%^Ant^                                                                                                                                                                [@B92]
  K383^7.37b^                                                                    A                                   WT^M,Ant^                  56                           WT^Ant^                                 ΔLog *τ*~c~ = 1.18                                                                                                              [@B92]
  L384^7.38b^                                                                    A                                   WT^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B92]
  L384^7.38b^                                                                    A                                   ND^C,Ag^                   41                           WT^cyt^                                                                                                                                                                 [@B534]
  L384^7.38b^                                                                    A                                   48^C,Ant^                  41                           WT^cyt^                                                                                                                                                                 [@B534]
  L384^7.38b^                                                                    V                                   ND^C,Ag^                   16                           WT^cyt^                                                                                                                                                                 [@B534]
  F385^7.40b^                                                                    A                                   WT^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B92]
  T386^7.41b^                                                                    A                                   WT^M,Ant^                  WT                           18%^Ant^                                                                                                                                                                [@B92]
  E387^7.42b^                                                                    A                                   WT^M,Ant^                  WT                           43%^Ant^                                ΔLog *τ*~c~ = 0.52                                                                                                              [@B92]
  E387^7.42b^                                                                    A                                   WT^M,Ant^                  WT                           WT^Ant^                                                                                                                                                                 [@B68]
  E387^7.42b^                                                                    D                                   13^C,Ag^                   10                           WT^cyt^                                                                                                                                                                 [@B534]
  E387^7.42b^                                                                    D                                   12^C,Ant^                  10                           WT^cyt^                                                                                                                                                                 [@B534]
  E387^7.42b^                                                                    N                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  L388^7.43b^                                                                    A                                   ND^C,Ag^                   208                          WT^cyt^                                                                                                                                                                 [@B534]
  L388^7.43b^                                                                    I                                   5^C,Ag^                    81                           WT^cyt^                                                                                                                                                                 [@B534]
  L388^7.43b^                                                                    F                                   WT^C,Ag^                   WT                           WT^cyt^                                                                                                                                                                 [@B534]
  T391^7.44b^                                                                    A                                   WT^M,Ant^                  WT                           64%^M,Ant^                                                                                                                                                              [@B68]
  T391^7.44b^                                                                    A                                                              WT                           WT^Ag^                                                                                                                                                                  [@B477]
  S392^7.47b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E,^ ^Ant^                                                                                                                                                            [@B525]
  Q394^7.49b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E,^ ^Ant^                                                                                                                                                            [@B525]
  Q394^7.49b^                                                                    N                                   WT^C,Ant^                                               WT^E,Ant^                                                                                                                                                               [@B526]
  M397^7.52b^                                                                    L                                   WT^C,Ag^                   WT                                                                                                                                                                                                   [@B93]
  Y402^7.57b^                                                                    A                                   ND^C,Ant^                  10                           21%^E^, ND^Ant^                         ΔLog *τ*~c~ = 1.59                                                                                                              [@B525]
  C403^7.58b^                                                                    A                                                              5.4                                                                                                                                                                                                  [@B476]
  N406^7.61b^                                                                    A                                   WT^C,Ant^                  WT                           WT^E,Ant^                                                                                                                                                               [@B525]
  R421^CTT^                                                                      Q                                   WT^C,Ant^                  WT                           \<50%^E^                                                                                                                                                                [@B248]
  C438 ^CTT^                                                                     A                                                              WT                                                                                                                                                                                                   [@B476]
  C458 ^CTT^                                                                     A                                                              WT                                                                                                                                                                                                   [@B476]
  C462 ^CTT^                                                                     A                                                              WT                                                                                                                                                                                                   [@B476]

CTT, C-terminal tail; SB, specific binding of radiolabeled ligand; WB, Western blotting.

Note that potency changes can be due to changes in affinity, efficacy, and/or cell surface expression, and hence should be interpreted with caution, especially when either the affinity and/or expression levels are not known.

Also included in double mutations.

![Summary of GLP-1R mutagenesis. A snake plot of GLP-1R from <http://www.gpcrdb.org> that has been colored (see Key) to highlight the location of signal peptide, glycosylation, and phosphorylation sites, as well as the mutated residues in [Table 1](#T1){ref-type="table"}. It should be noted that the color coding of 74 of the 195 mutated residues (W39, W72, W87, W91, W110, F169-C174, R176, N177, H180, N182, A200-Q213, W214-G225, R227-F230, L232, M233, E262-L268, F321-I332, K334-K336, and R348-K351) reflects the effects of rat GLP-1R mutations projected on the hGLP-1R amino acid sequence. The color coding of 27 of the 185 residues (K202, W203, S206-Q211, Q213, W214, G216-Q221, S223-G225, R227-F230, L332, M233, I325, and F326) reflects the effect of double mutations, not single-point mutations. Information on the fold change in ligand affinity and potency as well as expression levels of the GLP-1R mutants is reported in [Table 1](#T1){ref-type="table"}.](pr.115.011395f3){#F3}

### 2. Seven-Transmembrane Domain. {#s35}

#### a. Structure of the 7TMD. {#s36}

To date, with the exception of a recently solved electron microscopy map of GCGR ([@B535]), there are no experimentally determined three-dimensional structures available for any full-length class B GCPR, but, in addition to the isolated ECD structures mentioned above, there are now X-ray crystal structures for the 7TMD of human GCGR ([@B435]; [@B215]) and CRF~1~R ([@B198]). The partial CRF~1~R structure (PDB: 4K5Y) was solved in the presence of a small-molecule antagonist (CP-376395) and contained 12 thermo-stabilizing mutations and a T4 lysozyme fusion partner inserted into ICL2 ([@B198]). The first GCGR 7TMD structure (PDB: 4L6R) was solved with an N-terminal fusion partner fused at residue 123 ([@B435]), and it is this structure that is of particular interest to understand GLP-1R because both the receptors and native ligands are closely related. Recently, another GCGR 7TMD crystal structure was solved that contained 11 thermo-stabilizing mutations and a T4 lysozyme fusion partner inserted into ICL2 (PDB: 5EE7) ([@B215]). In this structure, a small-molecule antagonist (MK-0893) is bound to an extrahelical allosteric binding site that is distinct from the orthosteric peptide ligand binding site, and the receptor adopts a similar overall conformation as observed in the previously solved GCGR crystal structure. Analogs of MK-0893 bind GLP-1R with moderate micromolar affinity ([@B530]), suggesting that the GCGR crystal structures may also offer a template for the design of small-molecule ligands that target the same extrahelical allosteric binding site in GLP-1R. Even though the general fold of the TM helices is similar to those observed in classes A and C GPCR crystal structures, both CRF~1~R and GCGR structures assume more open conformations toward the extracellular side than any other GPCR of known structure. In addition to this open 7TMD pocket, the GCGR structure revealed two other distinct structural features that are not observed in the CRF~1~R structure, namely, a long N-terminal extension of TM helix 1 (defined as stalk region) and a long helix 8 at the C-terminal end of the receptor that is differently oriented than helix 8 observed in the crystal structures of other GPCRs ([@B197]). Although the distinct orientation of helix 8 in the GCGR structure may be a result of crystal lattice contacts, the stalk is proposed to play a role in the positioning of the ECD relative to the 7TMD ([@B435]). The electron microscopy map of the full-length GCGR stabilized by a monoclonal antibody (mAb23) suggests that mAb23 interacts with the ECD (preventing glucagon from binding to the receptor) and stabilizes GCGR in an open conformation in which the TM helix 1 stalk connects the ECD and 7TMD and the ECD is almost perpendicular to the membrane surface ([@B535]). Hydrogen-deuterium exchange studies have indicated that des-His^1^-\[Nle^9^-Ala^11^-Ala^16^\]-glucagon-NH~2~ peptide antagonist binding protects the *α*-helical conformation of the stalk region of GCGR, consistent with molecular dynamics--simulation studies ([@B535]). Full-length crystal structure of GLP-1R and other class B GPCRs are required to show whether the stalk region observed in the GCGR 7TMD crystal structure is indeed a conserved structural feature among secretin-like receptors. The GCGR structure lacks the presence of a peptide or small-molecule ligand, but there is clearly a deep and extensive binding pocket comprised of the TM helices at the extracellular side of the 7TM bundle. A glucagon-bound full-length GCGR model ([@B435]) and models of agonist-docked full-length GLP-1R ([@B92]; [@B526]; [@B534]) have been proposed based on information from a variety of sources, including the crystal structures of the GCGR 7TMD ([@B435]), the antibody-bound GCGR ECD ([@B250]), the GLP-1--bound GLP-1R ECD ([@B475]), and molecular dynamics simulations ([@B526]; [@B534]). Although such models can be largely consistent with the results of mutation studies of GLP-1R ([Table 1](#T1){ref-type="table"}) ([@B92]; [@B526]; [@B534]), and can provide insights into GLP-1R--specific mechanisms of ligand-binding selectivity ([@B534]) and biased signaling ([@B526]), a complete interpretation of the mutagenesis data requires a high-resolution structure of the ligand-bound GLP-1R, and, hence, progress in this area is required and keenly anticipated.

#### b. Mutagenesis of the 7TMD. {#s37}

Although there are numerous molecular pharmacological analyses of various ligands (both peptidic and nonpeptidic) acting at GLP-1R, this section of the review will focus only on those studies that highlight the action of GLP-1 itself. Likewise, whereas GLP-1R can signal through several pathways, this section will focus on the effects of site-directed mutagenesis on signaling through the Gs protein that raises intracellular cAMP levels. The ability of GLP-1R to activate other G proteins and pathways will be examined in more detail below. The mutagenesis data are summarized in [Table 1](#T1){ref-type="table"} and [Fig. 3](#F3){ref-type="fig"}, with the TM numbering following the convention described by [@B525].

##### i. TM1 (S129^1.24b^-L167^1.62b^). {#s38}

The first TM helix of GLP-1R (TM1) contains two single-nucleotide polymorphism (SNP) sites at positions 131^1.26b^ (Arg/Asn) and 149^1.44b^ (Thr/Met). Although the R131^1.26b^N mutation did not significantly affect GLP-1 action ([@B248]), Beinborn and colleagues showed that the T149^1.44b^M mutation (which has been associated with T2DM) led to a 60-fold reduction in GLP-1 affinity and a 30-fold reduction in potency ([@B466]; [@B28]). The importance of this residue for GLP-1 action has been confirmed subsequently, demonstrating that the same mutation resulted in a 250-fold reduced affinity and a 160-fold reduced potency, whereas substitution by a variety of other residue types also led to compromised affinity and signaling ([@B246]), with the exception of the T149^1.44b^S mutant, which has similar ligand affinity and potency as wild-type GLP-1R ([@B534]). Mutation of Y148^1.43b^ to Ala, Asn, or Phe diminished GLP-1 affinity and potency ([@B534]), while that of Y152^1.47b^ to Ala reduced GLP-1 affinity by 30-fold---potency was compromised as well, although in this case the B~max~ was low ([@B68]), whereas Y152^1.47b^H does not affect either ligand affinity or potency ([@B534]). Mutation of the equivalent residue (Y149^1.47b^) in GCGR also caused low expression levels, whereas the mutation to His was expressed well and displayed sixfold reduced affinity. Mutation of S155^1.50b^ to Ala, in contrast, reduced coupling \[efficacy (E~max~), i.e., the maximal response = 38%, ΔLog *τ*~c~ = 0.75\] with a minor effect on affinity ([@B525]).

##### ii. ICL1 (G168-C174). {#s39}

The first residue in the loop is the site of a known SNP (Gly to Ser), but the simulated mutation had no effect on GLP-1 action ([@B248]). Residues comprising the region between F169^ICL1^ and C174^ICL1^ in the first intracellular loop were systematically mutated to Ala, but no significant effect upon GLP-1 action was found ([@B297]). However, C174^ICL1^ has also been mutated and exhibited a sixfold reduced potency when mutated to Ala and a sevenfold reduced potency when mutated to Ser ([@B476]).

##### iii. TM2 (T175^2.45b^-L201^2.71b^). {#s40}

A total of 17 sites within TM2 have been subjected to site-directed mutagenesis ([@B297]; [@B529]; [@B269]; [@B477]; [@B68]; [@B315]; [@B523]; [@B534]). Of these, eight mutations displayed GLP-1 pharmacology similar to the wild-type receptor (T175^2.45b^, N177^2.47b^, N182^2.^52b, and A200^2.70b^ in rat GLP-1R, and S186^2.56b^, L192^2.62b^, V194^2.64b^, and F195^2.65b^ in hGLP-1R). In contrast, R176^2.46b^ displayed compromised signaling with approximately 13-fold right-shifted potency and E~max~ reduced to 26% ([@B297]). The mutation of the conserved H180^2.50b^ to Arg resulted in a 21-fold reduced affinity ([@B187]), whereas substitution to Ala had led to no detectable binding, a 12-fold reduction in potency, and an E~max~ of 30% (ΔLog *τ*~c~ = 0.86) ([@B525]). R190^2.60^ has been mutated in multiple different studies: [@B529] found that its mutation to Ala in rat GLP-1R resulted in \>20-fold reduced affinity and only 27% of the wild-type response to 100 nM GLP-1; [@B68] observed a more than 30-fold reduction in affinity and 270-fold reduction in potency; [@B525] described a 20-fold reduction in GLP-1 affinity with a 34-fold reduction in potency and 56% E~max~ (ΔLog *τ*~c~ = 0.53); and [@B534] reported a diminished GLP-1 affinity and potency for the R190^2.60b^A mutant, and a 32-fold reduction in GLP-1 affinity with a 17-fold reduction in potency for the R190^2.60b^K mutant. The latter GCGR-mimicking R190^2.60b^K mutant does not affect binding affinity of the glucagon mimetic GLP-1 Glu^9^Gln point mutant, suggesting that this residue plays a role in GLP-1 versus glucagon selectivity ([@B534]). [@B315] mutated I196^2.66b^ to Ser and observed normal affinity but no activity. K197^2.67b^ has been mutated to Ala by both [@B529] and [@B68]; the former (rat GLP-1R) showed a fivefold reduction in affinity but only 25% of the wild-type response to 100 nM GLP-1, whereas the latter (hGLP-1R) observed a 28-fold reduction in affinity and a 630-fold reduction in potency. [@B534] showed that mutation of K197^2.67b^ to Gln and Ile also diminished GLP-1 affinity and potency in hGLP-1R, whereas the K197^2.67b^R mutant reduced GLP-1 potency by 23-fold. The equivalent residues have been mutated in the closely related receptors GCGR (I194^2.67b^) and GIPR (R190^2.67b^), respectively, with significant impact on their pharmacology and, in the case of GCGR, an association with Asp^3^ of the ligand ([@B372]; [@B404]; [@B537]; [@B435]). The neighboring residue D198^2.68b^ has also been mutated by several groups: [@B529] observed a 10-fold reduction in affinity and only 20% of the wild-type response to 100 nM GLP-1 at rat GLP-1R (D198^2.68b^A); [@B269] demonstrated a more than 60-fold reduction in affinity and a more than 40-fold reduction in potency for GLP-1 at rat GLP-1R (D198^2.68b^A); [@B68] described a more than 40-fold reduction in affinity but a more substantial 980-fold reduction in potency at hGLP-1R (D198^2.68b^A); [@B534] showed that in addition to D198^2.68b^A, D198^2.68b^N and D198^2.68b^E mutants also diminished GLP-1 and exendin-4 affinity and GLP-1 potency.

##### iv. ECL1 (K202-L218). {#s41}

The ECL1 of rat GLP-1R was scanned using double-Ala mutagenesis by [@B269]), and only the double mutation of M204^ECL1^-Y205 ^ECL1^ displayed some change from the wild-type (87-fold decrease in potency and 37-fold decrease in affinity). M204^ECL1^A and Y205^ECL1^A single mutants exhibited wild-type GLP-1 pharmacology in rat GLP-1R ([@B269]), but diminished GLP-1 affinity and potency in hGLP-1R in another study ([@B534]). Although the W214^ECL1^-D215^ECL1^ double mutation to Ala showed wild-type properties, [@B529] have reported that the single D215^ECL1^-A mutation has a fourfold reduced affinity and only 57% of the wild-type cAMP production when treated with 100 nM GLP-1. [@B534] showed that Q211^ECL1^D, Q211^ECL1^R, H212^ECL1^A, W214^ECL1^V, and L217^ECL1^A single amino acid mutants did not affect GLP-1R pharmacology, whereas W203^ECL1^A and Y220^ECL1^D diminished GLP-1 affinity and potency. In contrast, the equivalent region in GCGR plays a critical role in peptide ligand recognition with 15 residues between L198^ECL1^ and A220^ECL1^ affecting peptide response ([@B397]; [@B435]).

##### v. TM3 (S219^3.22b^-A256^3.59b^). {#s42}

Although the substitution of C236^3.39b^ appeared to have minimal effects on GLP-1 pharmacology, the mutation of the conserved C226^3.29b^ in two studies led to either no detectable activity or a 25-fold reduction in GLP-1 affinity with 38-fold lower potency; the latter was thought to be the result of the breaking of a disulfide bond and the creation of a hydrophobic side chain at position 296 ([@B293]; [@B476]). The equivalent cysteine in GCGR (C224^3.39b^) was also shown to be important for glucagon potency ([@B381]; [@B397]). The remaining residues spanning S219^3.22b^ to F230^3.33b^ were included in the double-alanine screening by [@B269]), and all were found to display wild-type--like GLP-1 pharmacology, although [@B529] reported that the single R227^3.30b^A mutation exhibited a more than 20-fold reduced GLP-1 affinity; the equivalent mutation in GCGR (R225^3.30b^A) had no detectable peptide binding ([@B435]). The double substitution of L232^3.35b^/M233^3.36b^ with V/T reduced affinity by 10-fold and potency by 100-fold ([@B315]), whereas the single substitution of M233^3.36b^ with A and T abolished GLP-1 affinity and potency ([@B534]). The single-alanine substitutions at Q234^3.37b^ and Y235^3.38b^, respectively, caused a 13- and 24-fold reduced affinity with 45- and 23-fold reduced potency ([@B68]), whereas the M233^3.36b^F and Q234^3.37b^N mutants did not affect GLP-1 affinity or potency ([@B534]). The Q234^3.37b^E substitution diminished GLP-1 affinity, which was restored by the mutation of Glu^9^ of GLP-1 into the corresponding Gln residue in glucagon ([@B534]). Position 3.37b has also been implicated in playing a role in the ligand-binding affinity of GCGR and GIPR ([@B537]; [@B435]). Replacement of N240^3.43b^ with Ala in rat GLP-1R reduced affinity by more than 20-fold and severely impeded cAMP production induced by 100 nM GLP-1 ([@B529]), whereas the equivalent replacement in hGLP-1R had minimal effects on affinity but reduced E~max~ of GLP-1 to 78% (ΔLog *τ*~c~ = 0.67; [@B525]). Likewise, in GCGR the N238^3.43b^A mutation had no effect on affinity, whereas in GIPR the N230^3.43b^A mutant reduced potency by sevenfold. In contrast, substitution of the conserved E247^3.50b^ to Ala in hGLP-1R reduced potency by 14-fold and E~max~ to 19% (ΔLog *τ*~c~ = 0.99; [@B525]), but the equivalent mutation in rat GLP-1R had no major effect ([@B529]).

##### vi. ICL2 (F257-I265). {#s43}

Mutations in the second intracellular loop to date have not shown any effects on GLP-1 pharmacology with the SNP swap Phe/Leu at 260 ([@B248]) and an Ala scan of E262^ICL2^-I265^ICL2^ ([@B297]) displaying wild-type--like properties.

##### vii. TM4 (F266^4.42b^-Y291^4.62b^). {#s44}

Two sites in TM4 have been highlighted as being key to GLP-1 activity. The first is W284^4.60b^, which, when mutated to Ala, led to a 32-fold reduced affinity and a 1350-fold reduced potency ([@B68]). The second important site in this helix is K288^4.64b^, which, when mutated to Ala or Leu in rat GLP-1R, respectively, resulted in a 79- and 63-fold reduction in affinity with a 251- and 79-fold lower potency ([@B5]). The K288^4.64b^L mutant also abolished GLP-1 affinity and potency in hGLP-1R ([@B534]). However, the K288^4.64b^ to Ala mutation in hGLP-1R caused a 126-fold reduction in affinity with no detectable cAMP production ([@B245]) and substitution of K286^4.64b^ in GCGR abolished radiolabeled ligand binding ([@B435]). The following mutations did not affect GLP-1 pharmacology: F266^4.42b^A, R267^4.43b^A, L268^4.44b^A, L278^4.54b^M, G285^4.61b^A, I286^4.62b^A/V287^4.63b^A, I286^4.62b^A, V287^4.63b^A, Y289^4.65b^A, L290^4.66b^A/Y291^4.67b^A, L290^4.66b^A, and Y291^4.67b^A ([@B297]; [@B293]; [@B475]; [@B245]).

##### viii. ECL2 (E292-Y305). {#s45}

The second extracellular loop is an important region for peptide ligand recognition ([@B293]; [@B95]; [@B245]; [@B315]; [@B92]). Aside from the key disulfide-forming C296^ECL2^, which has been shown to be crucial for affinity in rat GLP-1R and both affinity and coupling in hGLP-1R ([@B293]; [@B245]; [@B477]), residues E292^ECL2^, D293^ECL2^, E294^ECL2^, W297^ECL2^, R299^ECL2^, N300^ECL2^, N302^ECL2^, and N304^ECL2^ all play a role in GLP-1 action (Y305^5.35b^ is involved too---see TM5 below). [@B245] demonstrated that the individual substitutions E292^ECL2^ and D293^ECL2^ in hGLP-1R caused, respectively, ≥100-fold reduced affinity and potency (ΔLog *τ*~c~ = 0.57) and a 25-fold reduced affinity with 16-fold reduced potency, but no change in efficacy. Double mutations of both sites in rat GLP-1R and hGLP-1R support the importance of these residues in GLP-1 pharmacology ([@B293]; [@B92]). Substitution by Ala of the equivalent E290^ECL2^ and N291^ECL2^ in GCGR led to, respectively, no detectable radioligand binding and a threefold reduction in affinity ([@B435]). The region encompassing W297^ECL2^-N300^ECL2^ was identified as essential in rat GLP-1R and hGLP-1R by double-Ala scanning, whereas the residues spanning S301^ECL2^-N304^ECL2^ did not alter GLP-1 pharmacology ([@B293]; [@B95]; [@B92]). However, individual substitutions in hGLP-1R by [@B245] demonstrated that, along with E294^ECL2^, W297^ECL2^, and R299^ECL2^, amino acids N300^ECL2^, N302^ECL2^, and N304^ECL2^ were also important ([Table 1](#T1){ref-type="table"}). In GCGR, the equivalent tryptophan (W295^ECL2^) is indispensible for affinity ([@B435]). The double mutation of N302^ECL2^-M303^ECL2^ to Val-Lys caused a small affinity reduction with a 10-fold decrease in potency ([@B315]). Residues that appear to be unimportant for GLP-1--mediated production of cAMP are G295^ECL2^, T298^ECL2^, S301^ECL2^, and M303^ECL2^ ([@B293]; [@B245]; [@B92]), which correlates with available data for GCGR ([@B435]).

##### ix. TM5 (W306^5.36b^-K336^5.66b^). {#s46}

Three double-Ala scan mutations have identified the extracellular end of TM5 of rat GLP-1R as being important for GLP-1 recognition, with substitutions of Y305^5.35b^/W306^5.36b^ (this is the ECL2-TM5 interface), L307^5.37b^/I308^5.38b^, and I309^5.39b^/R310^5.40b^ with Ala residues displaying significantly reduced affinity and potency ([@B293]). The equivalent double substitutions in hGLP-1R supported a role for Y305^5.35b^/W306^5.36b^ and I309^5.39b^/R310^5.40b^. However, whereas single mutations of Y305^5.35b^, L307^5.37b^, and I308^5.38b^ to Ala did not significantly alter GLP-1 pharmacology in one study ([@B92]), the individual substitutions of Y305^5.35b^ and L307^5.37b^ with Ala resulted in 79-fold decreased affinity with 40-fold reduced potency and 13-fold reduced affinity with 25-fold lowered potency (ΔLog *τ*~c~ = 0.49), respectively, in a second ([@B245]). Although W306^5.36b^ was not expressed in levels sufficient for analysis in Chinese hamster ovary (CHO) cells ([@B245]), in HEK293 cells its mutation to Ala resulted in \>100-fold reduced affinity and \>200-fold reduced potency ([@B92]). R310^5.40b^A resulted in a \>1200-fold reduced potency, with little effect upon affinity, implying that it plays a key role in agonist-induced signaling ([@B68]; [@B92]) (ΔLog *τ*~c~ = 0.75). The equivalent mutation in GIPR, R300^5.40b^A, caused a 42-fold reduced affinity and 86% E~max~ ([@B537]). This first part of TM5 is also involved in glucagon affinity in GCGR, with several mutations showing some effect on binding ([@B435]). N320^5.50b^A had a modest effect on GLP-1 action with an 18-fold reduced affinity and a 10-fold decreased potency (ΔLog *τ*~c~ = 0.50) ([@B525]). [@B452] and [@B297] Ala scanned the C-terminal end of TM5, demonstrating that V327^5.57b^, I328^5.58b^, V331^5.61b^, and K334^5.64^ had reduced GLP-1 affinity and activity. However, the mutations of A316^5.46^T, F321^5.51^A, L322^5.52b^A, I323^5.53b^A, F324^5.54b^A, V325^5.55b^A, R326^5.56b^A, C329^5.59b^A, I330^5.60b^A, V332^5.62b^A, S333^5.63b^A, S333^5.63b^C, L335^5.65b^A, and K336^5.66b^A did not greatly alter GLP-1 pharmacology ([@B297]; [@B248], [@B245]).

##### x. ICL3 (A337-T343). {#s47}

ICL3 does not appear to play a critical role in GLP-1R pharmacology because [@B452] screened the entire ICL3 region via deletion mutagenesis in three- or four-residue sections but found no effect on GLP-1 action, whereas [@B476] found that C341^ICL3^-A also had no effect ([@B452]; [@B476]).

##### xi. TM6 (D344^6.33b^-F369^6.58b^). {#s48}

Takhar's ICL3 Ala screening also extended into the first eight residues of TM6, but no significant effect on GLP-1 action was shown ([@B452]). Whereas [@B476] confirmed that C347^6.36b^A also had no effect, [@B187] showed that R348^6.37b^G resulted in a 12-fold reduced affinity and inability to produce cAMP. T353^6.36b^A led to a 22-fold reduction in potency (ΔLog *τ*~c~ = 0.84) ([@B525]). The Ala substitution at E364^6.53b^ caused a 58-fold reduction in affinity with a 15-fold reduced potency ([@B68]), whereas the individual substitutions of E364^6.53b^ with Tyr, Asp, or Gln did not affect GLP-1 affinity or potency ([@B534]). Interestingly, the E364^6.53b^Q mutation resulted in a 50-fold and a 40-fold increase in GLP-1-- and exendin-4--binding affinity, respectively, in exendin~9--39~ radioligand competition studies ([@B534]). Mutation of H363^6.52b^ to Ala resulted in either a 100-fold reduced affinity with no detectable potency ([@B68]) or a 23-fold reduced affinity with poor coupling (17% E~max~, ΔLog *τ*~c~ = 1.71). Mutation of F367^6.56b^ into Ala, Ile, and His decreased GLP-1 affinity and potency by 72-fold, 20-fold, and 131-fold, respectively ([@B534]).

##### xii. ECL3 (V370-G377). {#s49}

Residues from M371^ECL3^ to G377^ECL3^ have been mutated to Ala (with A376 to Gly), showing only a modest effect upon GLP-1 pharmacology ([@B92]). D372^ECL3^A displayed wild-type affinity but a 60-fold reduced potency, although analysis with the operational model suggested no effect upon efficacy; hence, this is likely to be the result of reduced receptor expression (13% wild-type). A375^ECL3^G resulted in a 10-fold reduced affinity for GLP-1. ECL3 appears to play a role in ligand and/or ECD recognition in GCGR ([@B250]).

##### xiii. TM7 (Y378^7.33b^-Y402^7.57b^). {#s50}

Residues from T378^7.33b^ to E387^7.42b^ have been mutated to Ala, suggesting that several residues play no major role in GLP-1 recognition---T378^7.32b^, L379^7.33b^, F381^7.35b^, I382^7.36b^, F385^7.39b^, and T386^7.40b^ ([@B92]). However, [@B316] showed that, although F381^7.36b^R had no effect, F381^7.36b^E reduced potency and affinity by \>200-fold, and L379^7.34b^R and L379^7.34b^E resulted in a more than 10-fold reduced affinity and in the range of 150-fold decreased potency. R380^7.35b^A resulted in 128-fold reduced affinity, without reduced efficacy ([@B92]). The R380^7.35b^Q substitution resulted in a more than 15-fold reduction in GLP-1 affinity and abolished potency ([@B534]), whereas R380^7.35b^D lowered potency by 1850-fold, but affinity was only reduced by 21-fold, and R380^7.35b^G decreased potency by 40-fold and affinity by fourfold. K383^7.38b^A showed no significant change in agonist affinity, but displayed reduced potency and efficacy (56-fold reduced potency, ΔLog *τ*~c~ = 1.18) ([@B92]). Mutation of Y402^7.57b^A demonstrated a role for this residue in coupling because substitution to Ala resulted in a large decrease in efficacy (ΔLog *τ*~c~ = 1.59) ([@B525]), whereas the equivalent mutation in GIPR, Y392^7.57b^A, caused a fivefold reduction in potency ([@B537]). Substitutions at E387^7.42b^, T391^7.46b^, Q394^7.49b^, M397^7.52b^, and C403^7.58b^ to Ala did not affect GLP-1 pharmacology ([@B68]; [@B93]; [@B477]; [@B525]). Substitution of L384^7.39^ (Ala, Val) and L388^7.43^ (Ala, Ile) into other aliphatic residues diminished GLP-1 affinity and potency in a similar way as corresponding mutants of homologous L382^7.39b^ and L386^7.43b^ residues in GCGR. The L386^7.43b^F did not affect GLP-1R affinity or potency, whereas the corresponding L386^7.43b^F mutant of GCGR abolished glucagon affinity and potency ([@B435]; [@B534]). The E387^7.42b^N mutant did not affect GLP-1 binding or potency, whereas the E387^7.42b^D mutant decreased GLP-1 affinity and potency by 13-fold and 10-fold, respectively, and the double E364^6.53b^N/E387^7.42b^Q mutant completely abolished GLP-1 binding ([@B534]). The reciprocal Ser^8^Ala substitution of glucagon restored binding of the GLP-1R--mimicking D385^7.42b^E mutant of GCGR ([@B404]), indicating that this receptor--ligand residue pair plays an important role in ligand selectivity between GLP-1R and GCGR.

##### xiv. C terminus (C404-S463). {#s51}

The mutations of N406-A, R421-Q, C438-A, C458-A, and C462-A had no major effect on GLP-1 action ([@B248]; [@B476]; [@B525]). Widmann et al. (1996a) investigated the role of serine residues (four serine doublets in the C-terminal tail) in receptor desensitization. Single- and double-Ala mutations of the doublets S431/S432, S441/S442, S444/S445, and S451/S452 were analyzed to demonstrate their role in receptor phosphorylation and phorbol-12-myristate-13-acetate--induced desensitization ([@B510]).

C. Receptor Function {#s52}
--------------------

As a member of class B GPCRs, GLP-1R is highly conserved across species, thus underlining the physiologic importance ([@B205]). GLP-1R mediates the actions of GLP-1 via the incretin axis that is the functional connection between the intestine and the islets of Langerhans in the pancreas. Stimulation of the GLP-1R with GLP-1 primarily triggers the insulin release from islet *β* cells in a glucose-dependent manner and suppresses glucagon secretion from islet *α* cells, in addition to several other effects such as delay of gastric emptying and inhibition of appetite ([@B244]; *II*. Glucagon-Like Peptide-1).

### 1. Signaling. {#s53}

#### a. Recombinant cells. {#s54}

The physiologic effects of GLP-1 are mediated by its interaction with GLP-1R and subsequent activation of its downstream signaling pathways. GLP-1R is pleiotropically coupled and signals through G-protein--dependent and independent mechanisms. It couples to G*α*s-elevating cAMP when overexpressed in recombinant cell lines, including CHO, HEK cells, Chinese hamster lung (CHL) fibroblasts, and COS cells ([@B505]; [@B507]; [@B313]; [@B523]). Increased calcium mobilization has also been observed in CHO, HEK, and COS, but not CHL cells ([@B505]; [@B507]; [@B313]; [@B67]; [@B249]). The mechanism behind this, however, is controversial. Azidoanilide-GTP cross-linking provided evidence for GLP-1R activation of G*α*q/11 in CHO cells, whereas in HEK cells GTP*γ*S binding and immunoprecipitation studies showed no activation of G*α*~q~ or G*α*~i~ ([@B313]; [@B67]). Furthermore, although Wheeler et al. observed a rapid increase in inositol trisphosphates, corresponding with increased calcium levels, and suggesting phospholipase C activation in GLP-1R/COS cells, these intermediates did not seem to be involved in other studies with COS and HEK cells ([@B505]; [@B507]; [@B67]).

Azidoanilide-GTP cross-linking developed by Montrose-Rafizadeh and colleagues also revealed GLP-1R activation of G*α*i1,2 but not G*α*i3 in CHO cells. In this cell line, GLP-1 also activates MAPKs, including ERK1/2 ([@B313]; [@B249]), and p38, through a cholera toxin--dependent pathway ([@B313]). GLP-1R can also elicit G-protein--independent signaling, via recruitment of the regulatory/scaffolding *β*-arrestin proteins ([@B440]; [@B385]). *β*-arrestin 2 recruitment has been observed in CHO, HEK293, and COS-7 cells, and *β*-arrestin 1 in CHO cells ([@B221]; [@B416]; [@B523]).

#### b. Pancreatic *β* cells. {#s55}

Research has largely focused on characterizing the GLP-1R signaling in *β* cells, where it mediates increased insulin secretion, storage, and synthesis as well as increased *β* cell mass. Consistent with the findings in recombinant cells, elevated cAMP is vital in *β* cells for glucose-dependent insulin secretion mediated by GLP-1R, and, although calcium mobilization, phosphorylation of ERK, and *β*-arrestin are important, G*α*q/11 does not seem to play a major role. A summary of known pathways involved in pancreatic *β* cell function is illustrated in [Fig. 4](#F4){ref-type="fig"}.

![Summary of the main characterized pathways of glucose and GLP-1 signaling in the pancreatic *β* cell. Glucose enters the cell through glucose transporter 2 and undergoes glycolysis to produce pyruvate that enters the mitochondria for oxidative metabolism and ATP production. This increase in cytosolic ATP closes the K~ATP~ channels, depolarizing the membrane and opening the voltage-dependent calcium channels, increasing calcium influx into the cell, causing insulin exocytosis. GLP-1 increases insulin exocytosis through a number of mechanisms. GLP-1R couples to G*α*s, activates adenylate cyclase that converts ATP to cAMP, and mobilizes two downstream effectors, PKA and Epac. These have a range of effects, including closing K~ATP~ channels, enhancing fusion of insulin secretory granules with the membrane, whereas PKA also closes Kv channels, inhibiting membrane repolarization. PKA and Epac also increase intracellular calcium by facilitating CICR through the opening of inositol 1,4,5-trisphosphate receptor and ryanodine receptor calcium channels, respectively. This increase in calcium has also been proposed to upregulate mitochondrial ATP production and activate calcineurin, so nuclear factor of activated T cells promotes insulin gene transcription to increase insulin stores. Alongside increasing insulin synthesis and exocytosis, GLP-1 signals through a number of pathways to increase *β* cell mass. PKA reduces ER stress through ATF-Gadd34 signaling, increases *β* cell neogenesis by activating cyclin D, and elevates the expression of insulin receptor substrate 2 (IRS2), a *β* cell survival factor, as well as anti-apoptotic proteins Bcl-2 and Bcl-x~L~ through CREB. PI3K is activated by IRS2 and transactivation of epidermal growth factor receptor, and this further promotes increased *β* cell mass through upregulation of PDX-1 and nuclear factor *κ*B, which upregulates anti-apoptotic Bcl-2 /Bcl-x~L~ and inhibitor of apoptosis protein-2.](pr.115.011395f4){#F4}

##### i. Insulin Secretion. {#s56}

*β* cells undergo glucose-stimulated insulin secretion. Glucose enters the *β* cell through glucose transporter 2 and is converted through glycolysis to pyruvate, which enters the mitochondria for oxidative phosphorylation, increasing the cytosolic ATP/ADP ratio ([@B279]). The increased ATP closes K~ATP~ channels, depolarizing the plasma membrane and increasing calcium influx through L-type voltage-dependent calcium channels, causing release of calcium from intracellular stores through calcium-induced calcium release (CICR) ([@B279]). Increased cytoplasmic calcium stimulates exocytosis of the insulin secretory granules.

GLP-1R signaling enhances this glucose-dependent insulin secretion through activation of G*α*s, upregulation of cAMP, and subsequent activation of PKA and exchange protein activated by cAMP (Epac). PKA is a holoenzyme composed of both regulatory and catalytic subunits; the latter are released upon binding of cAMP to the regulatory subunits, leading to phosphorylation of downstream substrates, whereas Epac2 primarily functions as a guanine nucleotide exchange factor for small Ras-like G proteins, thereby regulating their activity. PKA phosphorylates the sulfonylurea receptor (SUR1) subunit of the K~ATP~ channels, closing them and further depolarizing the membrane ([@B266]). Epac also inhibits K~ATP~ by increasing its sensitivity to ATP ([@B224]). The cAMP/PKA pathway, in concert with the PI3K/protein kinase C (PKC)*ζ* pathway (discussed in more detail below), also inhibits voltage-gated potassium channels, which in response to depolarization, opens and allows K^+^ efflux, repolarizing the cell ([@B280]). This delays repolarization, allowing increased calcium influx via voltage-dependent calcium channels ([@B280]). PKA and Epac1/2 are also involved in CICR from the ER, which is mediated by PKA via the inositol 1,4,5-trisphosphate receptor and by Epac1/2 through ryanodine receptors, increasing intracellular calcium ([@B223]; [@B469]; [@B104]). These mechanisms, therefore, enhance the ability of *β* cells to exocytose insulin secretory granules. There is evidence that CICR also contributes to increased mitochondrial ATP, in conjunction with GLP-1--induced increases in ATP ([@B469]). It was proposed that the intracellular calcium may enter the mitochondria to activate mitochondrial dehydrogenases to increase ATP production ([@B469]). PKA and Epac also seem to have a role in the exocytosis of insulin secretory granules, with PKA phosphorylating snapin, a protein that is vital to the regulation of vesicle assembly, and Rab-3--interacting molecule (Rim) and Munc-131, which are involved in vesicle fusion ([@B254]; [@B439]). Epac2 also interacts with Rim2 and Piccolo, a calcium sensor, to form a complex that is important for insulin secretion ([@B129]). Studies in islets of phospholipase C and Epac knockout mice also suggest that Epac2 acts via Rap1-regulated phospholipase C*ε* to cause calcium-induced insulin exocytosis ([@B431]; [@B106]). GLP-1 enhances glucokinase activity through Epac2 in a Rim2/Rab3A-dependent manner, sensitizing *β* cells to glucose. Knockdown of *β*-arrestin 1 in cultured pancreatic cells resulted in a reduction of both GLP1-mediated cAMP production and insulin secretion ([@B440]). Evidence suggests that this occurs via an increase in *β*-arrestin 1--mediated ERK1/2 phosphorylation that enhances cAMP response element-binding protein (CREB) activation and cAMP levels, subsequently contributing to insulin secretion ([@B385]).

##### ii. Insulin Synthesis and Storage. {#s57}

GLP-1 also acts to increase insulin stores in *β* cells by promoting insulin gene transcription, its mRNA stability, and biosynthesis. This occurs in both cAMP/PKA-dependent and independent manners ([@B20]). Studies with the rat insulin I promoter have implicated basic region leucine zipper proteins, similar in structure to CREB, which bind to the cAMP-responsive element site to upregulate insulin transcription in a cAMP/PKA-independent mechanism ([@B436]; [@B61]). The upregulation of the expression and activity of transcription factor pancreatic-duodenum homeobox-1 (PDX-1) and its increased activity also promote insulin transcription and biosynthesis via a PKA-mediated mechanism ([@B492], [@B494]). Glucose and GLP-1 potentiate insulin gene transcription, by increasing calcium levels, activating calcineurin that dephosphorylates nuclear factor of activated T cells, resulting in its nuclear localization and the promotion of insulin gene transcription ([@B258]).

##### iii. *β* Cell Survival, Proliferation, and Neogenesis. {#s58}

GLP-1 promotes *β* cell proliferation, neogenesis, and inhibition of apoptosis in rat models of T2DM ([@B48]). GLP-1R activation facilitates the release of *β*-cellulin by membrane-bound metalloproteinases, inducing transactivation of epidermal growth factor receptor, which then signals through PI3K and activates Akt/protein kinase B (PKB), PKC*ζ*, and p38 MAPK and ERK downstream ([@B48]).

PDX-1 is also critical in increasing *β* cell mass due to its proliferative and anti-apoptotic effects ([@B262]). As well as the increased activity mentioned above, GLP-1R enhances its expression. Akt inhibits forkhead transcription factor (Foxo1) action through its nuclear exclusion, relieving its inhibition on expression of forkhead box protein A2, which controls PDX-1 expression ([@B233]; [@B50]). In addition, GLP-1--mediated activation of PKA upregulates CREB, increasing the expression of IRS2, a *β* cell survival factor, leading to activation of PI3K/PKB and the anti-apoptotic protein Bcl-2 ([@B519]; [@B396]; [@B217]). Bcl-2 and Bcl-x~L~ are also upregulated through the activation of nuclear factor *κ*B downstream of PKB ([@B49]). Nuclear factor *κ*B increases expression of inhibitor of apoptosis protein-2, thereby preventing apoptosis ([@B49]). GLP-1 signaling has also been implicated in downregulation of proapoptotic caspase-3 and decrease in the cleavage of poly-ADP-ribose ([@B208]; [@B77]). ERK1/2 signaling via *β*-arrestin 1 also activates p90RSK, which phosphorylates proapoptotic Bad and inactivates it ([@B385]).

PKA activation of MAPK and cyclin D1 is important in the transition of the G1/Gs phase essential to cell cycle progression: they promote *β* cell neogenesis ([@B127]). GLP-1R agonists also improve *β* cell function and survival upon ER stress. This is believed to occur through PKA activation of C/EBP homologous protein and growth arrest and DNA damage-inducible protein (Gadd34), which prevents the dephosphorylation of translation initiator elF2*α*, allowing the ER to recover from stress ([@B539]).

#### c. Extrapancreatic signaling. {#s59}

Although GLP-1 signaling mediates many other physiologic effects, and GLP-1R is expressed in extrapancreatic tissues, the mechanistic basis for these effects is less well characterized. Therefore, there is limited knowledge regarding the underlying signaling mechanisms, although some important pathways and molecules have been identified in a limited subset of tissues.

##### i. Liver. {#s60}

GLP-1 reduces hepatic gluconeogenesis and lipogenesis and increases glycogen formation, but there is some debate over whether these effects are mediated by GLP-1R in hepatocytes, or whether the effects may be indirectly mediated through CNS or insulin release. GLP-1 promotes glycogen synthesis and decreased gluconeogenesis in vitro through upregulation of glycogen synthase that occurs downstream of PI3K/PKB, PKC, and serine/threonine protein phosphatase 1, and also by reduced expression of gluconeogenetic enzyme phosphoenol pyruvate carboxykinase in rat hepatocytes ([@B392]; [@B386]). In this system, GLP-1 also increases the phosphorylation of MAPK and p70s6k that perhaps are involved in other GLP-1 effects ([@B392]). However, in both studies, the presence of GLP-1R in these hepatocytes was not confirmed.

Signaling mechanisms for fatty acid oxidation and insulin sensitization, important in reducing hepatic steatosis, however, have been characterized in rat hepatocytes confirmed to express GLP-1R ([@B448]). Exendin-4 treatment resulted in increased peroxisome proliferator-activated receptor (PPAR) activity and PPAR*γ* expression through the activation of PI3K and 5′ AMP-activated protein kinase (AMPK) pathways ([@B448]). Increased PPAR activity induced the transcription of fatty acid *β*-oxidizing enzymes such as acyl-coenzyme A oxidase 1-palmitoyl and carnitine palmitoyltransferase 1 A, thereby reducing fatty acid levels in hepatocytes ([@B448]). Increased PPAR*γ* expression allowed increased insulin sensitization through the reduction of Ser^307^ c-Jun N-terminal kinase phosphorylation ([@B448]). GLP-1R activation also seems to reduce insulin resistance by intersecting the insulin-signaling pathway. In HepG2 and Huh7 cells expressing GLP-1R, exendin-4 treatment led to the phosphorylation of key mediators of the insulin-signaling pathway; PDX-1, Akt1, and PKC*ζ* and small interfering RNA of GLP-1R knocked down this phosphorylation for PDX-1 and PKC*ζ* ([@B164]).

##### ii. Kidney. {#s61}

GLP-1R activation in the kidney mediates natriuretic and diuretic effects of GLP-1, including decreasing renal proximal tubule reabsorption, improving endothelial integrity, and reducing hypertension. The transporter NHE3, which largely mediates this reabsorption, is inhibited by GLP-1 through PKA and Epac. Exendin-4 causes decreased NHE3 function in the porcine kidney epithelial cell line, LLC-PK(1), with phosphorylation at serine 552, a PKA consensus site. The mechanism by which Epac inhibits the NHE3 transporter has not been determined ([@B54]). It is known that angiotensin II signaling increases NHE3 activity, and oxidative stress is inhibited by GLP-1R--mediated cAMP elevation. In glomerular endothelial cells, exendin-4 promoted PKA-dependent phosphorylation of c-Raf(Ser^259^), preventing the activation of the angiotensin II--dependent pathway, p-c-Raf(Ser^338^)/ERK1/2/plasminogen activator inhibitor-1, a pathway upregulated in diabetes due to a hyperglycemic increase in PKC-*β* ([@B307]).

GLP-1R may also mediate renal protective effects through a reduction of PPAR*α* as exendin-4 treatment decreased PPAR*α* expression in both *db/m* and *db/db* mouse models ([@B360]). This decreased expression of PPAR*α* was paralleled by decreased transforming growth factor-*β*1, decreased type IV collagen, decreased caspase-3 expression, and reduced mesangial expansion ([@B360]).

##### iii. Adipocytes. {#s62}

GLP-1R signaling has been implicated in increased glucose uptake in human adipocytes, believed to be mediated by PI3K and MAPK ([@B411]). GLP-1R also promotes increased adipocyte mass through preadipocyte proliferation and inhibition of apoptosis, mediated by ERK-, PKC-, and AKT-signaling pathways ([@B55]).

##### iv. Nervous System. {#s63}

GLP-1R expressed in the nucleus tractus solitarius signals to suppress food intake and reduce body weight, and this is proposed to be mediated through PKA ([@B182]). PKA decreases phosphorylation of AMPK and increases phosphorylation of p44/23 MAPKs/mitogen-activated protein kinase (MEK) ([@B182]).

##### v. Cardiovascular System. {#s64}

GLP-R is thought to confer cardioprotection through a number of mechanisms, including reducing damage caused by ischemia via inhibiting apoptosis and through oxidative stress, and improving energy utilization. GLP-1 is able to reduce infarct size in rat hearts, an effect that is attenuated by inhibition of cAMP, PI3K, and p42/44 MAPK and GLP-1R, and also requires activation of the mTOR/p70s6 kinase pathway ([@B37], [@B38]). Murine studies have implicated additional important signaling molecules. The GLP-1R--dependent cardioprotective effects of liraglutide in mouse cardiomyocytes were associated with an elevation of cAMP and increased caspase-3 activity ([@B349]). In addition, liraglutide-mediated suppression of glycogen synthase kinase 3-*β* (GSK-3β) and caspase-3 activation in murine hearts was not evident in GLP-1R knockout mice ([@B349]), confirming that these effects are receptor-dependent. Stimulation of GLP-1R also decreases H~2~O~2~-induced production of reactive oxygen species and upregulation of antioxidant enzymes in an Epac-dependent manner ([@B291]).

GLP-1 may signal via AMPK and Akt to improve glucose metabolism after an injury to promote recovery. These were important mediators upon exenatide treatment of TG9 mice that caused improved cardiac contractility, elevated myocardial GLUT4 expression, and increased uptake of 2-deoxyglucose ([@B490]).

### 2. Ligand-Directed Signal Bias. {#s65}

As described above, GLP-1R is pleiotropically coupled to a range of signaling effectors, each of which can impact on the physiologic response elicited by receptor activation. This allows the potential for individual ligands to evoke different patterns of response upon interaction with the receptor in what is termed ligand-directed biased signaling ([@B434]). Such biased signaling and regulation are thought to arise through the stabilization of distinct ensembles of receptor conformations that occur through the varying chemical contacts between ligands and the receptor. Although gross changes in signal bias can be recognized as a reversal of potency or efficacy ([@B227]; [@B243]; [@B434]), less dramatic effects require a quantitative framework to identify significant differences in ligand response. The most robust method to quantify efficacy is the operational model of Black and Leff ([@B226]), with the transduction ratio of *τ*/K~A~ used to define strength of signaling of an individual ligand for a specific pathway, and this ratio can be determined from classic concentration-response experiments ([@B228]).

#### a. Peptide-mediated signal bias. {#s66}

There are multiple endogenous peptides that can interact with and activate GLP-1R, including the fully processed GLP-1~7--36\ amide~ and GLP-1~7--37~ peptides, the extended 1--36 and 1--37 forms of these peptides, as well as oxyntomodulin. The search for more stable forms of GLP-1 has also provided a range of mimetic peptides, including exendin and modified forms of GLP-1 that have been developed for therapeutic use (*V. Pharmaceutical Development and Therapeutic*s). Evidence for biased signaling requires measurement of multiple signaling endpoints. Early work characterizing ligands for GLP-1R was largely limited to measurement of cAMP, as the latter is the most well-coupled pathway and critical for the incretin effect on *β* cells. Therefore, it is only relatively recently that evidence for ligand-directed signaling has emerged.

Initial studies used heterologously expressed GLP-1R to more broadly examine three canonical pathways that have been linked to physiologic signaling in *β* cells, specifically cAMP accumulation, ERK phosphorylation, and intracellular calcium (iCa^2+^) mobilization. Even with this relatively limited assessment of signaling, quantitative evidence for peptide-mediated signal bias was observed, with oxyntomodulin exhibiting a relative bias toward pERK over cAMP and iCa^2+^ signaling compared with either GLP-1 or exendin ([@B249]), and this supported earlier observations of differences in cAMP signaling and *β*-arrestin recruitment between oxyntomodulin and GLP-1~7--36\ amide~ ([@B220]). Likewise, the extended form of GLP-1~1--36\ amide~ had a relative bias toward pERK, but a loss of iCa^2+^ signaling. Thus, this work demonstrated GLP-1R was subject to the potential for peptide-mediated biased signaling, although no significant bias was observed between amidated and nonamidated forms of GLP-1~7--36~ or between GLP-1 and exendin for these pathways ([@B249]). More extensive analysis of signaling and regulatory pathways that included recruitment of arrestins revealed additional tiers of biased signaling with both exendin and oxyntomdulin exhibiting stronger arrestin recruitment relative to GLP-1~7--36\ amide~, whereas GLP-1~1--36~ did not recruit arrestins ([@B523]) ([Fig. 5](#F5){ref-type="fig"}, left panel), at least in this recombinant system. The synthetic 11-mer peptide, BMS21, although much less potent than GLP-1~7--36\ amide~, had a relatively similar profile of activation of the canonical pathways (cAMP, pERK, and iCa^2+^), but did not elicit recruitment of arrestins ([@B523]). Intriguingly, the principal metabolite of GLP-1, GLP-1~9--36\ amide~, displays a relative preservation of pERK signaling ([@B261]; [@B522]), despite a marked attenuation of cAMP production and ability to induce insulin secretion ([@B522]), indicating that this peptide is strongly biased toward pERK and may be capable of signaling in a physiologically relevant manner. Additional evidence for peptide-mediated signaling bias is seen with a yeast assay of chimeric G protein activation ([@B499]), consisting of the yeast G protein GPA1 substituted by five amino acids from the human G*α* sequence. In this system, exendin, oxyntomodulin, and glucagon exhibited relative bias toward the GPA1/G*α*i chimera over the GPA1/G*α*s chimera when compared with signaling by GLP-1~7--36~, whereas liraglutide had a similar profile of signaling to GLP-1 across these two pathways ([@B499]). This indicates that biased signaling occurs even at the level of G protein recruitment and is consistent with stabilization of different ensembles of receptor conformations by different peptide ligands.

![Web of bias illustrating distinctions in the pattern of signaling of different peptide agonists (left panel) or nonpeptidic modulators (right panel) at GLP-1R. The web of bias plots ΔΔ*τ*/K~A~ values on a logarithmic scale for each ligand and for every signaling pathway tested. Formation of these values included normalization to the reference ligand GLP-1~7--36\ amide~ and the reference pathway, cAMP accumulation. The plots do not provide information on absolute potency, but on relative efficacy for signaling of individual pathways in comparison with that for cAMP. Data are from [@B249]; [@B515]; and [@B523].](pr.115.011395f5){#F5}

#### b. Nonpeptide-mediated bias. {#s67}

There has been considerable interest in the development of nonpeptidic ligands for GLP-1R as leads with improved bioavailability ([@B56]; [@B236]; [@B516]). Although these ligands are principally tested in assays of cAMP formation and insulin secretion, a number of these compounds have now been evaluated across a more broad range of pathways, enabling assessment of the extent to which these compounds exhibit bias relative to native GLP-1 signaling. The most extensively studied are the Eli Lilly compound, 4-(3-benzyloxyphenyl)-2-ethylsulfinyl-6-(trifluoromethyl)pyrimidine (BETP), and the Novo Nordisk compound 2 ([@B67]; [@B249]; [@B60]; [@B515]; [@B523]), but there are now some data comparing signaling for Boc5 and the TransTech Pharma compound TT15 ([@B523]). Although these compounds have low potency for cAMP production, relative to native GLP-1~7--36\ amide~, they also exhibit distinct patterns of signal bias ([@B249]; [@B523]). This can be illustrated in a web of bias ([Fig. 5](#F5){ref-type="fig"}, right panel), which reveals that Boc5 and TT15 have similar patterns of signaling via GLP-1R for canonical pathways (cAMP, pERK, and iCa^2+^), but have diminished ability to recruit arrestin proteins. In contrast, compound 2 and BETP have a relatively enriched ability to recruit arrestins, but distinct effects on pERK and iCa^2+^ mobilization, where BETP trends towards reduced pERK but higher iCa^2+^, and compound 2 has the opposite profile (compared to the reference cAMP pathway and the signaling profile of GLP-1). Additional differences in the behavior of compound 2 and/or BETP have also been noted by others ([@B67]; [@B60]; [@B458]), albeit that a lack of a quantitative framework for these analyses meant that potential implications for signaling bias were not fully explored. The fact that these nonpeptidic compounds have distinct profiles of signaling is not surprising, as their chemical diversity means that they interact with the receptor very differently from peptidic ligands. Indeed, BETP and compound 2 interact with the intracellular face of GLP-1R in a manner that involves covalent modification of C347 in ICL3/TM6 ([@B347]).

### 3. Molecular Basis for Signal Bias. {#s68}

There is increasing evidence demonstrating that the conformational change that drives activation transition involves reordering of hydrogen bond networks and intrahelical packing. Such a change promotes reorganization of the intracellular face of the receptor, thereby enabling interaction with intracellular effectors ([@B545]; [@B75]; [@B12]; [@B211]). These networks are relatively well conserved within GPCR subfamilies and involve conserved polar residues ([@B483]). This is best studied for class A GPCRs, and suggests that there is evolutionary conservation of the mechanisms underpinning activation transition. Although there is limited direct homology in the amino acid sequence of the TM domains between the major receptor families, it is expected that such conserved polar residues within class B GPCRs play a similarly important structural role and contribute to the mechanism of ligand-directed biased signaling. This view is supported by experiments in which conserved intramembranous polar residues in GLP-1R were mutated to alanine. A cluster of residues, including R190^2.60b^, N240^3.43b^, H363^6.52b^, and Q394^7.49b^, when mutated, was shown to change the signaling profile of the receptor for cAMP, pERK, and iCa^2+^ in both a residue-specific and ligand-specific manner ([@B525]). Although differences were particularly marked between GLP-1 and oxyntomodulin, selective differences in the effect of mutation were also seen between GLP-1 and exendin, providing molecular evidence that the mechanism of receptor activation differs between these two peptides, despite relatively similar overall efficacy for the peptides across these pathways at the wild-type receptor ([@B525]). In addition to these residues that displayed ligand-specific effects, there was a series of serine residues (S155^1.50b^, S186^2.56b^, and S392^7.47b^) that played a role in the control of receptor-dependent signal bias; however, these had global effects on all peptides ([@B525]). These residues sit at the interface between either TM1 and TM7 (S155^1.50b^ and S392^7.47b^) or TM2 and TM3 (S186^2.56b^) and are most likely involved in tight packing of these helices. With the solution of crystal structures of the TM domain of the related CRF~1~ and glucagon receptors ([@B198]; [@B435]; [@B215]), it is now possible to model the location of these residues with improved precision. Intriguingly, such modeling indicates that these residues reside at a fulcrum position of the receptor TM bundle, where the splayed helices of the open extracellular face of the receptor converge ([Fig. 6](#F6){ref-type="fig"}), with the residues that contribute to ligand-dependent signaling forming a central interaction network and the smaller polar residues that are globally important for signaling external to this core.

![Homology model of GLP-1R illustrating the relative position of key residues involved in the receptor-signaling bias. The modeling indicates that these residues reside at a fulcrum position of the receptor transmembrane bundle, where the splayed helices of the open extracellular face of the receptor converge, with the residues that contribute to ligand-dependent signaling forming a central interaction network (space fill, red) and the smaller polar residues that are globally important for signaling external to this core (space fill, blue). The receptor is displayed in three views at different horizontal rotation. Transmembrane helices are numbered with Roman numerals.](pr.115.011395f6){#F6}

Although not broadly conserved across the class B subfamily, there is an additional polar threonine in TM1, at position 149^1.44b^, that is the site of a naturally occurring polymorphism leading to incorporation of a methionine in this position ([@B28]). Methionine at this position leads to a marked loss in coupling of the receptor to cAMP accumulation ([@B125]; [@B248]) and iCa^2+^ mobilization, whereas ERK phosphorylation is relatively preserved ([@B248]). This is a global effect for peptide activators of the receptor ([@B248]). Exploration of the tolerance of this position to different amino acids revealed that serine substitution had relatively minimal detrimental effect, suggesting that maintenance of the polar nature of this residue is important. However, amino acids of similar size, although leading to attenuation of response in a pathway-specific manner, were the least affected, indicating that side chain packing was also important ([@B246]). Thus, this mutation changes the physiologic bias of the receptor in addition to markedly attenuating peptide-mediated signaling.

Although these experiments have been principally interpreted in the context of in cis signaling of receptor to effectors, GLP-1R, like most, if not all class B GPCRs, undergoes functionally important dimerization ([@B177], [@B176], [@B178]; [@B133]; [@B416]). Intriguingly, disruption of the TM4 dimer interface of GLP-1R differentially impacted the signaling elicited by agonist peptides with a greater abrogation of iCa^2+^ mobilization relative to that of either cAMP accumulation or ERK phosphorylation ([@B178]). This indicates that differential ligand-mediated signaling could also involve the allosteric interaction of protomers within a receptor dimer.

In addition to an emerging appreciation of how ligands can selectively alter key hydrogen-bonding networks, there is some limited information on how extracellular loop residues contribute to peptide-mediated bias, in particular for ECL2 ([@B245],[@B247]). K288^ECL2^, C296^ECL2^, W297^ECL2^, and N300^ECL2^ had critical roles in governing signal bias of the receptor, but were also globally important for peptide signaling. Nonetheless, peptide-specific effects on relative efficacy and signal bias were most frequently observed for residues 301--305, although R299^ECL2^A mutation also exhibited different effects for individual peptides. M303^ECL2^ appeared to play a greater role for exendin and oxyntomodulin actions than those of GLP-1 peptides. Interestingly, ECL2 mutation was generally more detrimental to exendin-mediated iCa^2+^ mobilization than GLP-1~7--36\ amide~, providing additional support for subtle variances in receptor activation by these two peptides.

### 4. Allosteric Modulation. {#s69}

As described above (*II. Glucagon-Like Peptide-1* and *III. Glucagon-Like Peptide 1 Receptor*), peptide ligands engage GLP-1R via a diffuse pharmacophore that includes key interactions for affinity with the N-terminal extracellular domain, as well as poorly defined interactions with the extracellular loops and TM domain core that drive receptor activation. Nonpeptidic ligands have a distinct mode of binding, and in many cases can do so via topographically distinct, allosteric sites from those of the native peptides. Such ligands can bind simultaneously with peptide ligands and interact in a cooperative manner to alter the binding and/or efficacy of peptide signaling (and vice versa) ([@B259]; [@B301]; [@B229]; [@B521]; [@B140]). Allosteric modulation of GPCRs is now a well-established paradigm that provides both advantages and challenges for drug discovery when compared with classic orthosteric ligands ([@B521]). The first characterized allosteric modulators of GLP-1R were identified by Novo Nordisk, and are exemplified by compound 2, which, as noted above, is an allosteric agonist of the receptor. In addition to its intrinsic efficacy, this series of compounds augmented the binding of radiolabeled GLP-1, indicating that it could act as a positive allosteric modulator ([@B236]). Nonetheless, there was only limited impact on the efficacy of GLP-1R for cAMP signaling. A hallmark of allosteric interactions is the phenomenon of probe dependence that describes the capacity for different effects, depending upon the orthosteric and allosteric ligand combination. This is also observed for ligands of GLP-1R. Although compound 2 has only limited effect on GLP-1~7--36\ amide~--induced cAMP production, it yields a ∼30-fold augmentation of oxyntomodulin signaling via this pathway ([@B249]; [@B516]; [@B523]). Probe dependence is also seen for effects on the extended GLP-1 peptides and exendin, where very limited augmentation of cAMP signaling is observed. A similar pattern of effect is observed for BETP in that this compound also augments oxyntomodulin signaling, but has minimal effect on GLP-1~7--36\ amide~--, exendin-, or GLP-1~1--36\ amide~--mediated cAMP production ([@B516]; [@B523]). A weak potentiation of compound 2--mediated cAMP production (or surrogate readouts such as cAMP response element--driven luciferase reporter) has also been reported for interaction of this ligand with truncated forms of exendin, including exendin~5--39~, exendin~7--39~, and exendin~9--39~, even in the absence of any measurable intrinsic activity ([@B67]; [@B60]).

Intriguingly, if the cooperative effect of BETP or compound 2 is studied over a broader array of signaling endpoints, then marked differences in effect are observed ([@B245]; [@B261]; [@B522], [@B523]). In contrast to the selective augmentation of cAMP response for oxyntomodulin, the allosteric ligands confer a similar, modest enhancement of arrestin recruitment for both GLP-1 and oxyntomodulin ([@B516]; [@B523]), although a greater degree of negative cooperativity is seen on pERK responses of GLP-1~7--36\ amide~ versus oxyntomodulin. Thus, the allosteric ligands also alter the signaling bias mediated by endogenous peptides. This is perhaps not surprising as both signaling bias and the cooperative effects of cobound ligands are driven through changes to the ensemble of conformations that the receptor samples ([@B521]). Indeed, the allosteric ligand-bound receptor can effectively be considered a distinct receptor for the interaction of the natural ligand(s).

Remarkably, both BETP and compound 2 very strikingly enhanced the cAMP response of the principal GLP-1 metabolite, GLP-1~9--36\ amide~, by up to ∼400-fold in the case of compound 2 ([@B261]; [@B522]). Parallel augmentation of insulin secretion was observed in isolated rat islets and in vivo when pharmacological levels of the metabolite were coadministered with subthreshold levels of BETP ([@B522]). The augmentation of signaling was principally limited to cAMP production, although weak potentiation of pERK and iCa^2+^ signaling was seen in HEK293 cells recombinantly expressing the receptor and INS-1E cells ([@B261]), but not in CHO cells recombinantly expressing the receptor ([@B522]), providing further evidence that allosteric modulators can alter the signal bias of the receptor. Nonetheless, the lack of effect on the extended GLP-1 peptide indicates that the magnitude of the cooperative effect of BETP and compound 2 is not driven solely by the intrinsic efficacy of the activating peptide.

Ligands such as BETP and compound 2 are highly electrophilic and can form adducts with free cysteine residues ([@B117]). This is a feature of the action of these molecules to form, in particular, the covalent interaction with C347^6.36b^ in ICL3/TM6 that is critical for both the intrinsic efficacy and the cooperative allosteric effect ([@B347]). Nevertheless, the covalent modification of the cysteine is insufficient to explain the full extent of activity of these compounds as BETP and compound 2 have differences in their profile of intrinsic efficacy (see above) and also in their cooperative effect ([@B523]). Interestingly, there is a naturally occurring polymorphism that can appear at position 333 of the human receptor, being either a serine or a cysteine with the latter occurring only rarely ([@B248], [@B246]). However, the C333^ICL3^ variant selectively abrogates compound 2--mediated cAMP production and cooperativity between compound 2 and oxyntomodulin for this pathway ([@B248]) while maintaining peptide-mediated signaling, suggesting that the environment surrounding C347^6.36b^ is important for the action of compound 2. In contrast to the effect of the C333^ICL3^ polymorphism, the M149^1.44b^ polymorphic variant has no effect on the intrinsic efficacy of compound 2, but, as noted above, causes a very marked attenuation of peptide-mediated cAMP signaling with over 100-fold loss of GLP-1~7--36\ amide~ or exendin potency. At this mutant, compound 2 could restore the potency of both GLP-1~7--36\ amide~ and exendin to that of the wild-type receptor ([@B248]). Thus, allosteric modulators have the capacity to alleviate genetic disease arising from the loss of function of GLP-1R.

Disruption of the TM4 dimer interface of GLP-1R also abolishes the intrinsic efficacy of BETP and compound 2, but the cooperative augmentation of cAMP signaling by oxyntomodulin is maintained, indicating that the allosteric effect occurs in cis at least for this class of ligands ([@B178]).

Although compounds such as BETP and compound 2 were among the first recognized and the most widely studied allosteric modulators of GLP-1R, a number of additional compounds have been reported to act as modulators of peptide response. This includes the flavonol, quercetin, which lacks intrinsic activity, but could selectively augment calcium signaling of efficacious peptides such as GLP-1~7--36\ amide~, GLP-1~7--37~, and exendin, albeit that an inhibition of response was seen with high concentrations of quercetin ([@B249]; [@B524]). This augmentation of iCa^2+^ was dependent upon the presence of a 3-hydroxyl group on the flavone backbone and was improved when a 3′4′-dihydroxyl modification was present ([@B524]). An additional series of compounds that could selectively enhance iCa^2+^ signaling was recently reported following high-throughput screening ([@B322]). Unlike the flavonols, this series of compounds had significant intrinsic efficacy for mobilization of iCa^2+^. An exemplar from this series, termed (S)-9b, was examined in further detail, in which it was reported to also augment liraglutide-mediated GLP-1R internalization in recombinant cells and exendin-mediated insulin secretion in primary mouse islets ([@B322]). This latter effect occurred in both high and low glucose, which would be problematic from a therapeutic standpoint, but may also require further investigation to determine whether this is mediated by GLP-1R. Likewise, compound (S)-9b reduced haloperidol-induced catalepsy in rats ([@B322]), but, again, it needs to be confirmed whether this effect is mediated via GLP-1R. In other work, using virtual screening against a molecular model of GCGR, [@B80] identified a number of compounds that had activity at both GCGR and GLP-1R, including weak antagonists and one compound that acted as an inhibitor of glucagon-mediated cAMP production at GCGR, but as a weak positive modulator of GLP-1R--mediated cAMP response.

At this point in time, the physiologic or therapeutic implications of biased signaling are largely unknown. Despite differences in the signaling/regulatory profile of compounds such as Boc5 or TT15, these compounds (or similar analogs) have demonstrated efficacy in modulation of ex vivo and in vivo insulin secretion ([@B56]; [@B183]). Allosteric compounds such as BETP or compound 2 likewise can augment insulin secretion, albeit that this is complicated by endogenous circulating peptides. Pharmacologically, both BETP and compound 2 can augment responses of oxyntomodulin and the GLP-1 metabolite (GLP-1~9--36\ amide~), and this is linked to increased in vivo insulin secretion, at least in the context of threshold doses of the allosteric and orthosteric peptides ([@B516]; [@B522]). In vitro assessment of the effect of the modulators on the signaling profile of oxyntomodulin or GLP-1~9--36\ amide~ indicates that their most prominent effect is to augment cAMP production, suggesting that this alone may be sufficient to improve insulin secretion, at least in the context of the baseline signaling of the peptides/modulators. The significance for GLP-1R function outside of insulin secretion is even less clear, as there has been very limited assessment of these other functions and none controlled for the influence of biased signaling. A major current limitation is the range of tools available to probe the significance of signaling differences. Most nonpeptidic compounds have low potency, nonfavorable pharmacokinetic profiles, or unknown interaction with other targets that limits their utility. Exendin is biased relative to GLP-1~7--36\ amide~, but this difference is subtle in the context of canonical signaling, making interpretation of physiologic data difficult. Oxyntomodulin is the most biased of the characterized peptides, displays good affinity for GLP-1R, and has distinctions in its physiologic actions from GLP-1, but dissecting the importance of this bias is complicated by its significant interaction with GCGR ([@B377]). Nonetheless, this may be a useful tool to study biased signaling in GCGR knockout animals. Additional approaches to infer the potential role of selective activation of signaling/regulatory pathways include the generation of knock-in mice that have receptors designed to selectively abrogate signaling via a specific pathway (e.g., G protein versus arrestin), although the development of potent biased peptide ligands could also provide novel scope for better understanding this phenomenon.

D. Receptor Regulation {#s70}
----------------------

### 1. Receptor Desensitization. {#s71}

The activity of GLP-1R, like all GPCRs, is regulated by a coordinated balance between molecular mechanisms governing receptor signaling, desensitization, and resensitization. Receptor desensitization, or the reduced responsiveness of GPCR signaling to an agonist with time, is an important physiologic feedback mechanism that protects against both acute and chronic receptor overstimulation ([@B123]). This has important biologic and therapeutic implications.

GLP-1R undergoes rapid and reversible homologous and heterologous desensitization that has been observed in recombinant cell systems, in primary islets of Langerhans, and in insulinoma *β* cell lines ([@B122]; [@B160]; [@B509],[@B510]). Homologous desensitization refers to the loss of response to subsequent agonist stimulation following direct stimulation of the receptor and can occur through controlling the number of receptors present at the cell surface or by regulating the efficacy of the receptors at the cell surface. Heterologous desensitization describes receptor activation-independent regulation of receptors as well as mechanisms that occur after receptor activation that do not discriminate between activated, and nonactivated, receptors ([@B123]).

Acute incubation of islet cells with native GLP-1 induces rapid homologous GLP-1R desensitization in vitro ([@B122]; [@B160]). In addition, exendin-4 also produces GLP-1R desensitization in islet cells following both acute and chronic exposure; however, this ligand is associated with a greater degree of desensitization compared with comparable incubations with GLP-1 ([@B21]). Heterologous desensitization has been demonstrated in islets in response to multiple stimuli. For instance, GLP-1R heterologous desensitization was observed via acute exposure to phorbol myristate acetate (PMA), an activator of PKC ([@B509],[@B510]; [@B21]). In addition, prolonged hyperglycemia can induce desensitization, followed by downregulation with diminished responses to GLP-1R agonists that include weakened insulin secretion, reduced phosphorylation of CREB, impaired cAMP responses and PKA activity, and a reduction in GLP-1R mRNA ([@B388]).

There is also the possibility that heterologous desensitization may occur due to activation of other receptors expressed in *β* cells that are involved in tightly controlling insulin secretion. To date, this has only been assessed with the ligand for GIPR. GLP-1R can heterodimerize with GIPR in vitro, with evidence that this heterodimerization can alter cellular signaling and trafficking profiles of GLP-1R ([@B416]; [@B398]). However, despite their overlapping functions for signaling and insulin secretion, GIP does not produce meaningful heterologous desensitization of GLP-1R in islet cell studies ([@B388]).

### 2. Underlying Mechanisms. {#s72}

Desensitization is a consequence of a number of different mechanisms. They include uncoupling the receptor from heterotrimeric G proteins in response to receptor phosphorylation, the internalization of receptors to intramembranous compartments, and the downregulation of the total complement of receptors ([@B123]).

#### a. GLP-1R phosphorylation. {#s73}

The most rapid mechanism by which GPCRs are desensitized is through the covalent modification of the receptor as a consequence of phosphorylation by intracellular kinases, either G protein--coupled receptor kinases (GRKs) or second messenger kinases ([@B123]). Both homologous and heterologous desensitization of GLP-1R are accompanied by phosphorylation of serine residues within the last 33 amino acids of the C-terminal tail ([@B509],[@B510]).

#### b. GRKs. {#s74}

For most GPCRs, homologous desensitization is thought to involve phosphorylation by GRKs that results in recruitment of *β*-arrestins. In vitro studies in fibroblast cells expressing GLP-1R revealed that homologous desensitization was associated with phosphorylation of serine residues 441/442, 444/445, and 451/452 in the C terminus ([@B511]). Desensitization of GLP-1R--mediated cAMP responses after a first initial exposure of cells to GLP-1 was strictly dependent on the extent of phosphorylation with no, intermediate, or maximum phosphorylation observed in the presence of one, two, or three of the serine doublet phosphorylation sites, respectively.

Although various groups, using a number of techniques, have demonstrated that stimulation of GLP-1R leads to recruitment of both GRKs and *β*-arrestins ([@B221], [@B222]; [@B521]), to date, the direct involvement of these proteins in desensitization of GLP-1R response has not been demonstrated. In recombinant systems, GRK2 can interact with GLP-1R in response to stimulation by GLP-1 ([@B220], [@B222]). In addition, GRK2 has been linked to potentiation of *β*-arrestin 2 recruitment to the receptor. *β*-arrestin 1 is also recruited to GLP-1R upon activation by agonist ligands ([@B440]; [@B521]); however, whether recruitment of these proteins is required for internalization is currently not clear.

#### c. Second messenger protein kinases. {#s75}

Heterologous desensitization of GLP-1R occurs at least in part via the second messenger kinases, cAMP-dependent PKA and PKC ([@B510]; [@B388]). Direct activation of PKC by PMA markedly reduced the amplitude of GLP-1R--mediated calcium responses, whereas inhibitors of PKC slowed desensitization and increased the duration of calcium transients ([@B160]). Using fusion proteins of wild-type and mutant GLP-1R C-terminal tails, in vitro phosphorylation experiments revealed that PKC-mediated phosphorylation occurred predominantly at residues 431/432, and, whereas positions 444/445 and 451/452 could be phosphorylated by PKC, they were poor substrates. In these studies, the serine doublet 441/442 was not a substrate for PKC ([@B509]). In contrast, studies performed in intact COS-7 cells showed all four of these doublets could be phosphorylated following PKC activation by PMA. This could be attributed to different isoforms of PKC in intact cells or the possibility that other kinases downstream of PKC activation may be important for PMA-induced GLP-1R phosphorylation. Phosphorylation of at least two of these serine doublets was required to engender PMA-induced heterologous desensitization, with removal of any pair of doublets leading to receptors that were completely resistant to PMA-induced GLP-1R desensitization ([@B509]).

PKA has been implicated as a mediator of desensitization and downregulation of GLP-1R from the cell surface in pancreatic islets in conditions of chronic hyperglycemia ([@B388]). In MIN6 cells, reductions in cell surface receptor numbers in conditions of high glucose were mimicked by overexpression of a constitutively active PKA or continuous activation by forskolin. In addition, inhibition of PKA activity attenuated glucose-mediated downregulation of GLP-1R from the cell surface of these cells. Phosphorylation at serine 301, within the third intracellular loop of the receptor, is implicated in this PKA-mediated activity, with mutation of this residue abolishing glucose-dependent loss of the receptor from the cell surface. This was associated with a loss of an interaction between the receptor and the small ubiquitin-related modifier, SUMO ([@B388]). Sumoylation of GLP-1R causes intracellular retention of the receptor and desensitization of receptor signaling as well as prevents resensitization of the receptor back to the cell surface ([@B389]). This heterologous desensitization and subsequent downregulation of GLP-1R on the *β* cell surface by chronic hyperglycemic conditions have substantial implications for the efficacy of GLP-1--based therapies. Because SUMO expression is increased in mouse islets exposed to high glucose ([@B389]), its interaction with GLP-1R may in part contribute to the reduced efficacy of incretin therapies in some T2DM patients with poorly controlled hyperglycemia ([@B128]; [@B444]; [@B234]).

### 3. In Vivo Evidence of Desensitization. {#s76}

Given the clinical interest in the therapeutic benefits of achieving sustained chronic elevations of GLP-1R agonists in the plasma through repeated or continual administration, the scope of GLP-1R desensitization has direct therapeutic relevance. Up to now, only a few studies have addressed the relevance of GLP-1R desensitization in vivo. Chronic or intermittent intracerebroventricular GLP-1 administration inhibited food intake and reduced weight gain in rats ([@B78]). Similarly, chronic intermittent administration of GLP-1R agonists to diabetic rodents is associated with inhibition of food intake, improvement of glycemia, and reduction in hemoglobin A1c (HbA1c), demonstrating that repeated administration of GLP-1 is not associated with a diminished therapeutic response in vivo ([@B450]; [@B400]; [@B230]).

Considering the prolonged activity and stability of GLP-1 mimetics compared with native GLP-1 ([@B538]), it seems likely that islet cells and extrapancreatic GLP-1R would be exposed for a greater period of time with these ligands than the endogenous peptides. In vitro studies showed that exendin-4 is more potent than GLP-1 in producing GLP-1R desensitization; however, chronic exposure to exendin-4 in normal or transgenic mice that express exendin-4 was not associated with significant downregulation of GLP-1R--dependent responses coupled to glucose homeostasis ([@B21]). Furthermore, patients treated with twice-daily exendin-4 or once-weekly liraglutide continue to exhibit a decrease in HbA1c and marked reductions in postprandial glycemic excursion ([@B47]; [@B83]). Therefore, although in vitro experiments clearly demonstrate that GLP-1R has the capacity for desensitization, there is little evidence that it undergoes clinically meaningful desensitization in vivo in terms of glucose regulation.

There is, however, some limited evidence for desensitization occurring in vivo ([@B335]). Administering native GLP-1 continuously into healthy human subjects for 8.5 hours, followed by assessment of glucoregulatory responses to liquid test meals given 5 hours apart with ongoing continuous GLP-1 infusion, demonstrated a reduced ability of GLP-1 to suppress gastric emptying and glucagon levels by the second test meal. In addition, levels of pancreatic polypeptide, a marker of vagal activation, were not as inhibited during the second test meal compared with the first. However, C-peptide and insulin levels were preserved with only a small reduction in the second meal. These studies reveal that even short-term continuous GLP-1R stimulation may be associated with some degree of rapid tachyphylaxis, most evident in effects mediated through the vagus nerve and gastric emptying ([@B335]). Despite this evidence for in vivo desensitization, the physiologic significance of this is still unclear.

### 4. Receptor Internalization. {#s77}

GLP-1R rapidly internalizes as a complex associated with its bound ligand. This has been observed for GLP-1, exendin-4, liraglutide, and compound 2 ([@B508]; [@B252]; [@B399]). In BRIN-BD11 cells, antibody-labeled GLP-1R and fluorescently labeled GLP-1 were colocalized at the perinuclear space following internalization ([@B252]). Furthermore, internalization of fluorescently labeled GLP-1, exendin-4, and liraglutide has been observed in both recombinant cell systems and primary mouse pancreatic islets ([@B399]). There is also some evidence of ligand-directed bias with GLP-1R internalization, although this has not been directly quantified. The potencies for internalization by GLP-1 and exendin-4 were 10-fold higher than liraglutide, although kinetics of internalization were similar for all three ligands ([@B399]).

Currently, the mechanism for GLP-1R internalization in vivo is unclear, as there is evidence that this mechanism may be cell-type dependent ([@B508]; [@B481]; [@B449]; [@B458]). As GLP-1R is expressed in multiple tissues throughout the body with distinct physiologic functions depending upon the location of the receptor, this implies that the mechanism and role of receptor internalization and desensitization may be tissue-dependent. In different cell backgrounds, two distinct mechanisms of internalization have been observed, with both mechanisms dependent on dynamin ([@B508]; [@B449]; [@B252]).

Studies performed in CHO and CHL cells recombinantly expressing GLP-1R revealed internalization via clathrin-coated pits, although these studies indicated that there might not be complete internalization via this method ([@B508]; [@B481]). Studies in CHL fibroblasts demonstrated that the same three phosphorylation sites linked to homologous desensitization of GLP-1R--mediated cAMP responses (441/442, 444/445, and 451/452) are also important for internalization, supporting a correlation between phosphorylation at these sites and internalization ([@B511]). However, the exact contribution of each phosphorylation site to desensitization of the cAMP response and internalization is different, indicating that the precise molecular basis for control of receptor desensitization and endocytosis is, at least in part, distinct. In addition to phosphorylation of these serine doublets, a region of the C-terminal tail close to the bottom of TMD7 is also of importance in mediating agonist-dependent GLP-1R internalization ([@B481]).

Traditionally for GPCRs, *β*-arrestin recruitment targets receptors for clathrin-mediated internalization ([@B123]). However, the literature indicates that this may not be the case for GLP-1R in some cell backgrounds, despite the ability of the receptor to interact with these proteins ([@B449]). Although there is little literature on the role that *β*-arrestin 2 plays in GLP-1R internalization and desensitization, there is some evidence that these processes can occur independently of *β*-arrestin recruitment, in a clathrin-independent mechanism. Studies performed in HEK293, COS-7, and MIN6 cells exhibited caveolin-1 regulation of internalization ([@B449]; [@B458]). GLP-1R contains a classic caveolin-1--binding motif within the second intracellular loop such that it interacts and colocalizes with the protein intracellularly. Occurrence of this interaction was also supported by studies using inhibitors of caveolin-1. This mechanism of GLP-1R internalization has been proposed to occur through activation of G*α*q proteins, followed by activation of PKC ([@B458]). In support of *β*-arrestin--independent internalization, it was shown that knockdown of *β*-arrestin 1 in INS-1 cells had no effect on internalization or desensitization of GLP-1R ([@B440]).

Although internalization can contribute to desensitization of receptors, internalization and desensitization are two distinct phenomena. Internalization has the potential to contribute to termination of some GLP-1R--mediated signaling events; however, it does not terminate all components of this signaling ([@B252]; [@B398]). A recent study revealed that inhibition of internalization using a dominant-negative form of dynamin (K44E) resulted in decreased cAMP formation, ERK1/2 phosphorylation, and calcium signaling, suggesting that at least some of the signaling mediated by these pathways occurs via internalized receptors. In addition, inhibition of GLP-1R internalization also attenuates insulin secretion, confirming that internalization is an integral part of the signaling process for this receptor ([@B252]). Using fluorescently labeled ligands and receptors, studies in recombinant systems displayed colocalization of internalized GLP-1R with adenylate cyclase in endosomes ([@B252]). Taken together, these findings all imply that GLP-1R continues to signal following internalization, and that internalization is not necessarily part of the mechanism for desensitization. This level of spatiotemporal control achieved by the compartmentalization of signaling through internalization may be vital to specific, fine-tuned responses from GLP-1R activation and may have substantial implications both physiologically and therapeutically for targeting this receptor in disease management.

### 5. Receptor Resensitization. {#s78}

GLP-1R resensitization has not been extensively studied. Following desensitization, GLP-1R--mediated calcium signaling resensitizes after removal of extracellular ligand within 1 hour and does not require de novo protein synthesis ([@B160]). After internalization, GLP-1R colocalizes with transferrin, a marker for recycling endosomes, suggesting that it is recycling GLP-1R that is returned back to the cell surface after internalization ([@B399]). Moreover, there is evidence in HEK293 cells that GLP-1R recycles back to the cell surface in response to GLP-1, exendin-4, and liraglutide, even after prolonged agonist treatment. However, recycling was two to three times slower for exendin-4 and liraglutide compared with GLP-1 ([@B399]). In the presence of GLP-1, receptors were found in transferrin-positive endosomes up to 45 minutes post ligand addition, whereas in the presence of exendin-4 and liraglutide colocalization of internalized GLP-1R and transferrin was observed for up to 60 minutes following ligand addition. Resensitization is important, as irreversible desensitization would leave a cell unable to respond to external stimuli, and therefore this mechanism protects against prolonged desensitization ([@B123]). Nonetheless, to date, the mechanism of GLP-1R resensitization remains largely unknown and requires further investigation.

There is also evidence of partial degradation of GLP-1R upon prolonged activation with exendin-4, liraglutide, and GLP-1, with colocalization observed between the receptor and lysosomes ([@B252]; [@B399]). This mechanism leads to downregulation of receptor numbers.

IV. Pharmacological Tools {#s79}
=========================

A. Traditional Bioassays {#s80}
------------------------

As GLP-1 exerts its vital physiologic and pharmacological functions through interacting with its receptor on the cell membrane, it is important to measure and determine the activities of the peptide and its analogs through the biologic actions of the protein. There are traditional bioassays ([Table 2](#T2){ref-type="table"}) to determine receptor-binding affinity and activation of the receptor, and several unique methods have been reported for assessing molecular recognition and biochemical consequences. In addition, molecular imaging of the receptor has demonstrated a potential for noninvasive monitoring of pancreatic *β* cells, which may be of great value in the diagnosis and prognosis of diabetes, tracking the disease progression, and evaluating therapeutic interventions, including islet regeneration and transplantation.

###### 

Summary of traditional biologic assays for GLP-1 analogs

  Molecular/Cellular Measurement                                                                     Description/Outcome                                                                                                                                                                                                                                  References
  -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  **Receptor-binding assays:**                                                                                                                                                                                                                                                                                                                            
  Radioligand competition                                                                            Determines binding affinity (IC~50~ or K~d~) by measuring radioactivity remaining on the receptor after competitive inhibition of radioligand with a GLP-1 analog.                                                                                   [@B297]; [@B462]; [@B528]
  Time-resolved fluorescence resonance energy transfer (FRET)                                        Determines binding affinity (IC~50~) by measuring a decrease in FRET signal between Tb-labeled receptor and fluorescent ligand after competitive inhibition with a GLP-1 analog.                                                                     [@B300]; [@B547]; [@B399]
  Circular dichroism and fluorescence spectroscopies                                                 Determines binding affinity by measuring conformational changes of a receptor protein upon ligand binding.                                                                                                                                           [@B405]
  Isothermal titration calorimetry                                                                   Determines thermodynamic parameters of binding, such as the dissociation constant, enthalpy change, entropy change, and reaction stoichiometry by measuring heat changes during receptor--ligand interaction.                                        [@B520]; [@B27]; [@B95]
  Total-internal reflection fluorescence imaging                                                     Determines equilibrium constants and dissociation rates by monitoring fluorescence-labeled single molecule on lipid bilayer.                                                                                                                         [@B126]; [@B330]
  Surface plasmon resonance                                                                          Determines dissociation constants by real-time measurement of receptor--ligand interaction.                                                                                                                                                          [@B27]; [@B423]; [@B268]
  Photoaffinity labeling                                                                             Identifies residues of peptide and receptor at binding interface that are spatially proximal to each other.                                                                                                                                          [@B62]; [@B218]; [@B489]; [@B58]; [@B306]
  **Receptor functional assays:**                                                                                                                                                                                                                                                                                                                         
  Homogeneous time-resolved fluorescence (HTRF) or alpha screen cAMP assays                          HTRF technology is an immunoassay based on a FRET between a Tris-bipyridine europium cryptate used as a long-lived fluorescent donor and a chemically modified allophycocyanin used as acceptor. Alpha technology is a bead-based proximity assay.   [@B141]; [@B111]
  Radioimmunoassay                                                                                   Determines receptor-stimulating potency (EC~50~) by quantitative analysis of cAMP production with immobilized anti-cAMP or anti-cGMP antibodies and radiolabeled cAMP/cGMP.                                                                          [@B121]; [@B504]
  FRET-based cAMP assay                                                                              Determines receptor-stimulating potency (EC~50~) by measuring a decreased FRET signal between fluorescent proteins (CFP and YFP) and Epac protein.                                                                                                   [@B204]; [@B344]; [@B256]; [@B174]; [@B437]
  Luciferase reporter assay                                                                          Determines receptor-stimulating potency (EC~50~) by measuring luminescence that is increased by transcription of transfected luciferase reporter plasmid linked to cAMP response element.                                                            [@B163]; [@B74]; [@B35]; [@B308]; [@B328]; [@B438]
  Intracellular calcium ion                                                                          Determines receptor activation by measuring intracellular Ca^2+^ level with calcium-sensitive dye, Fura-2.                                                                                                                                           [@B163]; [@B74]; [@B35]
  **Determination of incretin effects:**                                                                                                                                                                                                                                                                                                                  
  Glucose tolerance test (GTT; oral GTT, OGTT; intraperitoneal GTT, IPGTT; intravenous GTT, IVGTT)   Determines insulinotropic action of GLP-1 analogs by measuring glucose level after their administration.                                                                                                                                             [@B251]; [@B464]
  Insulin secretion                                                                                  Determines potency of GLP-1 analogs by measuring insulin secretagogue action.                                                                                                                                                                        [@B7]; [@B11]; [@B146]; [@B464]; [@B234]; [@B375]

B. Other Bioassays {#s81}
------------------

### 1. Receptor Trafficking. {#s82}

Endocytosis of GPCRs and postendocytic trafficking between recycling and endosomal degradation are fundamental mechanisms that control the signaling capacity of receptors. [@B449] studied the trafficking of green fluorescent protein--fused GLP-1R stably expressed on HEK293 cells in response to a GLP-1 agonist. It was found that GLP-1R associates with caveolin-1 in the lipid rafts of the cell membrane of HEK293 cells transfected with the green fluorescent protein--GLP-1R plasmid and MIN6 cells endogenously expressing the GLP-1 receptor. With confocal fluorescence microscopy and immunoprecipitation techniques, it was observed that stimulation by an agonist induces rapid and extensive internalization of the receptor in association with caveolin-1, and nearly all of the receptor was internalized after 15 minutes.

Similarly, [@B399] combined microscopy and a time-resolved fluorescence resonance energy transfer--based technique for monitoring both receptor trafficking and signaling in living cells. The GLP-1 receptor rapidly and repeatedly internalizes and recycles upon ligand activation. GLP-1R recycling was found to be two to three times slower when induced by exendin-4 and liraglutide, compared with GLP-1 at equipotent concentrations. Independent of the ligand, activated receptors demonstrated cycling for a prolonged period of time as well as sustained cAMP signaling.

### 2. Immunoassays. {#s83}

Determination of incretins, especially endogenous ones, by immunologic assays is considered difficult because differential processing of precursor molecules gives rise to a number of different peptides that may crossreact with antisera raised against GLP-1 ([@B84]). Subsequent degradation of the peptides by DPP-4 and NEP 24.11 further complicates the assay process ([@B185]).

When the full processing pattern of proglucagon was not fully elucidated, the assays were directed to the middle region of GLP-1 and became independent to the processing pattern. This caused peptides with a deletion or extension at either the N or C terminus to be detected in addition to GLP-1 itself. Antisera were then made toward either the C terminus ([@B189]; [@B201]; [@B355]) or the N terminus ([@B166]). However, it was found that C-terminally directed antisera reacted with peptides truncated or extended at the N terminus and could not distinguish the full-length GLP-1 from the metabolite resulting from DPP-4 degradation. Similarly, N-terminally directed antisera could not differentiate the intact peptide from truncated or extended peptides at the C terminus.

Kirk and coworkers developed a sandwich enzyme-linked immunosorbent assay for determining exogenous GLP-1~7--36\ amide~ in plasma samples collected from pharmacokinetic studies ([@B382]). It is referred to as active GLP-1 assay. This experiment employs an N-terminally directed antibody (polyclonal rabbit antibody directed to the residues at position 7--14) and a C-terminally directed antibody (monoclonal mouse antibody directed to the residues at position 26--33). When compared with a radioimmunoassay employing a polyclonal rabbit antibody directed to an epitope in the midregion of the peptide, it was found to be superior due to reduced crossreactivity with GLP-1 fragments. It has a working range from 10 to 500 pmol/L.

### 3. Pancreatic *β* Cell Regeneration. {#s84}

Besides insulin secretion from the pancreatic *β* cells in a glucose-dependent manner, GLP-1 can induce regeneration of the cells evidenced by immunohistochemical staining studies ([@B109]; [@B531]). PDX-1 is essential for pancreogenesis, pancreatic cell differentiation, and maturation. Perfetti and coworkers demonstrated that continuous infusion of GLP-1 to young and old rats upregulates PDX-1 expression in islets and total pancreas ([@B209]). They also found induced pancreatic cell proliferation and *β* cell neogenesis ([@B370]).

C. Molecular Imaging {#s85}
--------------------

Pancreatic *β* cells play an important role in glucose homeostasis, and their destruction is well documented with diabetes, in particular type 1. Whereas several clinical parameters, such as plasma glucose, glycated HbA1c, insulin, and C-peptide levels, indicate onset and progress of the disease, the majority of the *β* cells are destroyed by the time the symptoms appear ([@B299]). Late diagnosis of the disease results from the remaining *β* cells compensating for the loss of insulin production due to cell death, and abnormalities in blood glucose concentrations are not typically observed until *β* cell mass (BCM) is diminished by more than 50% ([@B441]). Thus, noninvasive imaging of BCM would provide accurate and in-time status as well as useful prediction. *β* cell imaging has potential in monitoring the disease progression, evaluating efficacy of therapeutic interventions in preserving and restoring BCM, and following up *β* cell replacement therapies such as islet transplantation ([@B170]).

Imaging modalities, such as positron emission tomography (PET), magnetic resonance imaging, as well as other nuclear imaging techniques like single-photon emission-computed tomography (SPECT), and optical absorption or fluorescence spectroscopy and imaging, have shown promises in visualizing and quantitating molecular targets ([@B441]). However, assessing BCM in vivo has been challenging because the *β* cells that exist in pancreatic islets are small (50--300 *μ*m in diameter), scarce (1--2% of pancreatic mass), and scattered throughout the organ ([@B474]).

As nonselective imaging modalities like magnetic resonance imaging and computed tomography have failed to offer a reliable detection method, *β* cell--specific biomarkers have been investigated and evaluated ([@B433]; [@B441]; [@B415]; [@B286]; [@B317]; [@B210]). Although a number of potential candidates for *β* cell imaging have been reported, such as vesicular monoamine transporter, GLP-1R, SUR1, glucose transporter 2, glycogen, zinc transporters, fluorodithizone, and monoclonal antibodies, many did not show promising results due to either low expression levels or insufficient *β* cell specificity ([@B329]; [@B422]; [@B317]). Vesicular monoamine transporter is expressed at dopamine nerve ends in the CNS and pancreatic *β* cells, and its ligands, ^11^C- and ^18^F-labeled dihydrotetrabenazine derivatives, have demonstrated a potential for *β* cell imaging ([@B441]; [@B180]; [@B253]). However, controversial findings of nonspecific binding of \[^11^C\]-dihydrotetrabenazine in human pancreas raised questions for its clinical application ([@B147]).

Compared with other *β* cell biomarkers, GLP-1R showed promise because of its highly specific expression in *β* cells and strong interaction with its ligands ([@B468]). However, its endogenous ligand, GLP-1, is difficult to be used as an imaging agent because of its extremely short half-life (*II. Glucagon-Like Peptide-1*) resulting from rapid metabolic degradation. This emphasizes that *β* cell imaging via GLP-1R as a biomarker requires GLP-1 analogs that have high metabolic stability as well as strong binding affinity.

Exendin-3 and exendin-4 are found to be resistant to DPP-4 degradation, and these stable GLP-1R agonists have been developed for *β* cell imaging ([@B153]; [@B512], [@B513]; [@B40]; [@B393]; [@B527]; [@B66]). Alternatively, bicyclic GLP-1 analogs developed by Ahn and coworkers have also demonstrated outstanding results in determining BCM ([@B3]; [@B134]). A metal chelator, such as DOTA, NOTA, or DTPA, was conjugated to these peptides and subsequently labeled with a radiotracer (e.g., ^64^Cu, ^68^Ga, ^99m^Tc, and ^111^In) for PET- and SPECT-imaging experiments.

A SPECT probe was developed based on exendin-4, \[Lys^40^(Ahx-DTPA-^111^In)NH~2~\]-exendin-4, to target GLP-1R for imaging insulinoma in Rip1Tag2 transgenic mice and showed high tumor uptake ([@B512]; [@B506]). Although imaging agents derived from these stable GLP-1R agonists showed a high renal uptake, the potential of GLP-1R in visualizing *β* cells has been demonstrated by PET and SPECT imaging of insulinoma with radiolabeled exendin-3 and exendin-4 ([@B153]; [@B40]; [@B513]). As an excellent PET tracer, ^64^Cu was used to label exendin-4, and the resulting ^64^Cu-labeled exendin-4 analog (^64^Cu-DO3A-VERSUS-Cys^40^-exendin-4) demonstrated a feasibility for in vivo imaging of intraportally transplanted islets in mice by showing high and specific uptake in INS-1 tumors despite substantial renal uptake ([@B527]). Remarkably, \[Lys^40^(Ahx-DTPA-^111^In)NH~2~\]-exendin-4 was successfully used to visualize autologous islets that have been transplanted into human muscle, proving a clinical potential of human *β* cell imaging via GLP-1R ([@B367]).

In addition to GLP-1R agonists described above, antagonists, such as exendin~9--39~, were also developed as *β* cell imaging agents ([@B325]). Radiolabeled at lysine residues with ^125^I-Bolton-Hunter reagent, exendin~9--39~ was examined for receptor specificity in vitro and in vivo. Accumulation of radioactive signals in *β* cells was observed, although the resolution of the imaging technique was low.

Ahn and colleagues have developed PET-imaging agents based on the GLP-1 sequence to quantitate BCM ([@B3]; [@B134]). As the endogenous GLP-1 suffers from rapid metabolic degradation, they introduced two lactam bridges to GLP-1, one in the N-terminal region and the other near the C terminus. These two strategically placed lactam bridges were found to protect the cyclic peptides from proteolytic cleavages by NEP 24.11 ([@B327]). In addition, Ala at position 8 was replaced with D-Ala to prevent the DPP-4 degradation. These modifications not only enhanced metabolic stability of the GLP-1 analog, but also increased binding affinity to the receptor. Dynamic PET scans over 60 minutes showed a high pancreatic uptake of a bicyclic GLP-1 analog, \[D-Ala^8^\]-c\[Glu^18^,Lys^22^\]-c\[Glu^30^,Lys^34^\]-GLP-1~7--36~, labeled with ^64^Cu or ^68^Ga, which disappeared in streptozotocin-induced type 1 diabetic mice or was competitively displaced by coinjection of unlabeled exendin-4 ([@B290]). Ex vivo scans and histology were also carried out to further confirm the PET-imaging findings (unpublished data).

V. Pharmaceutical Development and Therapeutics {#s86}
==============================================

As noted above, GLP-1 is a gastrointestinal peptide hormone that is secreted from L cells scattered in the distal small intestinal mucosa. It is released physiologically when ingested nutrients reach that level of the bowel, typically reflecting a meal large enough to benefit from the incretin effect of this hormone. Among its other physiologic effects is the slowing of gastric emptying, again reflecting the benefit of titration of the rate of delivery of nutrients to the absorptive surface so as not to overwhelm the absorptive capacity of the intestine. This peptide has a very short half-life in the circulation, with proteolysis, particularly by DPP-4, and renal clearance having prominent roles. This endoprotease cleaves the amino-terminal dipeptide from endogenous GLP-1 peptides; GLP-1~7--36\ amide~ or GLP-1~7--37~ is cleaved to yield GLP-1~9--36\ amide~ and GLP-1~9--37~, respectively, which are four orders of magnitude less active than the natural hormone ([@B314]). Recognition of this led to the earliest strategy to increase endogenous GLP-1 levels using DPP-4 inhibitors, rather than acting at GLP-1R. This was ultimately followed by the development of molecules having intrinsic GLP-1R agonist activity. As described below, most of these are peptides and their derivatives, but small-molecule agonists have also surfaced. All of them have potential importance for diabetes, obesity, and associated metabolic and cardiovascular complications. Other candidate applications are also discussed.

The earliest recognition that GLP-1 exhibited effects useful in the management of diabetes came from rodent studies ([@B167]; [@B336]). This was followed by a seminal study in which GLP-1 itself was administered s.c. over a 6-week period in patients with T2DM ([@B541]). These patients displayed reduced levels of fasting glucose and HbA1c, as well as improved insulin sensitivity and *β* cell function. The proof-of-concept for the use of GLP-1 in diabetes demonstrated in this study was clear, yet major challenges existed that involved acceptable modes of administration and the need to improve duration of hormonal action.

There are now a wide variety of different peptidic GLP-1R agonists with variable durations of action and different advantages and disadvantages for clinical use. The first GLP-1R agonists to enter clinical use were peptide analogs and derivatives, as exemplified by exendin-4 ([@B116]), liraglutide, albiglutide, and dulaglutide ([Table 3](#T3){ref-type="table"}). Unfortunately, these peptides require parenteral administration, due to instability in the proteolytic milieu of the digestive tract, making it impossible to deliver adequate drug reproducibly via oral route. Technology has advanced so much, however, that easy-to-use pens for s.c. administration has become quite common. Semaglutide is a potent peptide that was recently tested with s.c. administration in a phase 2 clinical study of 411 patients ([@B338]), showing improvement in HbA1c levels by 1.7%. This peptide is now being studied for oral dosing. This field has progressed so quickly that there are now even devices that allow longer-term activity being developed. Intarcia is an implantable device that releases exenatide over 6--12 months. This has been studied in two phase 3 trials ([@B326]).

###### 

Peptidic GLP-1R agonists that have been launched or are in late-stage clinical trials

  Analog                  Description                                     Company                                  Dosing Regimen   Status
  ----------------------- ----------------------------------------------- ---------------------------------------- ---------------- -----------
  Exenatide               Exendin-4                                       Amylin/Eli Lilly; AstraZeneca            Twice daily      Launched
  Exenatide once weekly   Exendin-4                                       Amylin/Alkermes/Eli Lilly; AstraZeneca   Once weekly      Launched
  Lixisenatide            Exendin-4 analog                                Sanofi-Aventis                           Once daily       Launched
  Liraglutide             GLP-1 analog linked with a fatty acid           Novo Nordisk                             Once daily       Launched
  Albiglutide             GLP-1 analog fused to albumin                   GlaxoSmithKline                          Once weekly      Launched
  Dulaglutide             GLP-1 analog fused to Fc                        Eli Lilly                                Once weekly      Launched
  Semaglutide             GLP-1 analog linked with a fatty acid           Novo Nordisk                             Once weekly      Phase 3
  Semaglutide (NN9924)    GLP-1 analog linked with a fatty di-acid        Novo Nordisk                             Oral             Phase 2
  Taspoglutide            GLP-1 analog formulated for sustained release   Roche                                    Once weekly      Suspended

We have finally entered an era in which small-molecule nonpeptidic GLP-1R agonists are now available ([Fig. 7](#F7){ref-type="fig"}), although it still poses a tremendous challenge to make them adequately potent and bioavailable ([@B536]). Most of these are thought to act within the helical bundle of GLP-1R. Crystallization of two members of the class B GPCR subfamily in 2013 ([@B198]; [@B435]) provided a clue to why development of nonpeptidic modulators has been so difficult. Unlike the class A GPCRs that have tight helical bundles with a well-defined pocket for small-molecule ligands, the class B helical bundles appear to be much more open without defined small-molecule docking sites. Recently, one of the small-molecule agonists (BETP) had its site of action determined as covalently binding to a cysteine residue in intracellular loop 3 on the cytosolic side of the plasma membrane ([@B347]), a molecular mechanism that was a major surprise, without precedent in other members of this subfamily. A molecule from TransTech Pharma, TTP054, is presently undergoing phase 2 clinical trials ([@B326]).

![Nonpeptidic GLP-1R modulators and peptide mimetics. Liraglutide (Novo Nordisk) was the first approved human GLP-1 analog to teat diabetes (European Union, 2009; United States, 2010) and obesity (United States, 2014; European Union, 2015). Liraglutide has 97% sequence homology to human GLP-1 and was designed to reversibly bind to albumin by attachment of palmatic acid via a L-*γ*-glutamic linker to lys^26^ in Arg^34^ GLP-1~7--37~. The modification of Lys^34^ to Arg^34^ made it possible to produce Arg^34^ GLP-1~7--37~ in yeast, followed by acylation of Lys^26^. The native GLP-1 peptide has a half-life of approximately 2 minutes due to rapid cleavage of GLP-1~7--37~ to GLP-1~9--37~ by DPP-4 ([@B85],[@B87]; [@B487]). Liraglutide comprises the natural GLP-1 N terminus, but has a half-life of about 11 hours after s.c. dosing to humans combined with a delayed absorption from sub cutis that gives a pharmacokinetic profile applicable for once-daily administration. The reason for extended circulation is due to reversible albumin binding that protects from DPP-4 degradation and glomerular filtration, whereas the delayed absorption is explained by the ability of liraglutide to form heptamers by self-assemble controlled by the fatty acid side-chain at position 26. Liraglutide is well tolerated and capable of substantially improving glycemic control with low risk of hypoglycemia and weight loss benefit ([@B237]; [@B235]; [@B285]; [@B443]; [@B89]; [@B493]).](pr.115.011395f7){#F7}

A. Peptidic Analogs {#s87}
-------------------

### 1. GLP-1 Analogs. {#s88}

Several GLP-1 analogs have successfully reached the market and become an important treatment of obesity and T2DM today ([Table 3](#T3){ref-type="table"}). Several reviews have been published during the past that describe the approved and emerging GLP-1R agonists and also summarize the most important clinical trials as well as toxicological considerations ([@B274]; [@B283]; [@B135]; [@B305]; [@B312]; [@B273]; [@B470]; [@B471]; [@B282]; [@B540]).

Taspoglutide (BIM-51077; Roche, Basel, Switzerland) is a potent GLP-1 analog with 93% homology to human GLP-1~7--36\ amide~ as it has two amino acid substitutions in positions 8 and 35 with aminoisobutyric acid (Aib). Taspoglutide is protected against DPP-4 degradation by the Aib^8^/Aib^35^ substitution but is still cleared rapidly by the kidney. A sustained-release formulation that contains zinc-chloride and precipitates as a sub cutis deposition was developed. This once-weekly dosing formulation of taspoglutide has shown promising antidiabetic efficacy in clinical trials. Unfortunately, the analog was discontinued in phase 3 clinical trials due to severe gastrointestinal side effects ([@B395]; [@B94]; [@B135]).

The GLP-1 human serum albumin fusion protein, albiglutide, also known as albugon, discovered by Genentech (South San Francisco, CA) and developed by GlaxoSmithKline (Brentford, UK), was approved by the Food and Drug Administration (FDA) in 2014. To have a free N-terminal, which is important for GLP-1 activity, the peptide was fused via the C terminus to albumin. The construct is composed of a tandem repeat of Ala^8^ to Gly^8^ GLP-1~7--36~ that is fused to the N terminus of human albumin. Gly^8^ GLP-1 was used to protect for DPP-4 degradation of the N terminus. The plasma half-life was extended to about 6--8 days, which made this fusion construct applicable for once-weekly dosing. One drawback relates to a significantly reduced potency that was probably due to a combination of the Gly^8^ modification and the covalent attachment to the larger protein human serum albumin. The tandem repeat of GLP-1 was used to obtain longer distance between albumin and the distal GLP-1 peptide, but the affinity for GLP-1R is 0.61 nM compared with 0.02 nM of the native peptide. The approved initial dose to treat T2DM is 30 mg given s.c. once per week, which may be increased to 50 mg on the same day of each week if the glycemic response is inadequate ([@B230]; [@B467]; [@B442]).

Dulaglutide (LY2189265; Eli Lilly, Indianapolis, IN) is a GLP-1R agonist fused to a modified Fc fragment of immunoglobulin that acts as a carrier to secure long residence time by reduced in vivo clearance. The sequence of the fusion protein Gly^8^Glu^22^Gly^36^-GLP-1~7--37~-(Gly~4~Ser)~3~Ala-Ala^234,235^Pro^228^-IgG~4~-Fc is modified in the N terminus of GLP-1 to protect against DPP-4 cleavage (Gly^8^), and the IgG~4~ Fc is modified to reduce interaction with high-affinity Fc receptors and avoid antibody-dependent cell-mediated cytotoxicity. The linker (Gly~4~Ser)~3~Ala was carefully selected to retain high GLP-1R affinity as direct fusion dramatically reduced in vitro activity by ∼95%. The half-life is above 1.5 days in rats and more than 2 days in monkeys. Dulaglutide was approved by the FDA in 2014 for once-weekly dosing of 0.75 mg s.c. ([@B142]).

There is still a need for optimization of once-weekly GLP-1 analogs because both albiglutide and dulaglutide are less efficacious than liraglutide with respect to weight loss ([@B99]; [@B378]).

The next generation of GLP-1 analogs using the reversible albumin affinity is represented by semaglutide (Novo Nordisk, Bagsværd, Denmark) currently in phase 3 clinical trials. This analog Aib^8^Lys^26^Arg^34^-GLP-1~7--37~ has a more complex side chain composed of hexadecandinoyl attached to Lys^26^ via an L-*γ*-glutamic acid linker and a small hydrophilic spacer. The Aib^8^ was introduced to improve the DPP-4 stability beyond that of liraglutide, and the new side chain increased the albumin affinity, resulting in a half-life in humans long enough for once-weekly dosing. In a phase 2 study over 12 weeks, semaglutide dose-dependently reduced HbA1c and body weight, with higher doses being more effective than liraglutide ([@B339]; [@B470]; [@B257]).

### 2. Exenatide Experience. {#s89}

In 1993, exendin-4 was isolated from the salivary glands of the gila monster (*Heloderma suspectum*) and found to be highly active on GLP-1R ([@B144]). Exendin-4 is a 39--amino-acid peptide that shares approximately 50% amino acid sequence identity with human GLP-1. The discovery of the antidiabetic effects of exendin-4 increased the interest in this peptide, and several pharmaceutical companies thus focused on its clinical development as well as on discovery efforts in exendin-based GLP-1 analogs.

In 2005, the first GLP-1R agonist exenatide (AstraZeneca, Cambridge, UK) was approved by the FDA for treatment of T2DM. Exenatide, as well as other GLP-1R agonists, reduces blood glucose through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, suppression of excess glucagon secretion, reduction of food intake, and slowing of gastric emptying. It is administered s.c. twice daily with doses between 5 and 10 *μ*g ([@B76]).

The very low therapeutic dose of exenatide made it an excellent candidate for an extended release formulation. Amylin Pharmaceuticals (San Diego, CA), Eli Lilly, and Alkermes (Dublin, Ireland) developed a formulation to prolong exenatide release, using biodegradable polymeric microspheres that entrap exenatide. The microspheres consist of exenatide incorporated into a matrix of poly (D,L-lactide-co-glycolide), which is a common biodegradable medical polymer with a history of safe use in humans. The final formulation was approved in 2011 as Bydureon for once-weekly dosing ([@B231]; [@B288]).

Lixisenatide (Sanofi, Paris, France) is a once-daily short-acting GLP-1R agonist used in the treatment of T2DM. The discovery of lixisenatide was inspired by the development of structure-inducing probe technology, which improves the half-life of structure-inducing probe conjugates compared with the parent peptide by enhancing stability and, as a consequence, creating resistance to proteolytic degradation. Lixisenatide, des-Pro^36^-exendin-4~1-39~-Lys^6^ amide, comprises 44 amino acids and is based on the exendin-4 sequence with a proline deletion in position 36 and C-terminal extension with six lysines. Lixisenatide has an extended in vivo half-life of 91 minutes after i.v. administration (in rabbits) compared with 43 minutes for exendin-4. Lixisenatide was approved in 2013 and has a substantial sustained effect on gastric emptying and postprandial glucose excursions that may be related to the relatively shorter half-life. The combination with basal insulin to lower fasting plasma glucose is clinically valuable and could differentiate lixisenatide from other GLP-1R agonists, especially from those long-acting ones with little effect on gastric emptying and postprandial glucose ([@B498]; [@B63]; [@B401]).

### 3. GLP-1 Mimetics. {#s90}

A novel class of 11--amino-acid GLP-1R agonists was discovered that consist of an analog of only the first 9 amino acids of GLP-1, in which the remaining 21 amino acids have been truncated and attached to an unnatural biphenyl diamino acid at the C terminus. The optimization of the sequence with several unnatural amino acids provided 11-mer GLP-1 mimetics with similar in vitro potency as the natural 30-mer peptide. The optimized 11-mers (e.g., BMS-686117) were reported to reduce plasma glucose and increase plasma insulin concentrations in diabetic *ob/ob* mice after a single relative high s.c. dose of the peptide ([@B295]; [@B173]). Based on NMR studies, the structures of these 11-mer peptides were determined and used to design lactam- and disulfide-based cyclic constrained peptides that retained high GLP-1R potency ([@B194]).

BMS-686117 has a relatively shorter half-life of about 2 hours in dogs, and, accordingly, a sustained release formulation is required for clinical use. Formulation with Zn (II) forms a poorly water-soluble adduct such that the BMS-686117 content and reversible release of which can be tailored by varying the Zn:peptide ratio. An in vivo pharmacokinetics study in dogs of an optimized sustained release formulation concluded that a minimal initial burst and constant release are applicable to once-daily dosing ([@B384]).

B. Nonpeptidic Modulators {#s91}
-------------------------

Even though more than two decades have passed since the cloning of the GLP-1R ([@B459]), very few nonpeptidyl-based GLP-1R agonists have been published. One might speculate on the reason: the ligand--receptor interaction leading to activation requires multiple interfaces that are difficult to mimic with a small molecule. The majority of the nonpeptidyl-based GLP-1R agonists described in the literature are receptor modulators that bind to allosteric sites and do not compete with GLP-1 in the orthostatic site. Many such GLP-1R agonists were only mentioned in patents and are not included in this section, as their experimental data have not been peer-reviewed. There are also small numbers of nonpeptidic GLP-1R antagonists, and these will be discussed in the last part of this section. One review article is also referred concerning nonpeptidic GLP-1R modulators ([@B515]).

To date, only one nonpeptidic GLP-1R agonist has entered into clinical trials. The compound has not been specifically disclosed, but a publication from the company described that it stimulated glucose-dependent insulin release in isolated islets from rodents and improved glycemic control in an oral glucose tolerance test ([@B165]).

Boc5, a substituted cyclobutane with four chiral centers, is among the few nonpeptidic GLP-1R agonists that have been comprehensively studied. It was discovered during a high-throughput screening against 48,160 small molecules using a luciferase reporter assay in HEK293 cells expressing the rat GLP-1R ([@B56]). Boc5 is the only nonpeptidic GLP-1R agonist that has been shown to compete for ^125^I-GLP-1 in binding assays and to be functionally antagonized by exendin~9--39~, thus acting like the natural peptide ligand.

The antidiabetic effect of Boc5 was demonstrated in various animal models. A 4-week dose-response study was performed in *db/db* mice with daily i.p. dosing of Boc5 at 0.1--3 mg. There was a dose-dependent decline in HbA1c during the treatment that continued to decrease until 2--3 weeks after the last dose. In contrast, Boc5 had no effect on HbA1c in nondiabetic C57BL/6J (wild-type) mice. Boc5 also inhibited food intake and decreased body weight of *db/db* mice by up to 16% during the study with reduced fat mass. In addition, it was demonstrated that Boc5 decreased the elevated levels of fasting insulin in *db/db* mice, and the insulin sensitivity was improved after 4 weeks of treatment. Thus, the effects of Boc5 seen both in vitro and in vivo suggest that this compound has similar pharmacological properties as peptidic GLP-1R agonists. Medicinal chemistry efforts were made to understand the SAR, and one analog, WB4-24, was found to be more potent in vitro compared with Boc5. WB4-24 was shown to have beneficial effects on glucose homeostasis and body weight in diet-induced obese mice ([@B445]; [@B184], [@B183]; [@B267]).

After an unsuccessful screening of 500,000 discrete small molecules with a GLP-1 competitive binding assay, a substituted quinoxaline was identified in subsequently performed functional screening of 250,000 compounds. This hit as well as some closely related analogs activated the formation of cAMP in BHK cells expressing the GLP-1R ([Fig. 7](#F7){ref-type="fig"}, compounds 1 and 2). However, it did not compete with ^125^I-GLP-1 in a binding assay, but augmented the binding of the tracer. Furthermore, its functional effect could not be antagonized by exendin~9--39~. Functionality counter-screening analysis showed that the quinoxalines were inactive in BHK cells expressing GIPR, GLP-2 receptor, and GCGR. They were capable of releasing insulin from wild-type mouse islets, but not from islets isolated from GLP-1R knockout mice. These quinoxalines were thus concluded to be selective GLP-1R ago-allosteric modulators. Further SAR studies around these initial leads as well as some of the later identified nonpeptidic modulators have all been published ([@B236]; [@B455]; [@B67]; [@B213]; [@B249]; [@B60]; [@B261]).

Pyrimidine-based ago-allosteric modulators ([Fig. 7](#F7){ref-type="fig"}, compounds A and B) of GLP-1R were found by screening of a small library enriched with relevant pharmacophores for GPCRs. The screening was performed in HEK293 cells coexpressing hGLP-1R and a cAMP response element luciferase reporter. Like the quinoxaline-based modulators, the pyrimidines did not compete with ^125^I-GLP-1 in a binding assay and the functional effect was not antagonized with exendin~9--39~. They were shown to enhance GLP-1--induced cAMP signaling and insulin release in isolated rat islets. Compound B (BETP) increased plasma insulin levels in a glucose tolerance study using Sprague Dawley rats as well as hyperglycemic clamped Spraqgue Dawley rats. One drawback for further development of both quinoxaline- and pyrimidine-based leads is the chemical instability in the presence of nucleophiles ([@B437]).

Recently, a tricyclic pyridoindole-based series of GLP-1R allosteric modulators was identified by high-throughput screening measuring intracellular calcium mobilization in the presence of low levels of GLP-1 or glucagon. These compounds were shown to potentiate glucose-dependent insulin release in primary mouse islets, but no in vivo studies were described ([@B322]).

The potential use of GLP-1R allosteric modulators to enhance the effect of endogenous GLP-1 was studied in vivo. An i.v. glucose tolerance study was carried out in which coadministration of BETP to rats dosed with subsaturating concentrations of oxyntomodulin markedly increased the insulinotropic effect of oxyntomodulin ([@B516]).

C. Currently Approved Clinical Applications {#s92}
-------------------------------------------

A number of GLP-1R agonists have been approved for clinical use to improve glycemic control in adults with T2DM. Diet and exercise are the expected initial approach to treat these patients, with GLP-1R agonists prescribed as second-line drugs for patients who are refractory to the current standard of care. GLP-1R agonists have no current role in the management of patients with type 1 diabetes, and should be avoided in those patients having a history of pancreatitis or medullary thyroid cancer. The use of this category of drugs in T2DM reflects their direct effects on the *β* cells within the pancreatic islets to increase insulin biosynthesis and secretion, to stimulate cell proliferation, and to reduce apoptosis. A key benefit of GLP-1R agonists is the glucose-dependent effects on the *β* cell, with reduction in blood glucose only in patients exhibiting hyperglycemia. This eliminates the hypoglycemia risk of many other antidiabetic drugs. In fact, GLP-1R agonists have now largely replaced the use of thiazolidinediones (e.g., rosiglitazone). Adverse responses such as peripheral edema, weight gain, congestive heart failure, and osteoporosis associated with the latter are not observed in patients treated with GLP-1R agonists ([@B97]). GLP-1R agonists also exhibited cardiovascular benefits, such as lowering blood pressure, improving lipid profiles, and possibly even enhancing cardiac contractility and endothelial function. In addition to its action on islet *β* cells, this hormone exerts effects on the following: 1) pancreatic *α* cells to reduce glucagon secretion and hepatic glucose output; 2) the cardiovascular system to elevate glucose utilization and protect the heart and vasculature against inflammation; 3) the brain to decrease food intake; and 4) the gut indirectly to slow gastric emptying.

### 1. Selection. {#s93}

As the number of GLP-1R agonists in clinical use and trials expands, it will become clearer whether there are advantages of one drug over another in a specific clinical setting. We have already observed differences in the frequency of nausea, presumably reflecting the reduced gastric emptying, among these drugs. There is also variation in the pathway of inactivation and excretion of these drugs, making the selection of agent in patients with renal insufficiency important. Although biased agonism is now recognized for some of these agonists, there is still insufficient information on the broad pharmacodynamics properties of these drugs to differentiate the contribution of biased agonism from pharmacokinetic behavior to differential clinical responses, side effects, or toxicities, although this is likely to be an important consideration in future therapeutic development.

A very practical and useful categorization of GLP-1R agonists is based on their duration of action. The shortest-acting agents, like exenatide and lixisenatide with half-lives of 2--5 hours, seem to exert their beneficial effects predominantly by slowing gastric emptying and thereby reducing the rate of carbohydrate delivery, digestion, and absorption, leading to normal postprandial glucose levels. Of course, other nutrients also empty more slowly, and this has resulted in lower postprandial levels of free fatty acids and triglycerides, which has some metabolic benefits. For instance, decreased levels of chylomicrons are desired in patients with diabetes or metabolic syndrome. As the duration of GLP-1R agonist action is extended with peptides like albiglutide, dulaglutide, long-acting release exenatide, or liraglutide (half-lives of 12 hours to several days), the impact on blood glucose levels is enhanced as insulinotropic action and activity to reduce glucagon become more prominent than the effect on gastric emptying. Such prolonged activities have also been associated with increased side effects, such as diarrhea, tachycardia, immune responses, and injection site reactions. Of interest, nausea and vomiting appear to have greater incidence with the shorter-acting peptides. The longer-acting agents have typically provided more consistent effects on GLP-1R activation and blood glucose levels. Because the insulinotropic action of GLP-1 is dependent on the presence of hyperglycemia, long duration activity does not increase the risk of hypoglycemia. Therefore, long-acting release formulations have obvious advantages if the goal is to lower early morning glucose levels, because they retain efficacy throughout the night.

It is curious whether the induction of nausea, which is believed to be a result of slowed gastric emptying, is similar in the short-acting and longer-acting GLP-1R agonists, yet this seems to be attenuated quickly in the longer duration agonists and may take weeks to months to improve for the shorter duration agonists. Such a phenomenon most likely reflects differences in desensitization of GLP-1R, but the underlying mechanism has not been carefully studied. Although the weight loss effect seen with some of these GLP-1R agonists was thought to be related to slowed gastric emptying, the long-acting agents seem to result in greater weight reduction than the short-acting ones, suggesting certain other mechanism is dominant. This might relate to reduced appetite, potentially following GLP-1 action in the hypothalamus or other CNS regions.

### 2. Efficacy. {#s94}

The first phase 2 trial to study a GLP-1R agonist in T2DM was started in 1999, comparing twice-daily administration of exenatide to saline ([@B242]). Not only was the exenatide effective in reducing glucose levels, but it did not induce hypoglycemia in patients who were on insulin therapy. Although exenatide was approved by the FDA for use in diabetes in 2005, concerns about hypoglycemia in insulin-requiring patients persisted, and this was finally studied in 2008 ([@B46]). The dramatic observations of enhanced reduction in HbA1c and no increase in hypoglycemic episodes, as well as weight loss, formally launched a new series of clinical studies to follow. A meta review published in *Lancet* in 2014 ([@B116]) chose 15 of 2905 studies that represented 4348 subjects to evaluate. HbA1c levels were decreased by an average of 0.44%, and weight was reduced by an average of 3.22 kg, without any increase in hypoglycemic episodes. Of note, the levels of HbA1c were not different using GLP-1R agonist with boluses of insulin, but the frequency of hypoglycemic episodes was significantly reduced with the former.

Short-acting GLP-1R agonists known to better control postprandial glucose levels have not been directly compared with that of long duration administered with basal insulin. Each has theoretical advantages and perhaps should be chosen based on the characteristics of the patient. Because long-acting agents can be given with short-acting insulin at meal time now, another important option exists, but needs to be evaluated.

The DURATION-3 trial ([@B90]) compared long-acting release exenatide administered once per week to insulin glargine (a long-acting, man-made version of human insulin) in 456 patients with T2DM who had not achieved satisfactory glucose control with maximal tolerated doses of oral agents. Exenatide was able to better manage the blood glucose, with HbA1c levels being reduced by 1.01%, whereas glargine plus oral agents only reduced this by 0.81%. Again, the most notable observation was a much lower incidence of hypoglycemia in patients taking the GLP-1R agonist.

The AWARD-4 study did use dulaglutide injected only once per week and rapid-acting insulin with each meal to demonstrate improved levels of HbA1c than were observed in basal and bolus insulin administration ([@B216]). Fixed-dose combinations of GLP-1R agonist and basal insulin have substantial appeal for convenience, although, at the current time, expense is a major concern. The DUAL-1 and DUAL-2 studies exhibited a 1.9% reduction in HbA1c in patients who followed a titration algorithm with a pen delivery device ([@B46]; [@B154]).

### 3. Benefits. {#s95}

In addition to its action on blood glucose, mediated largely by impact on the pancreatic islet *β* and *α* cells, GLP-1R agonists have been shown to display favorable cardiovascular effects. This includes improvements in serum lipids, myocardial contractility, and endothelial function ([@B324]). The effects on lipids are likely to reflect slowed gastric emptying and reduced delivery for absorption, as well as impact on hepatic and fat cell metabolism. Presumably, the direct cardiovascular benefit was achieved via abundant levels of GLP-1R expression in cardiomyocytes and blood vessels ([@B347]). Experiments in rodents showed that GLP-1R agonists can reduce myocardial infarct size and improve left ventricular function, including better wall motility and ejection fractions ([@B346]; [@B349]). There also exists encouraging evidence in rodents of the neuroprotective role of GLP-1 for AD, PD, and even stroke ([@B179]; [@B303]; [@B456]), although this has not been followed up by clinical studies.

A recent meta-analysis explored the impact of GLP-1R agonists on lipids in clinical trials ([@B447]). Thirty-five trials with 13 treatments lasting a minimum of 8 weeks were included, and GLP-1R agonists were associated with modest improvements in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels, whereas there was no change in high-density lipoprotein cholesterol. It is not yet clear whether this translates into an improvement in cardiac and vascular events. It follows that a latest retrospective review of macrovascular outcomes in patients with T2DM who had been treated with insulin alone or with GLP-1R agonists ([@B368]) suggested that heart failure, myocardial infarction, and stroke were less common in patients who were taking the drug. Although such epidemiologic studies need to be interpreted carefully, this is inspiring and clearly worthy of prospective evaluation. A nested case-control study was also recently performed ([@B138]). T2DM patients who developed one or more of these cardiovascular problems were compared with control patients with diabetes who did not develop such cardiovascular events. More than 10,000 patients were included, and 1,947 had one or more of these events. Liraglutide was associated with significant risk reduction, with the degree of reduction being dose- and duration-dependent. Another retrospective cohort study also showed a reduction in heart failure in patients with diabetes ([@B482]). More than 19,000 adult patients with diabetes were studied and matched with twice as many controls, and 1,426 patients with diabetes used GLP-1R agonists. This was also encouraging, but only points toward the need for prospective studies.

There is increasing excitement about the potential role for fixed-dose combinations of a long-acting insulin preparation and a GLP-1R agonist as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Two such preparations have recently been recommended for FDA approval by advisory committees, based on portfolios of clinical trials, including double-blinded designs. These include IDegLira from Novo Nordisk, combining Tresiba (insulin degludec) and Victoza (liraglutide) into a once-daily injectable product (<http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm502074.pdf>), and iGlarLixi from Sanofi, combining Lantus (insulin glargine) and Lyxumia (lixisenatide) into a similar product (<http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm502559.pdf>). Both of the component drugs in IDegLira and the insulin glargine in iGlarLixi are already FDA approved, whereas lixisenatide is currently undergoing independent regulatory review. The efficacy of both combination products was superior to that of the components alone, leading to the successful outcomes. The safety of them appears to be consistent with that of the individual components, and there are indications that some side effects like nausea and weight gain may actually be less in the combination preparations than for some individual components. It seems likely that at least one of these products or something alike will achieve a prominent role in therapy soon.

D. Potential Applications for Other Diseases {#s96}
--------------------------------------------

### 1. Neurologic Disorders. {#s97}

The expression of GLP-1R in multiple sites of the nervous system and the involvement of GLP-1 in satiety and food intake regulation are well-established (*II. Glucagon-Like Peptide-1*). Because this incretin was also shown to improve learning in rats ([@B351]) and exert neurotrophic or neuroprotective effects when given intracerebroventricularly, its potential therapeutic value for AD, PD, and pain has been investigated ([@B103]; [@B303]; [@B150]).

AD is characterized by progressive cognitive decline with a defined neuropathology of A*β* production and tau hyperphosphorylation ([@B64]). T2DM has been identified as a risk factor for AD, and an epidemiologic study indicated that 65% of T2DM patients showed evidence of featured AD plaques in their autopsied brains ([@B26]), indicating that insulin desensitization in the periphery may be a factor in initiating or accelerating the development of neurodegenerative processes. It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. In preclinical models of AD, GLP-1 decreases A*β* toxicity in vitro ([@B103]; [@B374]). A follow-up study demonstrated that GLP-1 and exendin-4 could protect cultured rat hippocampal neurons against glutamate-induced apoptosis ([@B374]). Furthermore, Val^8^GLP-1 blocked synaptic degradation and rescued synaptic plasticity in the hippocampus ([@B139]). The neuroprotection effect of GLP-1 was further displayed in studies in which treatment with liraglutide, lixisenatide, or geniposide in the transgenic amyloid precursor peptide/presenilin 1 mice produced improvements in synaptic plasticity and reduced neuronal damage, tau hyperphosphorylation, microglial activation, plaque, and oligomer formation in the CNS ([@B373]; [@B303]; [@B278]; [@B302]). These GLP-1 analogs also attenuated memory deficits, restored impaired signaling within the Akt/GSK-3*β* pathway, and reversed elevated levels of reactive oxygen species in amyloid precursor peptide/presenilin 1 mice. The recent reported effect of liraglutide on an early-stage sporadic AD model supports the notion that liraglutide-induced GLP-1R activity might be a viable target in AD therapy ([@B172]).

PD is typified by a loss of dopaminergic neurons and cellular degeneration in the striatum ([@B548]). Epidemiologic data suggest an association between T2DM and some neurodegenerative disorders, such as PD ([@B380]). In patients with PD, it was found that the levels of insulin receptors were markedly reduced in the basal ganglia and the substantia nigra ([@B320]). Furthermore, increased IRS2 phosphorylation, a marker of insulin resistance, was found in the basal ganglia of the 6-hydroxydopamine lesion rat PD model ([@B323]). An earlier report demonstrated that in high-fat-diet--fed rats, insulin resistance was accompanied by attenuated dopamine release and diminished dopamine clearance in the basal ganglia ([@B321]). Neuropathological studies in patients with PD also revealed that loss of insulin receptor immunoreactivity and mRNA coincides with loss of tyrosine hydroxylase mRNA (the rate-limiting enzyme in dopamine synthesis) ([@B451]).

GLP-1 and exendin-4 have been shown to exert a neurotrophic effect on 6-hydroxydopamine--treated dopamine neurons ([@B265]). A growing body of evidence now exists to support the neurotrophic properties of GLP-1: activating GLP-1R--signaling pathways in neurons leads to proliferation and differentiation of cells from precursors into neurons, thereby drawing a striking similarity between cellular responses in pancreatic *β* cells and neurons ([@B103]). Indeed, such a protective action was observed in rodent models of PD: GLP-1 and its mimetics were effective to protect tyrosine hydroxylase--positive dopaminergic neurons and to preserve dopamine levels in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine--treated animals. Treatment with a GLP-1R agonist resulted in improved motor function, as demonstrated by rotarod and pole tests ([@B232]; [@B264]). Recently, a single-blind clinical trial of exendin-4 in PD patients showed that exenatide was well tolerated, and the treated group exhibited clinically relevant improvements across motor and cognitive measures compared with the control group ([@B18]).

In a study to investigate glucoregulatory effects of exendins, a research group in Shanghai serendipitously discovered that GLP-1 produced a potent antinociception in the formalin test ([@B149]). They further examined the inhibitory role of the spinal GLP-1R signaling pathway in pain hypersensitivity states and its mechanism of action. Specific expression of GLP-1R on the spinal dorsal horn microglia was found, and the efficacy as well as potency of GLP-1, exenatide, and geniposide on antinociception in a variety of animal models of pain hypersensitivity versus acute nociceptive responses were evaluated ([@B150]). The involvement of GLP-1 in antinociception was also verified by a nonpeptidic GLP-1R agonist (WB4-24) indicating that the effect is mediated by GLP-1R ([@B148]; [@B120]).

### 2. Oncological Association. {#s98}

As previously described above, GLP-1--based therapy is a long-term approach to the control of metabolic disorders exemplified by T2DM, whereby chronic adverse events become a major concern, including an increased risk of cancer ([@B119]). Pancreas and thyroid are the main tissues of the concern.

Since the first case report of exenatide-induced pancreatitis in 2006 ([@B88]), increasing numbers of controversial observations were reported associated with the risk of pancreatitis when treating T2DM patients with GLP-1R agonists or DPP-4 inhibitors. Acute pancreatitis may potentially progress to chronic pancreatitis and ultimately develop pancreatic cancer ([@B532]; [@B333]). Safety alerts have been issued by the FDA for exenatide and sitagliptin in 2008 and 2009, respectively, for patients who have a history of pancreatitis or current symptoms suggestive of pancreatitis. In 2013, a workshop sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute on *Pancreatitis-Diabetes-Pancreatic Cancer* was held in Bethesda, MD ([@B10]). Based on current data, neither the GLP-1R agonist liraglutide nor the DPP-4 inhibitor sitagliptin established a solid link with the increase of risk for pancreatic ductal adenocarcinoma in the therapy of patients with T2DM. Ongoing surveillance will be important in future outcome and epidemiologic studies that will be performed as the indications for use of these drugs expand; however, existing studies have been reassuring to date.

The effects of GLP-1R activation by liraglutide on human pancreatic cancer cells, MIA PaCa-2 and PANC-1, were studied recently ([@B544]). Liraglutide dose- and time-dependently increased GLP-1R expression, arrested cell cycles in the S phase, and induced apoptosis through stimulation of cAMP production and inhibition of Akt and ERK1/2 pathways. Pancreatic tumor growth was also attenuated by liraglutide in a mouse xenograft model in vivo. In patients with pancreatic cancer, 43.3% were GLP-1R--negative (13 of 30) and, in GLP-1R--positive tissues, tumor size was inversely correlated with GLP-1R expression. This is the only report of the cytoreductive effect of GLP-1R signaling activated by liraglutide on pancreatic cancer cells ([@B544]).

Thyroid cancer is a relatively rare disease, although its incidence has increased at an alarming rate in both men and women in the United States ([@B13]; [@B473]). C cells constitute a minor fraction of the thyroid mass (0.1%) and are the only cells that produce calcitonin ([@B206]). GLP-1R agonists are capable of inducing increased calcitonin gene expression and C cell hyperplasia in the thyroid of wild-type, but not the GLP-1R knockout (*Glp-1r^−/−^*) mice ([@B533]; [@B284]). Long-term exposure to GLP-1R agonists resulted in C cell proliferation and the formation of C cell adenomas and (medullary thyroid) carcinomas in rodents ([@B114]; [@B42]; [@B402]). Data derived from the FDA Adverse Event Reporting System database also indicate a significantly elevated risk for thyroid cancer (histology not specified) with exenatide, but not sitagliptin treatment ([@B333]). Several cases of thyroid cancer were reported during the liraglutide clinical development program ([@B342]; [@B114]). Thus, a Black Box warning regarding the risk of thyroid C cell cancer was labeled in all approved long-acting GLP-1 analogs ([@B361]; [@B10]). However, a meta-analysis of serious adverse events reported with GLP-1R agonists indicates that neither liraglutide nor exenatide had an association with an increased risk of thyroid cancer ([@B9]). Such a discrepancy between humans and rodents may reside on the different expression level of GLP-1R in the thyroid because C cells are very sparse in primates when compared with rodents ([@B130]; [@B383]). Adequately powered long-term epidemiologic studies will be necessary to clarify the association between GLP-1--based therapies and the risk of thyroid cancer ([@B10]).

Besides the pancreas and thyroid, GLP-1R is widely expressed in other tissues, such as the stomach, pituitary, heart, lung, kidney, and nervous system. Analysis of the FDA Adverse Event Reporting System database suggests that for several malignancies, excluding pancreatic and thyroid cancers, exenatide and sitagliptin apparently significantly reduced the odds ratios of some special cancers, such as lung cancer, prostate cancer, lymphoma/multiple myeloma for exenatide, and colon cancer and prostate cancer for sitagliptin ([@B485]; [@B241]; [@B333]). However, the data need to be interpreted with caution because the results are based on relatively small numbers of tumors and most likely are subject to reporting bias.

E. GLP-1R Antagonists {#s99}
---------------------

Under normal physiologic conditions, GLP-1 is secreted directly by the L cells of the gastrointestinal tract and, as described in this review, acts predominantly to enhance insulin secretion, decrease glucagon secretion, and inhibit gastric motility (*II. Glucagon-Like Peptide-1*). Based on these data, the main therapeutic strategy targeting GLP-1R has been development of agonists for the treatment of hyperglycemia.

It is established that the insulinotropic action of GLP-1 is highly glucose-dependent such that excessive GLP-1 secretion or sensitivity will not lead to hypoglycemia. However, clinical studies demonstrate that administration of GLP-1 in the presence of a nonglucose-dependent insulin secretagogue (e.g., a sulphonylurea that acts on the K~ATP~ channel) or even directly infusing supraphysiological levels of GLP-1 into normal subjects is associated with an increased risk of hypoglycemia ([@B465]; [@B47]). These data suggest that under rare conditions in which either the secretion of or sensitivity to GLP-1 is significantly enhanced, patients may display an increased incidence of insulin secretion and concomitant hypoglycemia. Furthermore, these conditions would be predicted to be responsive to treatment with a GLP-1R antagonist.

GLP-1R has a limited expression profile, and its agonists exhibit an excellent safety record, as indicated by the successful treatment of patients with T2DM. Furthermore, mouse GLP-1R knockouts are viable, develop normally, and demonstrate no overt phenotype ([@B425]). Therefore, it is perhaps unsurprising that interest in the potential therapeutic opportunity for GLP-1R antagonists has emerged only recently, originating largely from a small number of reported clinical conditions that present severe hypoglycemia. These will be briefly discussed in the following paragraphs.

Congenital hyperinsulinism (CHI) represents the most frequent cause of severe, persistent hyperinsulinemic hypoglycemia in newborn babies and children, occurring in approximately 1/25,000 to 1/50,000 births ([@B272]). CHI is caused by genetic defects in key genes responsible for regulating insulin secretion and arises as a consequence of excess insulin secretion from the pancreatic *β* cells ([@B387]). Insulin directly lowers blood sugars, causing hypoglycemia, but insulin hypersecretion also reduces the supply of alternative sources of energy substrates for oxidative metabolism in the CNS. As these normally act as a protective measure against hypoglycemia, adverse neurodevelopment outcomes affect approximately one-third of all patients ([@B17]). The most severe forms of CHI accounting for approximately 45% of cases are due to recessive inactivating mutations in ABCC8 and KCJN11 that encode the two components of the *β* cell ATP-sensitive K^+^ channel (SUR1 and Kir6.2, respectively). The current treatment paradigm principally involves agonists of K~ATP~ channels (diazoxide) and somatostatin receptors. However, as the pathology of CHI mainly involves genetic defects in K~ATP~ channels, these patients (\>50%) will therefore be refractory to diazoxide treatment that acts via this receptor. Both targets are expressed on *β* cells, but also many other cell types; and this widespread expression profile contributes to multiple off-target complications of these drugs. Pharmacologically unresponsive CHI requires surgical intervention that may be a limited pancreatectomy/lesionectomy, or in some cases children will require a near-total pancreatectomy (95--98%). Despite surgery, patients with the diffuse form of the disease often require further surgical episodes, and a significant majority of them will develop iatrogenic and early-onset diabetes.

The initial link between CHI and GLP-1 was first reported in rodent models of hyperinsulinism in which the K~ATP~ channel subunit ABCC8 was knocked out ([@B82]). In this study, treatment with the GLP-1R antagonist exendin~9--39~ decreased cAMP levels, insulin secretion, and glucose disposal. Interestingly, these effects were generated in the fasting state (i.e., when glucose levels, and hence GLP-1 levels, should have been lowest) and in isolated islets to observe impact on both the basal and stimulated insulin secretion. Recently, these findings have been extended to testing exendin~9--39~ in adult human subjects with CHI owing to inactivating mutations in the K~ATP~ channel. Acute infusion of exendin~9--39~ significantly increased mean basal glucose levels and glucose area-under-the-curve, and markedly lowered the insulin:glucose ratios ([@B51]). Currently, it is unclear in this setting whether the levels of GLP-1 are increased, or whether the responsiveness to exendin~9--39~ reflects the inverse agonist property of this peptide in controlling excessive insulin secretion by *β* cells. Recent published data from the Dunne laboratory in Manchester support the identification of a specific subpopulation with elevated GLP-1 levels that may at least partly explain the pathophysiological role of GLP-1 in this condition.

Roux-en-Y gastric bypass surgery is being used increasingly in the treatment of morbidly obese type 2 diabetic patients, and in the vast majority of patients this results in a very beneficial outcome with significant weight loss and resolution of diabetes. However, in a small minority of patients, gastric bypass surgery can lead to a profound postprandial hyperinsulinemic hypoglycemic state that emerges several years after surgery ([@B366]; [@B14]). Typically, adult patients experience dizziness, weakness, headache, confusion, lethargy, slurred speech, coma, and seizures depending on the severity and duration of the hypoglycemic episode. In a landmark paper ([@B296]), the incidence of severe hyperinsulinemic hypoglycemia was highlighted in approximately 0.2--0.5% of 5040 patients undergoing gastric bypass surgery in Sweden between 1986 and 2006. Discussion with clinical trust representatives of United Kingdom National Health Service confirmed this as an increasingly recognized unmet need, with the figure requiring pharmacological therapy after bypass surgery in the United Kingdom likely to be closer to 1%, in which by the end of 2012 a total of 18,577 procedures had been performed under the National Health Service. In the United States, the American Society for Metabolic and Bariatric Surgery reported the number of procedures increased from about 16,000 in the early 1990s to more than 103,000 in 2003, with the total number of surgeries performed by the end of 2005 exceeding 590,000. Based on such evidence, it is likely that this condition represents an area of considerable future commercial value that is predicted to increase in market size as the awareness and related diagnosis continue to expand.

A number of alternative hypotheses have been suggested to explain postprandial hyperinsulinemic hypoglycemia, as follows: 1) an exaggerated form of dumping syndrome; 2) the result of failure of the pancreas to revert after weight loss; and 3) an outcome from altered incretin secretion. Roux-en-Y gastric bypass surgery has been demonstrated to significantly increase the levels of GLP-1 secretion. Although the mechanism behind the postsurgery hyperinsulinemic hypoglycemia syndrome remains to be confirmed, an emerging number of affected patients present with higher insulin and GLP-1 responses ([@B428]; [@B410]). Furthermore, the effects of exogenously administered GLP-1 on gastrointestinal motility and secretion can be blocked by exendin~9--39~ ([@B418]). Very recently, [@B409] have reported that this severe postprandial hypoglycemia in gastric bypass patients can be corrected by infusion of exendin~9--39~, consistent with a fundamental role for GLP-1 and its receptor in this mechanism.

Currently, no small-molecule GLP-1R antagonist is available that can be used to further understand the consequences of an overactive GLP-1 system. However, exendin~9--39~ is a selective, competitive GLP-1R antagonist that blocks GLP-1--mediated insulin secretion in vitro and in vivo and impairs glucose tolerance in response to endogenous and exogenous GLP-1 in humans and a variety of rodent models ([@B419]; [@B110]). Moreover, a number of groups have reported that exendin~9--39~ inhibits insulin secretion even in the absence of increased GLP-1 levels, suggesting that exendin~9--39~ may be an inverse agonist of GLP-1R ([@B427]; [@B410]). A modified version of exendin~9--39~ has also been developed ([@B365]) and was demonstrated to cause significant increases in glucose intolerance, food intake, and body weight in diet-induced obese mice, further supporting a role for endogenous GLP-1 as a key hormone in the obese state.

Clearly, the findings discussed above have a number of important implications that form the scientific basis for targeting GLP-1R with specific small-molecule antagonists. These not only highlight possible control of hyperinsulinemic hypoglycemia in different patient populations, but also suggest that an antagonist may reduce the enhanced rate of *β* cell expansion associated with CHI, thereby offering potential disease-modifying treatment opportunities.

VI. Conclusions {#s100}
===============

In this review, we have provided insights into the discovery, characterization, physiology, and pharmacology of GLP-1 and GLP-1R, a hormone-receptor system that seems to be ideally designed to facilitate the management of T2DM. This peptide hormone is secreted from enteroendocrine L cells in the distal intestine, exerting its effects through a class B GPCR on various target cells. Most prominent among these are the pancreatic islet *β* cell, where GLP-1 exerts a glucose-dependent insulinotropic action. It also has other roles in glucose homoeostasis, as well as in regulating gastric motility and appetite useful in the control of body weight. A series of analogs of the GLP-1 peptide have been developed to enhance activity and bioavailability, but efforts in obtaining therapeutically viable nonpeptidic GLP-1R modulators were less successful. The molecular basis of the docking and action of these ligands is reviewed, along with implications for their spectrum of biologic actions. Some of these GLP-1R agonists have already launched to the worldwide market with many more under development. Such an endeavor will definitely lead to better and more efficacious drugs to treat T2DM and obesity.
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Epac

:   exchange protein activated by cAMP

ER

:   endoplasmic reticulum

ERK

:   extracellular regulated kinase

FDA

:   Food and Drug Administration

GCGR

:   glucagon receptor

GIP

:   gastric inhibitory polypeptide

GIPR

:   GIP receptor

GLP

:   glucagon-like peptide

GLP-1R

:   GLP-1 receptor

GPCR

:   G protein--coupled receptor

GRK

:   G protein--coupled receptor kinase

HbA1c

:   hemoglobin A1c

HEK

:   human embryonic kidney

hGLP-1R

:   human GLP-1R

iCa^2+^

:   intracellular calcium

ICL

:   intracellular loop

IP1

:   intervening peptide 1

IRS2

:   insulin receptor substrate 2

K~ATP~

:   ATP-sensitive potassium

MAPK

:   mitogen-activated protein kinase

NEP 24.11

:   neutral endopeptidase 24.11

NHE3

:   Na^+^/H^+^ exchanger isoform 3

PACAP

:   pituitary adenylate cyclase--activating polypeptide

PD

:   Parkinson's disease

PDB

:   Protein Data Bank

PDX-1

:   pancreatic and duodenal homeobox-1

PET

:   positron emission tomography

PI3K

:   phosphatidylinositol 3-kinase

PKA

:   protein kinase A

PKB

:   protein kinase B

PKC

:   protein kinase C

PMA

:   phorbol myristate acetate

PPAR

:   peroxisome proliferator-activated receptor

Rim

:   Rab-3--interacting molecule

SAR

:   structure--activity relationship

SNP

:   single-nucleotide polymorphism

SPECT

:   single-photon emission-computed tomography

SRP

:   signal recognition particle

SUR1

:   sulfonylurea receptor

T2DM

:   type 2 diabetes mellitus

TM

:   transmembrane

7TM

:   seven transmembrane

7TMD

:   7TM domain
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